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Abstract 
A number of pathological conditions are associated with the build up of toxic 
substances within the systemic circulation. For example, renal and hepatic failure can 
lead to the accumulation of metabolites which are usually processed by these organs. 
There has been much interest over a number of years in techniques such as 
haemoperfusion that could help clear these toxins from the body and improve patient 
outcome. Haemoperfusion is an extracorporeal blood purification technique in which a 
patient’s blood is passed over a column containing a material designed to adsorb a 
board spectrum of biological toxic molecules. Direct blood contact with the adsorbent 
requires a material that is able to display good haemocompatibility whilst maintaining 
adsorption efficiency. Activated carbons (AC) have great adsorption capacity and have 
previously been used as haemoadsorbents. However the haemocompatibility of carbons 
has been questioned and they are often coated with biocompatible polymers that 
increase their haemocompatibility but also act as a barrier to the removal of larger 
toxins and middle molecules. The recent development of medical grade, synthetic, 
mesoporous (2-50 nm pore diameter) and macroporous (>50 nm pore diameter) AC 
beads has re-established AC’s potential as a haemoperfusion adsorbent. However, bead-
based packed-bed systems have poor flow dynamics, producing a large pressure drop 
across the system which is inappropriate to use in-line in an extracorporeal circuit. A 
more rational method for presenting the adsorptive beads to the blood in a flowing 
haemoperfusion system is via incorporation into a porous matrix. Poly (vinyl) alcohol 
(PVA) is a well-studied non-toxic polymer with a wide range of molecular weights. 
Recent studies suggest that cross-linking of the PVA using glutaraldehyde in sub-zero 
temperatures can lead to cryogelation and produce PVA cryogels with interconnected 
pores of size as large as 100 µm.  
A selection of AC beads from Mast Carbon International with different pore size 
distributions were tested for uraemic toxin, liver toxin and endotoxin removal. An 
improved adsorption in the larger molecular weight molecules was observed in AC with 
increasing pore sizes from the mesopore to the macropore range (diameter 30-120 nm). 
Therefore, macroporous ACs were used in the preparation of PVA/AC composite 
monolith cryogels. In vitro MTS and LDH assays revealed that neither the AC beads 
nor PVA were cytotoxic to cells. Composite materials were prepared with varying 
amounts of carbon resulting in a number of PVA-AC interactions ranging from partial 
coating of the adsorbents in a multilayer of PVA through to AC beads maintaining a 
large area of uncoated surface. Nitrogen and methylene blue adsorption analysis were 
used to optimise the composite preparation method. This allowed the preparation of a 
composite with only a small reduction in accessibility of AC in the composite for both 
nitrogen and methylene blue molecules. Data from p-cresyl sulphate and indoxyl 
sulphate (uraemic toxin) adsorption using the circulating system showed only partial 
preservation of AC adsorption for large molecules in the composite monolith at present. 
This study has identified the most appropriate AC for use as a haemoperfusion 
adsorbent. It has developed polymer/AC composite monoliths with AC beads 
incorporated into the porous matrix of a cryogel and has physically and biologically 
characterised the polymer/AC composite monolith cryogels for their potential use as a 
novel extracorporeal blood purification system. The results suggest that PVA/AC 
monolithic cryogels could be a suitable adsorbent/filtration system for haemoperfusion 
in a range of pathological conditions resulting in abnormal toxin levels in the patients’ 
blood.  
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Chapter 1. Introduction 
1.1 General introduction 
When organs such as the liver and kidney fail as a result of infection, trauma or 
disease, they no longer process and remove toxins and metabolites from the body. These 
toxins build up and can cause further damage through sustained and unregulated 
inflammatory stimulus, causing a cycle of progressive cell and tissue damage which 
may lead to multiorgan failure and death [1, 2]. Extracorporeal blood purification (EBP) 
systems currently in use for liver and kidney failure remove smaller toxins associated 
with kidney failure such as urea, creatinine and ammonia, and toxins associated with 
liver failure such as bilirubin and cholic acid. However, the removal of high molecular 
weight toxins and a wide selection of protein bound toxins remains a major issue in the 
optimisation of these systems [3]. Evidence suggests that these toxins have most 
damaging effects but are poorly removed by current devices [4]. 
Advances in activated carbon (AC) technology may be used to improve the 
efficacy of current EBP systems through the removal of high molecular weight and 
protein bound toxins by adsorption. However, packed bed columns creating undesirable 
high column back pressure and cross-column pressure drop could result in disruption of 
patient blood flow and coagulation problems during EBP treatments [5]. Further 
optimisation may be achieved through the development of novel methods to anchor AC 
beads within the blood perfusion system. A support matrix which anchors the porous 
carbon beads whilst allowing free flowing passage of blood and sufficient blood 
exposure for toxin removal may prevent the undesirable pressure drop which can occur 
in packed bed systems. 
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This chapter highlights the current challenges faced in EBP removal of toxins 
associated with liver and kidney failure. It describes current EBP systems in use. It 
reviews the history of AC use in EBP systems, the potential use of next generation ACs 
and the potential use of cryogelation technology as an AC anchoring backbone in new 
EBP systems. 
1.2 Extracorporeal blood purification therapies 
EBP therapy works by removing toxins from blood in a system external to the 
patient’s body [6]. Blood is withdrawn from the patient’s artery, pumped through a 
detoxifying unit in order to remove toxins and finally returned to the vein after addition 
of nutrient containing fluid (Figure 1-1). EBP techniques can be used for the treatment 
of a range of disease processes including hypercholesterolaemia, autoimmune disease, 
liver or kidney failure, acute poisoning and sepsis [7]. The techniques are often 
categorised into three main groups: haemodialysis/haemofiltration, plasmapheresis 
/plasmafiltration and haemoperfusion (Table 1-1) [8, 9]. 
 
Figure 1-1 Working principles and applications of EBP. 
Different EBP techniques may be applied to patients with liver or kidney failure, 
acute poisoning and even sepsis. During the EBP treatment, patient’s blood is 
withdrawn and passed through a purification/detoxification unit before the 
purified blood is returned to the patient. 
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Haemodialysis and haemofiltration are used for the treatment of kidney failure, 
and currently applied to patients with end stage renal disease (ESRD) [10]. During 
haemodialysis and haemofiltration, the patient’s whole blood is passed through a 
dialysis column where excess water, electrolytes and small, water soluble uraemic 
toxins such as ammonia, creatinine and urea are removed via diffusion (haemodialysis) 
or convection (haemofiltration) over a semi-permeable membrane [11, 12]. Diffusion 
describes the movement of solutes from an area of high to low concentration across a 
semi-permeable membrane. Toxin removal in haemodialysis is achieved by toxin 
diffusion across the membrane using a counter flow of dialysate which does not contain 
target toxins. Convection is a process where the movement of solutes occurs by 
generation of cross membrane hydrostatic pressure. In haemofiltration, blood flows 
across one side of the membrane while toxins and excessive liquid travels across the 
membrane due to the pressure difference created by the reduced pressure on the other 
side of the membrane.  
Plasmapheresis/plasmafiltration is an EBP process in which the plasma fraction 
is separated from the blood either by centrifugation or membrane filtration before the 
unwanted substances are removed from the patients’ plasma. Aimed to eliminate the 
larger pathological proteins and/or even cells, plasmapheresis can be used for the 
treatment of a range of conditions including liver failure, neurological diseases (e.g. 
myasthenia gravis,), haematological disorders (e.g. haemolytic uraemic syndrome), 
chronic inflammatory diseases (e.g. rheumatoid arthritis) and metabolic disorders (e.g. 
hypercholesterolemia) [13, 14]. Plasmapheresis and plasmafiltration techniques such as 
the molecular adsorbent recirculating system (MARS 
®
) and Prometheus
TM
 system are 
designed for the treatment of liver failure by targeted removal of selected protein bound 
liver toxins such as bilirubin, cholic acid and tryptophan [8]. However, increasing 
evidence suggests that due to the complex nature of liver failure and its association with 
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an escalated inflammatory response, targeted removal of selected liver failure related 
toxins such as bilirubin may not be enough to improve patient survival  [15].  
Haemoperfusion is a technique allowing the direct contact of blood with 
adsorbent. When the blood is passed through the adsorbent column, the undesirable 
toxins and metabolites are removed by adsorption onto the adsorbent. Early 
haemoperfusion techniques using charcoal were tested for the treatment of kidney 
failure. However, release of fines from the  charcoal adsorbents caused micro embolism 
in blood [6]. To overcome this problem, biocompatible polymers were used to coat the 
charcoal [16]. However, this resulted in a reduction in the adsorptive capacity and 
accessibility of middle to large molecular weight molecules, and therefore, limited the 
use of haemoperfusion treatment to cases of acute poisoning [7]. Haemoperfusion 
techniques have also been used for the removal of endotoxins and inflammatory 
cytokines such as tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin 
-8 (IL-8) for the treatment of sepsis [17, 18].  
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Table 1-1 List of EBP techniques, their working principals and advantages/limitations 
Method Target condition(s) Principle Limitation(s) 
Haemodialysis/ 
Haemofiltration 
End stage renal diseases 
(ESRD) 
Toxins are removed from the blood 
by diffusing though a semi-
permeable membrane 
 Successful for the removal of small, water soluble 
toxins 
 Removal of middle to large molecular weight 
toxins and protein bound toxins are limited by the 
pore size of the membrane used and diffusive/ 
convective limitations 
Plasmapheresis/ 
Albumin dialysis 
Chronic liver failure Cells are separated from the 
plasma, the albumin containing 
plasma is then passed over an 
adsorbent   
 Only successful in small water soluble toxin and 
selected protein bound toxin removal 
 Standard adsorbent without sufficiently tailored 
porous structure used 
Haemoperfusion Acute poisoning 
Sepsis 
Whole blood passed through an 
adsorbent column 
 Biocompatible polymer coating of standard 
activated carbon adsorbents, have inaccessible 
pores that reduces adsorption efficacy  
 Synthetic polymers selectively adsorb cytokines  
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1.2.1 EBP system in the treatment of kidney failure 
1.2.1.1 Structure and function of the kidney  
The kidney is a vital internal organ in the control of homeostasis. It acts to 
control blood pressure by regulating extracellular fluid volume and osmolarity; 
maintaining ion balance and pH. It excretes metabolic waste and foreign substances and 
is involved in hormone production and section [19]. The kidneys are located in the 
retroperitoneal cavity either side of the spine just below the ribcage. Each consists of the 
outer renal cortex and inner renal medulla and is divided into renal lobes (Figure 1-2 A 
& B) [20]. The urine producing, functional units of the kidney are the nephrons which 
span across the renal cortex and medulla. The nephrons consist of Bowman’s capsule, 
proximal tubule, loop of Henle distal tubule and collecting tubules (Figure 1-2 C). The 
blood flows into the kidney via the renal artery and enters the renal cortex via afferent 
arterioles into the glomerulus which is encapsulated by the Bowman’s capsule. Within 
the Bowman’s capsule, fluids and metabolic end products filtrated from the blood, and 
pass through the proximal tubule, loop of Henle and distal tubule before exiting the 
nephrons as urine [19]. However, the excretion of urine is not a one way 
filtration/removal processes. It also involves re-absorption and secretion of ions and 
fluids through homeostatic control mechanisms [19].  
Clearance of metabolic waste products is one of the most important functions of 
the kidney and is measured as an indication of kidney function. Clinically, clearance by 
the kidney is evaluated by the glomerular filtration rate (GFR) of creatinine, which is a 
metabolic product of creatinine phosphate breakdown in muscle [21]. The creatinine 
GRF is calculated by the fraction of creatinine excreted out of blood over the total 
creatinine concentration in 100 ml of plasma [22, 23]. Dysfunction of the kidney can 
lead to a failure to maintain body fluid, electrolyte and acid-base balance in the blood. 
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Without appropriate intervention, kidney dysfunction can result in further damage to the 
kidney and other organs causing kidney failure or even multi-organ failure and 
eventually death [24]. 
 
 
Figure 1-2 Anatomy of the kidney. 
The location of the kidneys is indicated in (A). A cross section of the kidney shows 
the outer cortex and inner medulla (B): blood enters the kidney via the renal 
artery and is taken into the cortex where fluid and metabolic waste products are 
removed before the cleared blood exits the kidney via the renal vein. The waste 
leaves the kidney via the renal pelvis and ureter. The layers of the renal cortex and 
medulla are formed by an arrangement of nephrons (C), the nephron consists of 
Bowman’s capsule for filtration of fluid and metabolic waste products from the 
blood. Filtered substances pass through the glomerulus and peritubular capillaries; 
proximal tubule, loop of Henle and distal tubule for the readsorption and secretion 
of ions and solutes by  blood passing through  the vasa recta; and finally the 
collecting duct for the excretion of urine (adapted from [19, 20]) 
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Risk factors such as high blood pressure, diabetes, infection, drug misuse, 
prostate disease, and genetic and autoimmune diseases can cause kidney dysfunction 
[25]. Renal dysfunction falls into two categories; acute kidney injury (AKI) and chronic 
renal disease (CKD) (Figure 1-3) depending on the disease onset. However, AKI could 
potentially progress into CKD if adequate treatments are not applied during AKI. 
Sudden disease progression can  lead to AKI [26]. AKI has been clinically classified 
into three stages according to serum creatinine levels in order to provide a general 
indication of treatment selection (Figure 1-3). CKD is classified into five stages 
depending on the kidney function, which is measured using glomerular filtration rate 
(Figure 1-3) [22].  
 
 
Figure 1-3 Classification of kidney failure and different stages of CKD. 
Kidney failure is classified into acute kidney injury (AKI) and chronic kidney 
disease (CKD) according to the speed of condition onset. (modified from [22, 26]). 
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1.2.1.2 Acute kidney injury (AKI) 
AKI is clinically identified by rapid reduction in kidney function resulting in a 
failure to maintain fluid, electrolyte balance and acid-base homoeostasis [27]. In the US, 
Wang et al (2012) reported that over 1 in 5 hospitalisations studied were associated with 
AKI. Furthermore, the incidence of AKI is responsible for a tenfold increase in the 
likelihood of patient death [28]. In the UK, an increase in the number of AKI patients 
identified and referred was reported during a 6 month study in 2003. Out of the 523,390 
population in the study area of Grampian region in Scotland, a total of 562 patients were 
identified as having AKI and 49% of patients whose serum creatinine rose 
to >300 µmol/l were referred to the nephrology service; a value more than double the 
referral percentage (22%) found in a similar study conducted in 1997 due to the updated 
AKI classification and a more efficient referral system [29]. An increase in viral 
infection and alcohol induced AKI prevalence is reported to cost the National Health 
Service (NHS) between £434m and £630m each year, and the severity of this condition 
resulted in nearly one in every ten critical care beds being occupied by an AKI patient 
[30]. Despite the high cost and clinical skill invested in the management of AKI, the 
high mortality rates among AKI patients remains [31, 32].  
The poor understanding of various casual factors and pathological pathways in 
the rapid onset of AKI leads to limited options in the treatment of this condition. In 
order to maintain homeostatic balance in patients with AKI they are treated using renal 
replacement therapies (RRT) such as haemodialysis and haemofiltration with closely 
monitored electrolyte levels [33]. The major advantage of RRT is its ability to reduce 
levels of electrolytes such as urea and creatinine in patient’s blood and efficiently 
reduce fluid build-up. However, reduction of these small water soluble molecules has 
failed to efficiently improve the survival of patients with severe AKI [21]. 
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Accumulating evidence links high AKI mortality with complications such as sepsis and 
multi-organ failure [26, 34, 35]. 
1.2.1.3 Chronic kidney disease (CKD) 
CKD is recognised as a global health problem affecting 5 to 10% of the world 
population [36]. Stevens et al. (2007) suggested that 8.5% of UK population aged over 
18 years were affected by stage 3 to stage 5 CKD [37]. However, it has also been 
reported that 84.8% of patients with CKD are unknown to the renal service due to the 
asymptomatic nature of the early stages of CKD [38]. Raising trend was recorded in the 
prevalence of stage 3 to stage 5 CKD in England from 1,186,715 individuals in 2006/07 
to 1,446,052 people in 2008 [22]. According to UK Renal Registry (2010), at the end of 
2009, 49,080 UK adult patients with CKD were developed to ESRD and were receiving 
renal replacement therapy [39, 40]. It has been reported that in 2001, the average annual 
cost for maintenance of ESRD therapy was between US $70 and $75 billion worldwide 
excluding kidney transplantation [41]. The enormous cost of ESRD management carries 
a huge health care burden especially in developing countries. In the UK, although only 
0.05% of UK population suffers from ESRD, treatment costs total 1-2% of the NHS 
budget costing a total of £1.3 billion annually [30]. 
CKD is characterised by abnormal kidney function and/or structure [24]. It is 
normally grouped into five stages based on the measured or estimated GFR. In stage 1 
and 2 the kidney retains its normal function with mildly decreased GFR level, in stage 3 
30-59% of GFR remains, in stage 4 15-30% GFR remains, in stage 5 or ESRD less than 
15% GFR remains and the patient must start RRT [23].  
Currently, management and treatment guidelines suggest that before the patient 
has progressed to ESRD, their blood electrolyte levels such as creatinine and urea are 
monitored and risk factors such as high blood pressure and cardiovascular diseases are 
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monitored. However, RRT treatments or kidney transplants are not carried out until the 
patient has reached ESRD [22]. The 2010 kidney disease fact sheet recorded that among 
40,000 people across the UK with ESRD requiring RRT in 2008, 47% received 
transplant, 44% were on haemodialysis and 9% were on peritoneal dialysis [30].  
1.2.1.4 Current challenges in the treatment of kidney failure 
Current interventions for treating renal failure are: 1) treating the underlying 
causes, such as controlling blood pressure and blood sugar levels, treating autoimmune 
diseases, and relieving obstruction and 2) replacing renal function by detoxifying the 
circulating blood. However, when the patients progress to ESRD, the treatment options 
are limited to kidney transplant and RRTs. Haemodialysis and peritoneal dialysis are 
currently used to help remove excess body fluid and small water soluble uraemic toxins 
that the dysfunctional kidneys fail to excrete, thus prolonging the patients' life [42]. 
However, RRTs cannot replace the full function of a healthy kidney, therefore the 
patient’s long term survival is affected by complications related to cardiovascular 
disease in particular [31, 43]. 
In kidney dysfunction, the build-up of toxins and metabolites which the kidney 
fails to regulate can lead to a condition named uraemia. The toxins and metabolites 
involved are called uraemic toxins. The classification, concentration and inter-
individual variability of uraemic toxins were reported by Vanholder et al. in 2003 and 
updated in 2012 [1, 44]. In their reports, 45 uraemic toxins were classified as free water-
soluble low-molecular-weight (Mw < 500 D) solutes, 25 as protein-bound solutes and 
22 middle molecules (Mw 500 to 32000 D). Among the three groups, only water-
soluble small-molecular-weight uraemic toxins can be efficiently removed by current 
haemodialysis treatments. Although creatinine and urea are used to determine RRT 
efficiency their significance in the progression of CKD has been questioned. An 
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increasing amount of evidence suggests that the removal of water soluble small-
molecular weight uraemic toxins fails to improve patient quality of life or to reduce 
AKI and CKD associated mortality [28, 31, 33, 43]. This has led to an increased interest 
in the possible impact and potential removal of middle molecules and protein bound 
uraemic toxins for improved patient prognosis [45, 46]. These molecules are generally 
poorly removed by current techniques, thus developing a new therapy that could remove 
them would be beneficial. In particular protein bound uraemic toxins such as p-cresyl 
sulphate and indoxyl sulphate have been identified and intensively studied as markers 
for the development of complications associated with CKD progression [47, 48]. 
1.2.1.5 Current EBP systems for RRT 
As mentioned in section 1.2 haemodialysis is an EBP technique which operates 
on the principle of diffusion to remove small water soluble uraemic toxins which build 
up in ESRD. During haemodialysis, the patient’s blood is passed through a dialysis 
column consisting of fibres made from semi-permeable membranes. When the blood is 
pumped through the fibres, a counter flow dialysate fluid is pumped through the outer 
space of the fibres to enable the diffusion of toxins from the patient’s blood to dialysate 
down a concentration gradient (Figure 1-4 A) [25]. Using haemodialysis, removal of 
small water soluble toxins with molecular weights of 500 to 5,000 Da can be achieved, 
maintaining electrolytic homeostasis [49]. In order to improve toxin clearance, high flux 
dialysis has been  developed to encourage larger molecular weight uraemic toxins to 
cross the membrane by increasing membrane pore size and using a higher dialysate 
throughput [3]. The Membrane Permeability Outcome Study (MPO Study) and 
Haemodialysis study (HEMO study) were two recent large randomized clinical trials 
designed to determine if increasing haemodialysis dosage and the use of high-flux 
membranes would improve patient survival. The trials were conducted in Europe and 
the US [50, 51] and the findings from both studies suggested that the use of high-flux 
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membranes and increasing haemodialysis dosage failed to improve overall patient long 
term survival rates.  
Haemofiltration is another RRT that utilises semi-permeable membranes for the 
clearance of uraemic toxins. It is mostly used in the ICU setting as a continuous RRT 
for the treatment of AKI. Unlike haemodialysis, haemofiltration operates on the 
principle of convection (Figure 1-4 B). No dialysate is used and the patient’s blood is 
passed through the membrane fibres under positive hydrostatic pressure causing 
movement of plasma water and ‘drag’ of uraemic toxins across the membrane for 
removal [52]. Improved removal of larger molecular weight uraemic toxins using 
haemofiltration compared to haemodialysis has been reported, however, with the cost of 
a reduction in the removal of small water soluble uraemic toxins [51]. 
By combining diffusion and convection techniques, haemodiafiltration is an 
EBP technique capable of removing fluid, small water soluble uraemic toxins with an 
improved clearance of middle to large molecular weight toxins [53, 54]. However, high 
plasma protein removal during high flux haemodialysis and haemodiafiltration remains 
a limitation of their use [55]. 
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Figure 1-4 Schematic representation of haemodialysis (A) and haemofiltration (B). 
In haemodialysis, patient’s blood is pumped through the membrane tubes and a 
counter flow of dialysis fluid is pumped through the outer voids of membrane 
tubes (diffusion). In haemofiltration, instead of dialysis fluid flow, a cross-
membrane hydrostatic pressure gradient is the driving force for the toxin removal 
(convection). 
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In current RRT systems, toxin removal efficiency is partly determined and 
limited by the semi-permeable membrane used. To prevent the loss of plasma proteins 
such as albumin, membranes used in  haemodialysis or haemofiltration have a lower cut 
off than the molecular weight of albumin (60 kDa) [12]. However, this low molecular 
weight cut off also largely limits the clearance of middle molecular uraemic toxins such 
as β2-microglobulin or IL-6 and protein bound uraemic toxins such as p-cresyl sulphate 
and indoxyl sulphate amongst many others [56, 57]. The diffusive haemodialysis system 
shows great ability at removing solutes such as urea, creatinine and electrolytes, i.e. 
those with a smaller molecular weight, but the clearance decreases as the solute’s 
molecular weight increases [3, 54]. In convectional haemofiltration, the purification 
efficiency is also limited by the ultrafiltration (pressure) rate and sieving characteristics 
of the membrane and solute. Use of higher pressure in ultrafiltration system resulted in 
better clearance of middle-molecular-weight substances such as peptides and larger 
molecules such as β2-microglobulin compares to haemodialysis [55, 58].  
Cellulose membranes were used in the older generations of haemodialysis 
systems. However, poor haemocompatibility of cellulose membranes resulted in a 
hypersensitivity type (type A) reaction and a non-specific type (type B) reaction 
characterized primarily by chest and back pain among patients receiving haemodialysis 
[59]. The new generation haemodialysis membranes used in RRT systems are prepared 
from a highly cross-linked copolymer of sucrose and epichlorohydrin and polystyrene 
with higher permeability and higher molecular weight cut off assisted with higher 
dialysate throughput which improves overall toxin removal [56, 60]. In the UK, most 
patients are currently treated with high flux polysulphone haemodialysis cartridges [30]. 
However the ability to remove protein bound uraemic toxins remains the major hurdle 
for haemodialysis and haemofiltration. Therefore techniques such as plasmafiltration are 
being developed and applied for the selective removal of albumin bound toxins.  
 16 
 
1.2.2 EBP system in the treatment of Liver failure 
Liver disease is the fifth biggest killer in the UK accounting for 2% of deaths 
between 2001 and 2009 [61]. Under modern medical care, liver disease is the only 
major cause of death that is still rising year on year, predominantly because of the 
increase in alcohol related liver injury (Figure 1-5) [62]. Although liver transplantation 
is currently the only efficient liver failure treatment, only 20% of advanced cirrhosis 
patients are treated with liver transplantation worldwide due to the limited number of 
liver donations available to meet the growing need [63]. EBP artificial liver support 
systems such as MARS
®
 and Prometheus
®
 can be used to improve patient quality of life, 
to prolong survival, and to provide a bridge to liver transplantation [64, 65]. However, 
the use of currently available artificial liver support systems do not improve the long 
term survival of patients with liver failure [66].  
 
 
Figure 1-5 The trend in different disease associated mortality in the UK from 1971 
to 2008. 
Change in mortality rate is expressed as a percentage calculated from the disease 
mortality in 1971 [62]. 
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1.2.2.1 Structure and functions of the liver 
The liver is the largest internal organ in the human body located in the right 
upper quadrant of the abdominal cavity (Figure 1-6) [19, 67]. As part of the digestive 
system, the liver performs as many as 500 functions including the  metabolism of amino 
acids, lipids and urea; detoxification of drugs and metabolic by-products and regulation 
of the immune response [68]. The liver is divided into two main lobes, which are further 
subdivided into approximately 100,000 small lobes. There are two main types of cells in 
the liver, parenchymal (often referred to as hepatocytes) and non-parenchymal cells [19]. 
Sinusoidal endothelial cells, kupffer cells and hepatic stellate cells are some of the non-
parenchymal cells that line the hepatic sinusoid. Hepatocytes account for 70 to 80% of 
total liver cells with the prime function of nutrient adsorption and blood detoxification 
[67]. 
As detoxification units, hepatocytes are constantly exposed to drugs, toxins and 
metabolic waste products. Therefore, the hepatocytes have a unique immunoregulatory 
function to prevent inadvertent organ damage [69]. However, infections such as 
Hepatitis C, drug overdose or long term alcohol abuse can cause hepatic pathogenesis 
and lead to rapid or gradual loss of liver function [70, 71]. 
Liver failure refers to a range of conditions associated with liver dysfunction. In 
the UK, the major causes of liver failure are viral infections, alcohol-related and non-
alcoholic fatty liver disease [72]. According to disease onset, hepatic failure is normally 
categorised into two main groups: acute liver failure (ALF) and chronic liver failure 
(CLF) [73]. 
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Figure 1-6 Anatomy of the liver. 
Anatomy of the liver showing its location in the right upper quadrant of the 
abdominal cavity (A), along with the spleen, pancreas, and gallbladder (B) [67]. 
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1.2.2.2 Acute liver failure (ALF) 
Acute liver failure occurs when a healthy liver suffers a rapid loss of function 
[74]. ALF was formally named fulminant hepatic failure and can be triggered by three 
main insults: 1) viral infections such as Hepatitis A, B, D and E, 2) drug/toxin induced 
liver injury and 3) cardiovascular disease which can cause disruption of the hepatic 
blood supply, and can thus induce hepatic hypoxia which triggers acute hepatic necrosis 
and eventually results in ALF [75]. During ALF, sudden and severe hepatic injury leads 
to abrupt loss of hepatic metabolic and immunological function and results in hepatic 
encephalopathy, coagulopathy, and, in many cases, progressive multiorgan failure [76]. 
ALF is an uncommon condition in the developed world with a prevalence of one to six 
cases per million people every year. It is predominantly caused by the overdose of drugs 
such as isoniazid, propylthiouracil, phenytoin, and valproate [77, 78]. In the developing 
world ALF is more prominent and is predominantly caused by viral hepatitis infections 
[79]. Despite its low prevalence in western countries this critical illness is associated 
with high mortality and resource costs. ALF carries a huge healthcare cost burden; 
especially in developing countries [79]. 
1.2.2.3 Chronic liver failure (CLF)  
CLF is a result of gradual degradation in liver function, caused by over 
accumulated toxin levels (alcoholic liver disease or nitrofurantoin), metabolic disorder 
(Haemochromatosis or Wilson’s disease), autoimmune malfunction (primary biliary 
cirrhosis or primary sclerosing cholangitis), and other miscellaneous causes 
(cardiovascular disease) [73, 80]. Fibrosis is a revisable condition in CLF and occurs 
when collagen fibre synthesis and decomposition balance are disrupted by inflammation. 
However, if untreated, fibrosis progresses to cirrhosis. Cirrhosis is an irreversible 
condition, and can result in a compromise in the patient’s immune function and hence 
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an increased risk of infection [81]. In addition to the impact of an accumulation of 
toxins, changes in the gut flora and increased bacterial translocation are associated with 
cirrhosis [82-85]. In the CLF patient, impaired gut epithelial integrity occurs due to 
altered tight junction protein expression by gut epithelial cells. Coupled with the over-
growth of bacteria in the gut, the lipopolysaccharide (LPS) produced by gram negative 
bacteria accumulates in the CLF patient promoting cytokine over expression and over 
activation of the host inflammatory response in immune compromised patients with a 
heightened propensity to sepsis [86]. CLF patients suffering from associated sepsis 
leading to multiorgan failure are admitted to the intensive care unit (ICU). Despite the 
high cost and complexity of ICU care, the mortality rates for ICU admitted CLF patients 
remain as high as 36-86% [87]. The high cost of CLF patient care in the ICU and the 
high CLF related mortality rates require improved treatment strategies. 
1.2.2.4 Acute-on-chronic liver failure (ACLF) 
ACLF is a condition resulting from an acute insult imposed on the already 
chronically diseased liver due to sepsis, hepatic inflammation, drug intoxication or 
bleeding. The condition can induce an inflammatory response in the liver and can result 
in organ failure of the circulatory system, brain, liver, kidney [88]. Despite the 
devastating effect of ACLF due to the rapid deterioration of liver function, the 
pathogenesis of ACLF remains unclear. In the past, ACLF was  believed to be linked to 
the accumulation of toxins such as aromatic amino acids, tryptophan, ammonia, and 
nitric oxide that the dysfunctional liver fails to remove [89]. Therefore, hepatic support 
EBP systems such as albumin dialysis and plasmapheresis were developed to selectively 
remove liver toxins. However, the clinical use of these hepatic support systems failed to 
improve survival [66, 90]. This suggests that more complex mechanisms other than the 
accumulation of liver toxins could be responsible for the development of ACLF. 
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Evidence suggests that a poorly regulated inflammatory response in CLF could be the 
cause of ACLF [2, 91].  
1.2.2.5 Current challenges in the treatment of liver disease 
A wide range of toxins and metabolites associated with liver failure have been 
identified. However, screening of all the identified liver toxins is a time consuming, 
labour intensive and costly process. Therefore, liver toxins such as bilirubin, cholic acid 
and tryptophan are often used as markers to access the adequacy of liver support 
systems. Furthermore, LPS accumulation and associated cytokine over expression leads 
to complications such as sepsis suggesting that the removal of these liver toxin markers 
is far from enough to improve patient survival in liver failure. A more comprehensive 
technique is required to tackle the board spectrum of liver and bacterial toxins, as well 
as inflammatory mediators, to improve the survival of CLF patients.  
In addition to non-cell based EBP artificial liver support systems, cell based liver 
failure treatments have also been developed. Using hepatic cell transplantation or 
hepatic cell embedded EBP artificial liver support systems, these devices aim to 
compensate for the lost functions of the failed liver [92]. Although transplantation using 
primary hepatic cells improved patient survival until liver transplantation [93, 94], the 
limited supply and slow expansion of the primary hepatic cells coupled with cell loss 
after transplantation are major limitations for clinical use [92]. The use of transplantable 
stem cells has also been explored. However, the in vitro and in vivo functionality of 
stem cells remain largely unknown, making development for clinical transplant trials 
difficult [92, 94-96]. 
1.2.2.6 Current EBP system for the removal of liver toxins 
Current EBP systems consist of non-cell based artificial liver support systems 
and cell based bioartifical liver support systems. Artificial liver support systems are 
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used to clear liver toxins and assist in liver recovery during ALF where, although liver 
function is disrupted by rapid onset of disease, this disruption has not yet resulted in 
permanent liver damage. With the assistance of liver support systems in clearing toxins 
and metabolites, the injured liver can recover its functionality after the disease causing 
the condition is treated [97]. In CLF and ACLF, EBP treatments are only used to bridge 
the patient to liver transplantation. 
1.2.2.6.1 Artificial liver support systems 
Plasmafiltration and albumin dialysis are two main EBP techniques currently in 
use as artificial liver support systems. Prometheus
TM
 (Fresenius Medical Care) (Figure 
1-7 B) is a plasmafiltration system which separates blood cells and plasma before 
removing the plasma bound toxins. In contrast to haemodialysis and haemofiltration, 
plasmafiltration is capable of reducing the target larger molecular weight and protein 
bound toxins such as bilirubin [98, 99]. The Molecular Adsorbent Recirculating System 
(MARS
®
, Gambro) (Figure 1-7 A) is an albumin dialysis technique utilising albumin 
enriched fibres as the dialysis filter for removing the protein bound toxins [90, 100].  
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Figure 1-7 Schematic representation of two artificial liver support systems: (A) 
molecular adsorbent recirculating system (MARS
®
), (B) Prometheus
®
 system. 
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The MARS
®
 system consists of three circuits; a high flux dialysis circuit, an 
albumin circuit and a low flux dialysis circuit (Figure 1-7 A). Although the membrane 
used in the high flux dialysis circuit of MARS
®
 has a molecular weight cut-off of 60 
kDa similar to the haemodialysis membrane, this membrane is formed by the 
implementation of albumin into a highly permeable polyalkyl sulfone hollow fibre 
membrane (MARSflux
®
) to competitively remove the albumin bound liver toxins from 
the patient’s blood [58]. An albumin rich (20%) fluid is flowing in a counter current to 
the blood circuit to remove the albumin bound toxins from the albumin embedded in the 
membrane. This albumin rich fluid is then passed through a low flux dialysis column 
where charcoal is used for small and middle molecular weight toxin removal 
respectively before passing through an anion exchange resin column for albumin bound 
toxin removal (Figure 1-7 A). The cleared albumin rich fluid is then recirculated to 
provide continuous toxin clearance from the patient’s blood [101].  
The Prometheus 
TM
 system consists of primary and albumin circulating circuits. 
The primary circuit includes a high-flux dialyser and an AlbuFlow 
®
 filter. A 250 kDa 
molecular weight cut-off polysulfone membrane is used in the AlbuFlow
®
 filter. The 
high molecular weight cut-off membrane allows the passage of up to 90% albumin from 
whole blood resulting in the separation of the albumin containing plasma fraction in the 
primary circuit (Figure 1-7 B) [98, 102]. In the albumin circuit, the albumin containing 
plasma fraction is passed through an anion exchanger resin column for the removal of 
albumin bound liver toxins such as bilirubin and a neutral resin column to remove the 
albumin bound bile acids and hydrophobic phenolic compounds such as the indoles and 
phenols [103]. While two adsorbent resin columns competitively remove the albumin 
bound liver toxins such as bilirubin and cholic acid, an in-line high-flux dialyser in the 
primary circuit is responsible for the removal of small water soluble toxins such as 
ammonia [98]. Using a combination of primary and albumin circuits, the Prometheus
TM
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system is designed for the removal of small water soluble and protein bound liver toxins 
in liver failure. 
Pre-clinical and initial clinical trials testing MARS
®
 for the treatment of liver 
failure indicated ability to detoxify blood, improve hemodynamics and prolong patient 
survival [104, 105]. However, recent clinical studies suggest that the MARS
®
 treatment 
failed to avoid the prognosis of sepsis and multi organ failure in CLF, and therefore, 
failed to improve patient’s long-term survival [106, 107]. In the US, the use of MARS® 
is still limited to the treatment of acute poisoning. The system has been used extensively 
for the treatment of ALF induced by intoxication of drug or toxin such as paracetamol 
or poisonous mushrooms, and positive outcomes of the treatment have been reported 
[108, 109].  
Several studies comparing the two plasmapheresis techniques suggested that 
both systems provide equally effective removal of bile acids such as cholic acid [110]. 
These studies also suggested that the Prometheus
TM
 system provides better removal of 
albumin bound toxins such as bilirubin compared to the MARS
®
 system [111]. Despite 
the reported toxin clearance efficiency, both systems failed to improve the long term 
survival rate among patients suffering from acute-on-chronic liver failure [15, 112]. 
This could be related to the limited removal of cytokines by either system [113]. 
Increasing evidence suggests that the mortality associated with ALF is not 
predominantly caused by the accumulation of toxins such as bilirubin or bile acids in 
the patient’s blood, but by pro-inflammatory cytokines such as IL-6, IL-8, IL-10 and 
TNF-α [89, 114, 115]. This indicates the need for an EBP technique capable of 
removing a broad spectrum of cytokines in addition to liver toxins. 
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1.2.2.6.2 Bioartificial liver support systems 
The limitations of current artificial liver support systems and the poorly 
understood pathogenesis of liver failure have led to an increased interest in the 
development of bioartificial liver support systems. In these systems, hepatic cells are 
imbedded in a hepatic bioreactor, which in principle provides both liver detoxification 
and synthetic functions [116]. Although no bioartificial liver support systems are 
currently available clinically, systems such as HepatAssist
TM
 (Arbios Systems Inc, USA) 
and ELAD
®
 (Extracorporeal Liver Assist Device, Vital Therapies, Inc.™, US) have 
progressed to randomised and controlled clinical trials. 
In Bioartificial liver support systems, the patient’s blood is separated in a plasma 
separator and stored in a plasma reservoir, before the plasma is cleared by passing it 
through a charcoal column and oxygenator and finally the bioreactor (Figure 1-8) [117, 
118]. In the HepatAssist
TM
 system, cryopreserved hepatocytes originating from swine 
are embedded in the hollow fibres in the bioreactor to carry out hepatic toxin clearance 
with the assistance of the charcoal column [119]. In the bioreactor of the ELAD
®
 
system, human hepatic tumour cell line hepatoblastoma cells are used [120]. In both 
systems, charcoal columns are used to remove small molecular weight liver toxins. The 
use of primary porcine hepatocytes and secondary human cell lines allows a rich supply 
of hepatocytes. However, the cells in the bioreactors have to be well encapsulated to 
avoid leaking into the blood circulation of patients [92].  
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Figure 1-8 Schematic representation of the bioartificial liver support system. 
Patient’s blood is firstly separated in a plasma separator (A), the plasma fraction is 
stored in the plasma reservoir (B). The plasma from the plasma reservoir is then 
passed through a charcoal column (C) for small molecular weight toxin removal 
and an oxygenator (D) before circulating through the hepatic cell embedded 
bioreactor (E) for further toxin removal. (adapted from [117, 118]) 
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The use of bioartifical liver supports for the treatment of ALF has been 
investigated in a number of studies. Heterogeneity in the quality and behaviour of the 
HepatAssist
TM
 system was observed [121, 122]. Although the use of porcine 
hepatocytes introduces the risk of porcine endogenous retrovirus all patients involved in 
the clinical trials were free from porcine endogenous retrovirus infection [121]. The 
initial clinical trial of the ELAD
®
 system evoked concerns over the safety of the system 
after the first patient to undergo the treatment died from septic shock [123]. However, 
later clinical trials carried out following adjustments in the system suggested the 
ELAD
®
 system was safe, while the treatment successfully bridged the trial patients to 
liver transplant [124].  
Despite positive clinical trial results indicating the initial success of the 
bioartifical liver support systems, the clinical use of this technique for liver failure 
treatment is still limited by the lack of large randomised clinical trial studies, regulatory 
restrictions, and the cost associated with the treatment [116, 125]. 
 
1.2.3 Haemoperfusion 
Haemoperfusion is an EBP technique involving withdrawing the patient’s blood 
and circulating it through an adsorbent column (Figure 1-9). The first recorded use of 
haemoperfusion can be dated back to the 1960’s, when Yatzidis experimented with 
direct haemoperfusion using a “new apparatus” containing a 20 cm long siliconized 
glass cylinder loosely packed with approximately 200 g of activated charcoal [126]. 
Their lab-based experiments showed that activated charcoal could be used to remove 
almost the entire content of plasma creatinine, uric acid, indican, phenolic compounds, 
and guanidine bases, along with an effective reduction of organic acids. Although these 
results indicated the great potential of haemoperfusion as a toxin removal method, this 
 29 
 
procedure also produced complications such as hypotension, hypocalcaemia, 
hypoglycaemia and thrombocytopenia [127]. As haemoperfusion requires the direct 
contact of whole blood with the adsorbent, fine particle release can occur and cause 
fatal complications [128]. Studies using early versions of AC derived from natural 
precursors such as coconut shells demonstrated the leaching of fine particles into the 
lungs of experimental animals, causing microemboli [129].  
 
 
Figure 1-9 Schematic representation of the working principle of haemoperfusion. 
Blood is withdrawn from the patient and passed through an adsorbent column for 
the removal of toxins before the purified blood is returned to the patient. 
 
Consequently, biocompatible polymer coatings were developed for activated 
carbon haemoperfusion. For example, Chang et al, developed a microcapsule, using 
semi-permeable microcapsule membranes to envelope adsorbents for direct 
haemoperfusion [130-133]. In addition to the capsulation methods, biocompatible 
polymer coatings such as hydroxylethylmethacrylate (HEMA) [134] were also 
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introduced. Although the coating can prevent the release of fine particles from the 
column these coatings also result in masking of the mesopores (pore diameter 2-50 nm) 
or macropores (pore diameter >50 nm) in the activated carbon. Recent findings suggest 
that the adsorption of cytokines by AC is largely due to the presence of meso- and 
macropores in the ACs [135-139]. Masking of the meso- and macropores results in the 
reduction or even elimination of cytokine removal capacity by polymer coated ACs [7]. 
Therefore, the commercially available cellulose coated AC haemoadsorbent Adsorba
®
 
(Gambro, Germany) is only used in a haemoperfusion system for the treatment of 
severe drug intoxication [140, 141]. Around 120,000 hospital admissions each year in 
England are associated with poisoning [142].  
Although AC is a popular haemoperfusion adsorbent, other polymeric synthetic 
haemoadsorbents such as Cytosorb
®
 (Renal Tech, USA) and Toraymyxin
TM
 (PMX, 
Toray, Japan) are also commercially available as  haemoperfusion treatments in Europe 
and Japan respectively [18, 143]. Both synthetic adsorbents are designed for the 
removal of cytokines from the circulating blood via haemoperfusion. Cytosorb
®
 is an 
adsorbent column consisting of polyvinylpyrrolidone coated polystyrene divinyl 
benzene copolymer beads [8, 17]. Toraymyxin
TM
 is a polymyxin B covalently 
immobilized fibrous adsorbent capable of selectively removing bacterial LPS, pro- and 
anti- inflammatory cytokines from the blood circulation [144, 145].  
Sepsis is a complex clinical syndrome characterised by a systemic host response 
to microbial insult. According to the American College of Chest Physicians/Society of 
Critical Care Medicine (ACCP/SCCM) Consensus Conference, sepsis can be 
categorised into three stages: 1) systemic inflammatory response syndrome (SIRS) and 
sepsis; 2) severe sepsis/SIRS and 3) septic/SIRS shock [146]. SIRS is the term used to 
define a systemic immune response to a wide variety of severe clinical insults. Sepsis is 
the term for a systemic immune response to a documented infection. Both SIRS and 
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sepsis are identified by two or more clinical symptoms including abnormal body 
temperature (>38°C or <36°C), heart rate (<90 beats/min), respiratory rate (>20 
breaths.min or Paco2 <32mm Hg) and white blood cell count (>12,000/mm3, 
<4000/mm3, or >10% immature forms) [147]. The use of EBP for the treatment of 
sepsis is relatively new compared to its use in the treatment of liver and kidney failure. 
The clinical evidence supporting efficacy of use is therefore more limited for this 
application. With limited clinical evidence, Toraymyxin
TM
 is currently available for 
clinical use in Japan and Taiwan [148]. Furthermore, the use of highly selective 
adsorption methods in the treatment of conditions such as sepsis with complex 
pathological pathways remains controversial [7, 149].  
1.2.4 Present and future of EBP techniques 
Current EBP techniques such as haemodialysis, haemofiltration and 
haemodiafiltration are capable of removing small water-soluble toxins, plasmafiltration 
systems have shown efficient removal of protein bound toxins and haemoperfusion 
adsorbents are available for the removal of poisons or sepsis associated cytokines from 
the circulating blood in an extracorporeal setting. However, no device is currently 
clinically available which improves long term survival. An adsorbent or adsorbents 
capable of absorbing a broad spectrum of uraemic and liver toxins as well as 
inflammatory associated cytokines may improve the long-term survival of patients. 
1.3 Activated Carbon Adsorbents and the use of AC in EBP systems 
1.3.1 AC Overview 
ACs are porous carbon materials prepared by the carbonising and activation of 
organic substances such as wood, petroleum, coal, pea, shells and more recently 
synthetic polymers. The porous characteristics of the ACs are largely determined by 
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their preparation. ACs produced from natural precursors such as wood, coal and resins 
have long been used orally in the removal of ingested toxins [6]. Later on, the use of 
activated carbons as EBP adsorbents was explored by Yatzidis in clinical experiments 
of direct haemoperfusion on patients with chronic renal failure for the removal of 
creatinine, uric acid and uraemic metabolites [150]. Recent developments in AC 
preparation using synthetic phenolic resins have allowed tailoring of porosity for the 
adsorption of larger molecules such as inflammatory cytokines [151]. 
The detoxification effects of activated carbons are in part due to their porous 
structure and adsorption of toxic molecules via physical adsorption. This indicates that 
controlling the pore structure and pore size of activated carbon could lead to the 
removal of specifically sized molecules. According to the International Union of Pure 
and Applied Chemistry (IUPAC), the pores are classified into macropores, mesopores, 
and micropores. Macropores are  larger pores with a diameter greater than 50 nm, while 
the diameter of mesopores is in the range of 2 to 50 nm, and micropores have a diameter 
smaller than 2 nm [152]. Studies suggest that the adsorption of solutes in aqueous 
solution by AC is initiated by the external diffusion of solute molecules though the 
liquid medium to the activated carbon particle, followed by internal diffusion of the 
solute from meso- or macro- pores into the micropores (Figure 1-10) [151, 153]. 
Therefore, the amount of the micropores in activated carbon determines its adsorptive 
capacity for very small molecules that fit into pores of less than 2 nm in size, whereas 
adsorption of specifically sized, larger molecules is determined by the availability of 
meso- and macropores. 
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Figure 1-10 Schematic representation of AC adsorption of different size molecules 
[154]. 
 
In addition to the physical adsorptive interaction between AC surface and solutes 
in aqueous environments, AC surface chemistry also plays an important role. The AC 
surface chemistry is determined by the presence of different functional groups on the 
AC surface and can be tailored to target the adsorption of solutes with specific chemical 
characteristics [155-157]. The use of activation agents such as carbon dioxide during 
activation of ACs can lead to a greater number and higher thermostability of oxygen 
groups on the resulting AC surface compared to when steam is used as an activating 
agent [158]. Alternatively, chemical modification can be carried out using a strong acid 
such as nitric or hydrofluoric acid or a strong base, such as sodium hydroxide, to 
introduce the desired functional groups on the AC surface [156].  
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1.3.2 Current use of AC in EBP 
The use of AC as an adsorbent for EBP in direct contact with blood requires 
good biocompatibility. For example, no packing of red blood cells or haemolysis, and 
limited loss and/or activation of platelets and white blood cells should occur during the 
perfusion procedure [7, 159]. As discussed previously, the ACs used currently in the 
EBP systems are coated with biocompatible materials. The coated ACs are found to 
exclude the binding of molecules with the molecular weight range from 1,500 to 20,000 
Da [160]. Therefore, the use of coated AC such as in Adsorba
®
 is limited to the use for 
the treatment of severe poisoning or the removal of small water-soluble toxins in the 
MARS
®
 system. 
1.3.3 Future of AC in EBP 
Recently, techniques have been developed by MAST Carbon International Ltd 
using phenolic-resin to produce activated carbon with a tailored pore structure for the 
removal of target molecules [161]. The use of phenolic resin as a precursor allows the 
preparation of AC with any desired physical form. Figure 1-11 shows that AC in beaded 
form can be prepared and sieved according to size, for use in packed adsorption 
columns; while the monolithic ACs with honeycomb internal channels can be used 
where high through flow is required; and AC cloth can be prepared for applications 
where flexible adsorbents are required [162]. By tailoring  the meso- and macro-pore 
structure of spherical porous phenolic-resin precursors, preparation of activated carbon 
with specific mesopores has been achieved (approximate volume of 1.6 to 1.7 cm
3
/g) 
without affecting the microporosity of the carbon adsorbents [151]. In addition, these 
ACs have surface areas between 500 and 2000 m
2
/g. This large surface area creates 
sufficient contact between materials and solute molecules for the efficient removal of 
solutes from an aqueous environment. Furthermore, the use of synthetic polymers as 
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precursors gives the activated carbon high physical strength, this prevents the release of 
fine particles and allows the beads to be used uncoated, leaving the macro- and/or meso-
pores accessible for target molecules. These advantages give phenolic-resin-derived 
activated carbons potential as uncoated adsorbents for extracorporeal haemoperfusion 
[136, 139, 163]. 
 
 
Figure 1-11 Different morphology of AC prepared from phenolic resin precursor 
by MAST Carbon International. 
A) AC beads (NovaCarb S), B) AC monoliths (NovaCarb F) and C) AC cloth 
(NovaCarb C) [162] 
 
Conventional use of AC for adsorption applications is in the form of a packed 
bead column. Loosely packed beads in the column assist solute adsorption by allowing 
contact between the aqueous solution and AC bead surface. However, the use of packed 
bead columns creates high back pressure and a pressure drop across the column. This 
may disrupt blood flow and activate platelets and white blood cells passing through the 
column producing low haemocompatibility [5, 164]. In order to overcome this problem, 
it study hypothesised that mesoporous AC can be presented to the flowing blood in a 
monolithic structure with interconnected flow through channels to reduce the back 
pressure and cross column pressure drop, thus limiting disruption to the blood. However, 
the surface area available for adsorption could be reduced. A system in which AC beads 
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are eld by a porous backbone allowing undisturbed blood flow in addition to maximised 
AC bead exposure for toxin adsorption is an alternative and challenging approach to 
effective EBP system design. 
1.4 Cryogelation technology in novel PVA-AC composite design for EBP 
systems  
Polymeric hydrogels are highly hydrated, crosslinked networks that are insoluble 
in water [165]. Hydrogels are often used in scientific research, for example, sodium 
dodecyl sulfate-polyacrylamide gel is commonly used as a matrix for the separation of 
proteins in Western blotting. Two main types of hydrogel formation (gelation) 
processes are used. One is radical polymerisation, in which monomers are connected to 
form polymers, and the other process utilises a crosslinker to crosslink the existing 
polymers for gel formation. In radical polymerisation, monomers with low molecular 
weight are mixed with initiator before gel formation. In the crosslinking process, long 
chain polymers are normally used. Common crosslinking agents such as glutaraldehyde, 
formaldehyde and divinylbenzene are able to react with long chain polymers and create 
covalent bonds or ionic bonds to hold the polymer chains in place and form a gel 
structure [166]. 
Different polymer gelation processes give these gel products various 
morphological properties, which in turn suggest a wide range of potential applications 
[166]. In the area of biotechnology, polymeric gels can be used in immobilising and 
cultivating cells as well as for electrophoresis matrices, immunodiffusion, and 
chromatography. In the biomedical sciences, there is the potential for using polymeric 
gels in drug delivery, tissue engineering and tissue replacement biomaterials. For 
example, hyaluronic acid hydrogels are non-toxic, biocompatible and biodegradable 
polymeric gels whose degradation can be determined by the cross-linking density 
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(depending on the chemical structure of the polymers). This gel is considered to have 
great potential as an anti-inflammatory drug delivery system [167]. Many advantages of 
gels and their possible applications have attracted increasing interest in the synthesis, 
characterisation and modification of macroporous polymeric gels. 
Cryogelation is a name given to a process in which hydrogel formation is carried 
out by a thermally induced solid-liquid phase separation when a solution freezes [168]. 
As illustrated in Figure 1-12, during cryogelation, precursors are frozen down to sub-
zero temperatures to encourage the crystallisation of the solvent, which in most cases is 
water. As the progression in solvent crystallisation occurs, the solvent systems reach the 
point in which the solvents are partially frozen and partially liquid. It is believed that the 
polymerisation process takes place in the unfrozen solvent (non-frozen liquid 
microphase) and the frozen solvent acts as the porogen. After thawing the gel, these 
solvent crystals melt away leaving the resulting gel with interconnected channels which 
can be as large as 100 µm in diameter [169]. The gels that are formed via cryogelation 
processes are termed cryogels. The cryogelation process gives rise to many of the 
unique properties of cryogels such as their spongy, elastic nature and abundance of large 
interconnected channels. The most outstanding property is the interconnected 
macroporous structure [170]. Both radical polymerisation and crosslinking of existing 
polymers can be used for cryogelation to prepare cryogels [168]. 
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Figure 1-12 Scheme of formation of macroporous gels during cryogelation 
(modified from Plieva et al.[170]). 
 
Poly (vinyl) alcohol (PVA) is one of the most well studied polymers with 
excellent film forming, emulsifying, and adhesive properties. In part due to its stability 
and non-toxic properties, it has become a very popular material in tissue engineering, 
and cell separation [168]. The use of PVA with different molecular weight and acetate 
content in cryogel formation has been reported [171, 172] (Chapter 2). PVA with 
molecular weight greater than 60,000 and a degree of hydrolysis greater than 98% is 
able to form a physically crosslinked network without the presence of crosslinking 
agent. Whereas PVA with a degree of hydrolysis less than 90% cannot form a 
physically crosslinked gel, therefore, its cryogelation requires an additional crosslinker 
[173]. Plieva et al used glutaraldehyde as a cross-linker under acidic conditions to 
promote the cryogelation of PVA and produced chemically crosslinked cryogel 
monoliths with large interconnected channels [169]. PVA cryogels with modifications 
and various composites can be produced into different cryogels in order to adapt to 
specific applications. For example, PVA cryogels were used for the isolation of anti-
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CD14 mAb labelled monocytes from t-lymphocytes, and B-lymphocytes. The procedure 
was performed by passing this cell mixture though PVA with a perfluorocarbon support 
expanded-bed [174]. Although the PVA-FEP composites were not produced by 
cryogelation, this technique opens up the opportunity of using PVA cryogels in blood 
cell separation.  
As discussed in section 1.4 of this chapter, despite the impressive adsorptive 
capacity of the AC beads, the use of packed bead AC adsorbent columns in 
extracorporeal haemoperfusion could potentially create high column back pressure and 
disrupt the blood flow by cross column pressure drop, resulting in adverse clinical 
effects. Cryogelation is capable of producing a flow through cryogel column with large 
interconnected channels. It is therefore hypothesised that the use of an AC-cryogel 
composite material could potentially overcome the problem of flow resistance seen in 
packed AC bead columns. The interconnected channels of the cryogels could allow 
passage of whole blood without causing an undesirable pressure drop or high back 
pressure. Furthermore, by presenting AC beads on the cryogel channel walls, the AC 
are in direct contact with blood and thus, the unwanted toxins could be removed by the 
AC. However, it is important to be able to engineer the composite materials to actively 
support the AC beads whilst maintaining the adsorptive capacity of the carbons and 
ensuring material biocompatibility. This study investigates the feasibility of preparing a 
novel haemoperfusion adsorption cryogel-AC composite material which allows the 
passage of whole blood whilst preserving the appropriate AC porosity for efficient toxin 
removal for applications related to liver and kidney failure. 
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1.5 Aims 
The aims of this study are listed below: 
1) To develop a PVA cryogel and PVA-AC composite system for EBP applications 
2) To develop and use physical characterisation techniques to assess AC porosity 
and relate this to toxin removal capacity 
3) To develop and use methods for the assessment of cytotoxicity of PVA cryogel 
and AC beads used for composite cryogel preparations 
4) To review and identify the hepatic and uraemic toxins poorly removed in current 
EBP systems for use as marker molecules in toxin adsorption studies 
5) To adopt and optimise synthesis methods for albumin bound p-cresyl sulphate 
and detection methods of p-cresyl sulphate and indoxyl sulphate and apply this 
to the adsorption studies 
6) To assess a range of ACs with varying porosity and identify the most appropriate 
candidate for liver and uraemic toxin removal, for use in the composite system 
7) To develop and run in vitro studies assessing the removal of protein bound liver 
and uraemic toxins by AC and PVA-AC composites 
8) To assess composite haemocompatibility using renal failure haemodialysis 
patient blood in a single pass ex vivo haemoperfusion experiment 
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Chapter 2. PVA-AC Composite Cryogel Preparation & Physical 
Characterisation 
2.1 Introduction 
2.1.1 Activated carbon 
AC is a popular adsorbent and catalyst support largely because of its high 
surface area and porosity [175]. These characteristics are the result of the special 
carbonisation and activation methods which are used during the production process. 
ACs may be derived from natural precursors including coal and nut shells or synthetic 
materials such as phenolic resins [161], using either physical or chemical activation 
methods. AC prepared by physical activation consists of carbonising raw materials 
under high temperature in an inert atmosphere to produce a char or pitch followed by 
their activation in an oxidizing atmosphere at high temperature [175]. The chemical 
activation process is a one step production process involving carbonization of the raw 
material mixed with chemicals such as acid, a strong base or salt, which act as the 
catalyst and porogen for AC production [176, 177]. 
Coconut shells, peat, wood, lignite, coal and petroleum pitch are popular 
precursors for AC production because of their economical price and availability [176, 
178, 179]. Although activation methods can be modified in order to control the porosity 
of these natural-precursor-derived ACs, their pore characteristics are largely related to 
the cellular structure of the precursors. The heterogeneity of the precursor materials also 
poses a huge challenge in the production of homogeneous, high strength adsorbents 
[161]. Elution of fines due to the low physical strength of the early version of natural-
precursor-derived AC adsorbents resulted in low haemocompatibility [150]. To 
overcome this problem, coating of AC using albumin was first suggested for 
extracorporeal blood purification applications. However, as described previously, the 
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coatings resulted in a major disadvantage, as albumin coating excludes the AC from 
binding molecules with a molecular weight range from 1,500 to 20,000 Da [160]. 
Although the more recent AC coating systems using semi-permeable film forming 
materials such as pyroxylin, polypropylene, and collagen were believed to preserve the 
AC adsorption capacity for kidney toxins and prevent large platelet activation [180], 
their limited ability to remove albumin bound toxins remains a major limitation of these 
materials. Adsorba
®
 C (Gambro, Sweden) is a commercially available cellulose coated 
AC haemoperfusion adsorbent. As a coated AC haemoadsorbent, Adsorba
®
 C has been 
shown to demonstrate negligible adsorption capacity of albumin bound toxins and 
cytokines such as IL6, IL8 and TNF-α, therefore, its use is limited to the treatment of 
acute poisoning [140]. 
2.1.1.1 Phenolic resin derived AC- NovaCarb 
The use of synthetic AC precursors makes it possible to control the structure and 
purity of the raw materials, therefore, improving the homogeneity of the AC produced. 
Synthetic materials such as phenolic resins and furfuryl resins, polvinylidene chloride, 
sugars and polyamide based materials have been used for the preparation of AC [161, 
181-183]. Among these polymer systems, phenolic resins are the most widely studied 
synthetic materials for AC production because a wide variety of physical forms can be 
prepared [161]. A variety of phenols and aldehydes can be used in phenolic resin 
production, although the use of phenol and formaldehyde is most common. During resin 
preparation, pore formers such as polyethylene glycol (PEG) and gamma-butyrolactone 
are added proportionally to the phenol/formaldehyde mixture to tailor the porosity of 
the final phenolic resins. The AC beads used in this work were NovaCarb beads 
manufactured by MAST Carbon International and prepared from a spherical porous 
phenolic resin precursor (Figure 2-1) [161, 184].  
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Figure 2-1 Preparation of highly porous NovaCarb S. 
(MAST Carbon International Ltd, UK) AC beads in lab based small scale 
production[161, 184]. 
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As illustrated in Figure 2-1, the NovaCarb S AC bead production technique 
patented by MAST Carbon International Ltd involves preparation of porous phenolic 
resin, with controlled meso- or macroporosity by adjusting the proportion of PEG in the 
phenolic resin precursor mixture before the resin is moulded into different shapes, 
carbonised then activated. The phenolic resin precursors are firstly dissolved in a 
solvent such as ethylene glycol and diethylene glycol at an elevated temperature of over 
120 °C. The mixture is then added into heated mineral oil with additional dispersant 
under agitation. The crosslinking of phenolic resin precursors in the oil mixture leads to 
the formation of phenolic resin beads. Meanwhile a phase separation process occurs due 
to the presence of pore formers in the crosslinking process and results in mesopore or 
macropore structure in the phenolic resin products. Patents from MAST Carbon 
International Ltd also claim the possibility of controlling the phenolic resin particle size 
between 5 to 2000 µm by adjusting the oil temperature, viscosity and volume ratio of 
the solution to the oil. In addition, by altering the precursor to pore former ratio, this 
method is capable of preparing ACs with mesopore size range from 2 to 50 nm in 
diameter and macropore size range from 50 to 500 nm in diameter [135, 184]. In order 
to expose the meso- or macropores occupied by the pore former, after the formation of 
phenolic resin beads and before the carbonisation process, the pore former, oil and 
dispersant are removed by water in a soxhlet system or vacuum distillation. During 
carbonisation, the phenolic resins are transformed into carbon due to the fact that non-
carbon materials in the resin are burned off at over 400 °C, resulting in a well-ordered 
graphitic structure and an increase in the surface area of the carbon materials [181]. 
After the carbonisation process, the materials are then activated in the presence of 
different activation reagents including steam, carbon dioxide and oxygen to further 
enhance the surface area by introducing microporosity. Activation produces a gradual 
broadening and deepening of the pores in the resulting AC. The activation process 
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utilising steam and carbon dioxide requires temperatures exceeding 677 °C or over 
800 °C if a higher activation rate is required. However, with the use of oxygen as an 
activation agent, a lower temperature of 350 °C is required due to its relatively reactive 
nature [161, 178].  
 
 
Figure 2-2 Scanning electronic micrographs of MAST Carbon AC beads. 
AC beads have a smooth outer shell (A) and a meso-/macro-porous inner structure 
formed by aggregates of nanospheres (B). (Modified from Tripisciano et al.[135]) 
 
2.1.1.2 Porosity and adsorptive capacity of NovaCarb 
Previous studies using ACs from MAST Carbon International have shown the 
presence of meso- or macroporosity using scanning electron microscopy (SEM) 
imaging techniques and nitrogen adsorption analysis [135, 151, 185]. As illustrated in 
Figure 2-2, MAST Carbon AC beads have a smooth outer surface and a pomegranate-
like inner nanosphere aggregate structure [120]. The voids between these nanosphere 
aggregates are thought to be the main contributor to the meso- and macro-porosity of 
these ACs [139]. The mesoporosity and macroporosity have been linked to the 
adsorption of inflammatory cytokines such as TNF, IL-6, IL-1β and IL-8 from blood 
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plasma [137, 139]. Although the microporosity of these ACs cannot be observed in the 
SEM images, their presence can be confirmed and quantified by low temperature 
nitrogen adsorption analysis (Figure 2-3) [185]. Figure 2-3 also shows that the meso- to 
macropore size distribution can be quantified by combining nitrogen adsorption analysis 
with mercury porosimetry. The combination of micro- and meso- or macroporosity in 
these ACs leads to impressively large surface areas of between 500 and 2000 m
2
/g [184]. 
This large surface area allows maximal contact between the adsorbent materials and 
solute molecules.  
 
 
 
Figure 2-3 Pore size distribution plot for a sample MAST Carbon AC bead. 
The blue line represents the AC porosity (0 - 100 nm) determined by nitrogen 
adsorption analysis; and the red line represents the meso- to macro-porosity 
determined by mercury porosimetry [185] . 
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2.1.1.3 Potential and limitations of MAST Carbon AC use as a haemoadsorbent 
In addition to the superior porosity, the use of synthetic polymers as precursors 
has given MAST Carbon ACs high physical strength, preventing the release of fine 
particles, and allowing the beads to be used uncoated with the macro- and/or meso-
pores accessible for the adsorption of target molecules [161]. As discussed in Section 
1.4 in Chapter 1, AC fines release has been a hurdle in the use of uncoated AC in 
haemoperfusion applications [161]. By overcoming this problem, the use of uncoated 
AC in haemoperfusion applications has been made possible. Studies investigating 
platelet, monocyte and granulocyte interaction with the MAST Carbon ACs under static 
cell-material interactive conditions showed that moderate levels of monocytes and 
granulocytes adhered to the AC surface. However, the granulocytes were not induced to 
activate. In addition, fully activated adherent platelets and activation of the complement 
cascade were not observed [163], suggesting that the uncoated MAST Carbon ACs were 
haemocompatible under static experimental conditions. 
A more recent study conducted by Tripisciano et al. (2011) investigated the 
potential of MAST Carbon ACs for an EBP liver application by determining their 
removal of albumin bound toxins, release of haemolytic substances and activation of 
coagulation upon blood-AC contact [135]. This study suggested that the ACs with a 
high degree of burn off (> 62%) showed efficient removal of inflammatory cytokines 
such as IL-6 and TNF-α as well as albumin bound liver toxins such as bilirubin and 
cholic acid. Furthermore, they also suggested that the ACs did not release haemolytic 
substances when extracted with 0.9% sodium chloride solutions at 37°C for 24 hours. In 
addition, they also reported that no significant changes in the intrinsic and extrinsic 
coagulation cascades were observed by determining the prothrombin time and the 
activated partial thromboplastin time, indicating the good haemocompatibility of MAST 
AC. 
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Despite the high porosity, surface area and haemocompatibility of the ACs, the 
use of small AC beads in a packed bed haemoadsorption column has a number of 
drawbacks such as high back pressure and pressure drop across the column [5, 164]. 
The packed bead column flow properties can be improved by increasing the particle size 
of the adsorbent beads to 250 – 500 µm in diameter (in haemoperfusion application) and 
by reducing the packing density when packing the column [5, 98]. However, the 
increase in adsorbent particle size leads to a reduction in total adsorbent outer surface 
area whilst reducing packing density directly results in a decrease in adsorbent content 
in the column. This reduces the column adsorption capacity and efficiency. In contrast, 
when adsorbents with a smaller particle size are used, the consequent total adsorbent 
surface area in the column increases improving adsorption capacity and efficiency. The 
dilemma of using packed bead haemoadsorbent columns requires a novel approach in 
column design. A haemoadsorbent column could be considered incorporating a 
monolithic polymeric matrix with large interconnected channels allowing unrestricted 
passage of whole blood whilst maintaining the capacity to present small AC beads with 
maximal surface area exposed to the path of blood flow. 
2.1.2 Poly (vinyl) alcohol (PVA) cryogel - a promising haemoperfusion 
matrix 
2.1.2.1 PVA production and properties 
PVA is a non-toxic, water soluble, long chain polymer with a wide range of 
molecular weights (ranging from 31,000 to 250,000) that is commercially available 
[186]. Unlike other polymers, PVA is commercially produced by hydrolysis of poly 
(vinyl) acetate (PVAc) (Figure 2-4) rather than radical polymerization of a PVA 
monomer. The primary raw material used in the production of PVA is vinyl acetate 
monomer, which is polymerised into PVAC to achieve the required molecular weight 
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[187]. The polymerised PVAC is then hydrolysed by replacement of an ester group in 
vinyl acetate with a hydroxyl group in the presence of saponification agent sodium 
hydroxide. By tuning the PVAC polymerisation and saponification time, PVA with 
variable molecular weight and degree of hydrolysis is manufactured [187]. The 
manufacturing method allows the commercial availability of various molecular weight 
PVAs in both highly hydrolyzed grades with the degree of hydrolysis above 98.5% and 
partial hydrolysis degrees ranging from 80.0 to 98.5% [188].  
 
 
Figure 2-4 Hydrolysis of PVAC during the production of PVA. 
The replacement of acetate groups on the PVAC to hydroxyl groups is carried out 
during its hydrolysis in the presence of water [187]. 
 
2.1.2.2 PVA gel production via physical and chemical crosslinking processes 
The abundant hydroxyl groups in the PVA polymer allow the use of crosslinking 
reactions to improve its physical properties in order to suit different applications [189]. 
PVA cross linking methods can be achieved via physical crosslinking including: freeze-
thaw, heat treatment, acid-catalysed dehydration, irradiation or radical production and 
chemical crosslinking with aldehyde groups containing di-functional compounds di-, 
tri-or polycarboxylic acids anhydrides or acid chlorides [190]. Using freeze-thawing 
methods, PVA with a high molecular weight and greater than 98% hydrolysis can 
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undergo physical crosslinking via hydrogen bonds (Figure 2-5) in the entangled areas of 
the PVA long chains [191, 192]. The crosslinking of PVA with an acetyl bond between 
aldehyde groups (Figure 2-6) from di-functional compounds such as glutaraldehyde and 
the hydroxyl groups of PVA is a popular method to obtain chemically crosslinked PVA 
[193]. Chemical crosslinking of PVA has been used to prepare materials for a wide 
range of applications from water treatment membranes to articular cartilage replacement 
[194]. Although chemical crosslinking produces a more stable PVA matrix when 
compared to the physically crosslinked PVA matrix, the toxic nature of chemical 
crosslinkers such as glutaraldehyde has made physical crosslinking of PVA a popular 
method for its use in biological applications such as in the development of drug delivery 
devices [189, 195].  
 
 
Figure 2-5 Two H-O interactions during the physical crosslinking of PVA. 
H-O interaction 1 represents the crosslinking of hydroxyl groups on different PVA 
polymer chains; H-O interaction 2 represents the crosslinking of hydroxyl groups 
among neighbouring hydroxyl groups in the same PVA polymer chain [196]. 
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Figure 2-6 Chemical crosslinking of PVA using glutaraldehyde as a crosslinker. 
The hydroxyl groups on the different PVA polymer chains are crosslinked by 
glutaraldehyde, resulting in a crosslinked network of PVA-glutaraldehyde [197] 
 
Physically crosslinked PVA cryogels prepared for cell immobilisation were 
developed by Lozinsky et al [196, 198, 199], using PVA with 69 to 81 kDa molecular 
weight and greater than 98% degree of hydrolysis. They determined that the mechanical 
properties of the cryogels formed can be tuned by changing the concentration of PVA in 
solution as well as the thawing rate (Figure 2-7) [196, 198]. With an increase in PVA 
concentration, a reduction in the ability to store compressive energy (measured as 
compliance) of the PVA cryogel product can be observed. In addition, with increasing 
thawing rate, an increase in compliance in the PVA cryogel product can also be 
achieved [196, 198].  
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Figure 2-7 Influence of PVA solution concentration and thawing rate on the 
resulting cryogel mechanical properties. 
Graph A shows a decrease in gel compliance with an increase in the PVA 
precursor concentration; Graph B shows that the faster the gels were thawed, the 
higher the compliance that can be achieved in the resulting gel [196]. 
 
2.1.2.3 Crosslinked PVA cryogels as a potential haemoadsorbent matrix 
Although physical crosslinking of PVA in cryogel production can avoid the use 
of chemical crosslinkers which are often harmful or even toxic, the physically 
crosslinked PVA cryogel only has an average pore size diameter of 1 µm [33]. For 
applications such as drug delivery and cell immobilisation, physically crosslinking PVA 
cryogels could be an ideal methodology. However, if the PVA cryogels are to be used in 
haemoperfusion applications, interconnected pores (channels) with a diameter greater 
than 20 µm are required to enable the free passage of blood cells. The use of physically 
crosslinked PVA cannot fulfil this requirement. 
Although PVA with less than 98% hydrolysis cannot physically crosslink, PVA 
hydrogels, films [190] or cryogel monoliths [172] can be prepared with the addition of a 
crosslinker such as glutaraldehyde. Such methods have previously been developed for 
the chemical crosslinking of PVA hydrogels for applications including articular 
cartilage replacement [194]. Plivia et al developed the cryogelation method for 
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preparing a crosslinked PVA cryogel which has interconnected channels with a 
diameter as large as 80 µm [172]. In this cryogelation method, low concentrations of 
PVA solution (5-10% 
w
/v) were mixed with 1% (
w
/v) glutaraldehyde at pH 1.1. The low 
concentration of both PVA polymer and crosslinker prevent crosslinking from occurring 
at room temperature. Once the temperature is dropped to -18 °C, ice crystals start to 
form in the mixture, and as the crystal size increases, the PVA and GA concentration in 
the non-frozen-liquid phase increases. The crosslinking occurs and when the ice crystals 
melt away, a crosslinked PVA cryogel matrix with interconnected channels remains 
[172]. 
PVA polymer with a flexible nature and interconnected channel structure of the 
PVA cryogel [172, 200] endorses its potential as a supporting matrix for a 
haemoperfusion column which can be used to hold the AC adsorbent beads in place 
without creating a high back pressure and pressure drop across the column.  
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2.1.3 The concept of a PVA-AC composite cryogel 
As discussed previously, the poor flow properties of packed bead columns 
manifest when the adsorbent particle size is reduced. Therefore, a study by Savina et al. 
explored the potential of incorporating nanoscale (20 – 30 nm) iron oxide particles into 
a polymeric cryogel matrix with large interconnected channels, to improve the column 
flow properties [201]. This study suggested the use of a HEMA and poly (ethylene 
glycol) diacrylate (PEGD) copolymer cryogel matrix to support and present the iron 
oxide nanoparticle (20-25 nm diameter) to the fluid stream consisting of aqueous 
solutions with contaminants such as As (III). This iron oxide nanoparticle-HEMA-
PEGD copolymer cryogel composite was reported to not only prevent the leakage of ion 
nanoparticles but also exhibited good flow properties and As (III) adsorbing capacity.  
This finding suggests that embedding the relatively small AC beads (diameter < 
45 µm) into the cryogel matrix can potentially improve the flow properties compared to 
the packed bead column (Figure 2-8). In addition to optimising the exposure of AC 
beads in the cryogel matrix thus, the toxin adsorption capacity of the AC may be 
preserved, offering a suitable alternative to the packed bead column.  
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.  
Figure 2-8 The flowing property of solvents in packed bead column. 
Based on monolithic porous gels and polymer beads (Adapted from: Savina et al. 
[201]) 
 
2.1.4 Material surface area and characterisation of porosity 
The adsorption capacity of an adsorbent is largely related to its surface area and 
porosity. Various methods are available for determining these characteristics. 
Visualisation of the materials at the microscopic scale is a direct method of identifying 
material structure and topography. A number of microscopy techniques have been used 
to visualise the internal structure of AC adsorbents and cryogels. Among the 
microscopic visualisation techniques, scanning electron microscopy (SEM) is popular 
due to its ability to provide high resolution images of sample structure [202]. Confocal 
laser scanning microscopy is another popular microscopy technique for the visualisation 
of material internal structure in hydrated or dehydrated state [203]. Although 
microscopy imaging techniques provide an insight into material topography and internal 
structure, these techniques are not designed for quantification of adsorbent material 
porosity, surface area and adsorptive properties. Therefore, methods such as low 
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temperature nitrogen adsorption analysis, mercury porosimetry and liquid phase 
adsorption studies are often used to supply quantitative data for material porosity and 
adsorption [204]. 
2.1.4.1 SEM and Confocal microscopy imaging techniques 
The SEM imaging technique utilizes electron beams to collect information 
regarding sample morphology and topography and provides high resolution images of 
samples down to the nanometre range [202]. In order to stabilise the electron beams and 
remove any fine particles in the electron beam path, samples are analysed under a 
vacuum environment. The structure of materials such as hydrated cryogels or hydrogels 
with a high water content, can collapse when the water is suddenly extracted from the 
sample examined in an SEM sample chamber under high vacuum [205, 206]. 
Furthermore, electron beams bombarding the material surface for SEM imaging will 
result in electron charging on the non-conductive material surface and will affect the 
imaging quality. Therefore, materials examined using SEM are normally coated with 
conductive materials such as platinum or palladium to reduce the material surface 
charging [202]. The use of a vacuum environment and the required coating of the 
samples for SEM imaging require drying of the cryogel materials prior to their 
examination.  
In Confocal microscopy imaging, a laser is used for excitation of fluorescence 
dyes attached on the material surface, to reveal the internal structure of sample materials 
[203]. The major advantage of confocal microscopy compared to SEM is the ability to 
examine samples such as hydrogels and cryogels in their hydrated state. By combining 
the SEM and Confocal imaging techniques, nanoscale sample topographic structure at 
the dehydrated state and the internal structure at the hydrated stage can be determined. 
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2.1.4.2 Mercury porosimetry 
Mercury porosimetry is a technique mainly used for quantifying the 
mesoporosity of materials; it can also provide information on material surface area and 
bulk density. This technique utilises high pressure to intrude mercury into the material 
pores under vacuum. The pressure applied and the amount of mercury intruded is used 
for quantification calculations based on Washburn's equation (Equation 2-1) assuming 
cylindrical pores. The pressure required for the intrusion of mercury is expressed as P, r 
is the cylindrical pore radius; γ is the surface tension and θ is the contact angle of 
mercury intruding into the pores. Since the contact angle of mercury to different 
surfaces is between 135° and 142°, an average of 140° is often used in these 
calculations. Furthermore, the surface tension of mercury under vacuum at 20°C is 480 
mN/m, with these two constants, by increasing the pressure, mercury can be intruded 
into smaller pores (decreasing r). At a certain pressure point, the recorded intruded 
mercury volume represents the pore volume of the pore size associated with this 
intrusion pressure [204]. Assuming that the cylindrical pores open each end, the surface 
areas of the test materials can be expressed as Equation 2-2 [204].  
 
           Equation 2-1 
  
 
 |    |
∫    
 
 
 Equation 2-2 
  
 58 
 
2.1.4.3 Nitrogen adsorption 
Low temperature nitrogen adsorption is a widely accepted method for the 
determination of material surface area and micro-/mesoporosity. The technique first 
involves the evacuation of air and moisture from the samples by applying heat under 
high vacuum. This is followed by the addition of helium, which is then removed before 
nitrogen gas is fed into the vacuumed system under constant temperature in a controlled 
manner [204]. By recording the relative pressure of the fed nitrogen volume, the gas 
adsorption isotherm data is collected. According to the IUPAC [207], adsorption 
isotherms can be classified into six physisorption models (Figure 2-9). The Type I 
isotherm represents typical microporous solids and chemisorption isotherms. Type II 
and III isotherms describe adsorption on macroporous adsorbents, where type II 
represents strong adsorbate/adsorbent interactions, and type III isotherms represent 
weak adsorbate/adsorbent interactions. Types IV and V represent monolayer and 
multilayer adsorption plus capillary condensation; the hysteresis loops are generated by 
the capillary condensation of the adsorbate in the mesopores of the solid. Finally, the 
rare type VI isotherm illustrates that adsorption isotherms can have multiple steps 
shown by nitrogen adsorbed on a planar surface [208]. Mathematical models such as 
Langmuir theory, Brunauer-Emmett-Teller (BET) theory, Barrett, Joyner and Halenda 
(BJH) method and density functional theory (DFT) calculations can be applied in order 
to calculate the materials specific surface area, pore volume and pore size distribution. 
Langmuir isotherm theory operates under the hypotheses of monolayer coverage 
of adsorbate over a homogenous adsorbent surface. It can be expressed as Equation 2-3, 
where q is the adsorption per gram of solid when the equilibrium pressure is Peq, and qm 
is the monolayer capacity, while K is the Langmuir equilibrium constant [204].  
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The BET equation (Equation 2-4) is operated based on three assumptions; (1) 
infinite number of gas molecule layers can be physically adsorbed onto the test material 
surface; (2) no interaction exists between each adsorption layer adsorbed; and (3) each 
layer can be described using the Langmuir equation. According to the BET equation, a 
linear relation can be observed between 
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Figure 2-9 IUPAC defined adsorption isotherms. 
(A is adsorption, D is desorption) The Type I isotherm is typical of microporous 
solids and chemisorption isotherms. Type II isotherm represents the adsorption 
onto macroporous adsorbent with strong adsorbent/adsorbate interaction. Type 
III is the macroporous adsorbent adsorption isotherm with weak 
adsorbent/adsorbate interaction. Type IV and type V adsorption (A)/desorption (D) 
isotherm both feature a hysteresis loop, which is generated by the capillary 
condensation of the adsorbate in the mesopores of the solid. Type VI multiple 
stepped isotherm can be found in nitrogen adsorbed on special carbon with an 
ideal planar surface structure [207]. 
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A minimum of three points are collected for a standard multipoint BET analysis. 
As illustrated in the Equation 2-5, the calculated wm is then used for the calculation of 
specific surface area (SBET) by multiplying the mass of monolayer gas (wm) by the 
Avogadro’s number (N= 6.023×1023) and the cross-sectional area of the adsorbate 
molecule (ACS), and dividing by the molecular weight of the adsorbate molecule (M). 
 
 BET  
 m     CS
 
 Equation 2-5 
 
The BJH and DFT are two mathematical calculations available in the nitrogen 
adsorption analytical software employing principles in quantum physical theories. The 
BJH method is applied during desorption of nitrogen from the adsorbent meso- and 
macropores, the filling of which is generally caused by capillary condensation. 
Operating based on the hypothesis that at the highest relative pressure point, all pores in 
the adsorbent are filled with adsorbate in a liquid state, and upon the decrease of relative 
pressure, the top layer of adsorbate in the largest pores evaporates first [204]. This 
assumption of the BJH calculation, results in its unavailability to estimate the micropore 
distribution and underestimation of the small to medium mesopore sizes. The DFT 
method is a relatively new approach for the estimation of microporosity of adsorbent 
materials. By assuming that the different sized pores on the adsorbent are uniform, 
displaying slit or cylindrical pore shape and the adsorbate is treated as a homogeneous 
fluid, the pore size distribution can be calculated using commercially available software 
such as AS1win from Quantachrome Ltd. The DFT method is believed to provide a 
more accurate estimation of the material’s micro- and meso-porous structure [207, 209]. 
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2.1.4.4 Adsorption from a liquid phase 
The Langmuir isotherm theory not only applies to gas adsorption but also to the 
adsorption from a liquid phase for the determination of an adsorbent’s adsorption 
capacity in its wet state [204]. In this case, the Langmuir equation can be rewritten into 
the Lineweaver-Burk equation (Equation 2-6), according to which a plot of  
 
  
 versus 
 
 eq
 
can be used to determine the adsorbent monolayer capacity qm and K. The qm can then 
be used in the determination of material surface area.  
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Adsorption kinetic studies are often carried out for a better understanding of the 
adsorption mechanisms. It is commonly accepted that three steps take place in a solid–
liquid adsorption process: 1) adsorbate molecules diffuse through the liquid-solid 
boundary layer and reach the external surface of the adsorbent; 2) the adsorbate is 
further transported into the adsorbent pores via internal diffusion and 3) adsorbate 
adsorption onto the active site of the adsorbent pores [210]. However, the simplified 
model is based on monitoring the reduction of adsorbed molecule concentration during 
the increase of adsorbent/liquid contact period and is often applied to describe the 
adsorption process as a one step process. The resulting adsorption kinetic profiles are 
fitted against Pseudo-first-order (Equation 2-7) and Pseudo-second-order (Equation 2-8) 
models [204]. The Pseudo-first-order model was first used by Lagergren in describing 
the kinetics of adsorption of oxalic acid and malonic acid onto charcoal [204]. Pseudo-
second-order model is often used for the chemical adsorption processes where sharing 
 63 
 
or exchange of electrons between adsorbate and adsorption active sites takes place [210, 
211]. Despite the controversies in the accuracy of using chemical reaction originated 
models to describe physical adsorption of the materials, Pseudo first and second order 
remain the most popular mathematical description of adsorption kinetics for the 
comparison of adsorption rate constant and capacity at the equilibrium at a selected time 
point [210, 212]. 
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A number of dye molecules such as methyl-orange, methylene blue and Congo 
red have been used for the study of liquid phase adsorption due to the ease of detection 
methods available. Methylene blue (Figure 2-10) is an anionic dye popularly used for 
the liquid phase adsorption studies of adsorbent materials due to its visibility under UV 
spectrophotometry, and well defined cross-sectional area [185, 213].  
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Figure 2-10 Chemical structure of methylene blue. 
Methylene blue also called 3,7-bis (Dimethylamino)-phenothiazin-5-ium chloride 
has a heterocyclic aromatic structure with two dimethylamine groups [213]. 
 
2.2 Hypothesis and objectives 
The hypothesis of this chapter is that, by combining the adsorptive capacity of 
the phenolic resin derived ACs from MAST Carbon and the large interconnected 
channels that PVA cryogel possess, it is possible to prepare a novel PVA-AC cryogel 
composite suitable for haemoperfusion applications. 
In order to test this hypothesis, a selection of methods was used for the 
preparation of PVA-AC cryogel composites using a tailor made macroporous NovaCarb 
from Mast Carbon Ltd. The macroporous AC was selected after a series of NovaCarb 
beads with increasing pore sizes from micropores (<2 nm in diameter) to macropores 
(120 nm in diameter) were tested for their adsorption capacity for selected liver and 
uraemic toxins (Chapter 4). Techniques including SEM and Confocal imaging, nitrogen 
adsorption, mercury porosimetry and methylene blue adsorption from a liquid phase 
were used to optimise the composite production technique and assess the feasibility of 
preserving AC porosity in the composite material.  
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2.3 Materials 
 PVA1: Poly (vinyl) alcohol (Mowiol® 8-88) (Sigma Aldrich: 81383)  
 PVA2: Poly (vinyl) alcohol (Mw 89,000-98,000) (Sigma Aldrich: 341584) 
 PVA3: Poly (vinyl) alcohol (Mowiol® 18-88) (Sigma Aldrich: 81365) 
 Glutaraldehyde 25% (w/v) solution (Agar Scientific R1012)   
 Hydrochloric acid (Fisher Scientific)  
 Rhodamine B (Sigma-Aldrich R6626) 
 A2 (tailor made macroporous NovaCarb S with particle size 250-500 µm in 
diameter, Mast Carbon International Ltd) 
 A6 (tailor made macroporous NovaCarb S with particle size smaller than 45 µm in 
diameter, Mast Carbon International Ltd) 
2.4 Methods 
2.4.1 Preparation of PVA cryogels and PVA-AC cryogels 
2.4.1.1 PVA cryogel preparation 
Three commercially available PVAs were used in order to determine the most 
appropriate linear PVA polymer for cryogel preparation (Table 2-1). The PVA cryogels 
were synthesised based on the method developed by Plieva et al. [169]. A stock of 10% 
(
w
/v) PVA solution was prepared by dissolving 10 g of PVA in 100 ml distilled water at 
90°C in a heated water bath whilst stirring. Once the PVA was completely dissolved, 
the solution was cooled to room temperature with constant stirring. The PVA stock 
solution was stored at room temperature. To prepare the PVA cryogels, the stock PVA 
solution was diluted to achieve a 5% w/v PVA concentration and adjusted to pH 1.0 - 
1.2 by adding 5 M hydrochloric acid drop wise. Chilled 25% (
w
/v) glutaraldehyde 
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solution in water was added to the pH adjusted PVA solution to give a final 
concentration of 0.5% and 1% (
w
/v).  
The solution was stirred for 30 seconds before 0.5 ml or 1.0ml solution was 
frozen in 7 mm or 9 mm inner diameter glass tube moulds and placed in a -12°C ethanol 
bath for 18 hours. The PVA cryogel columns were defrosted at room temperature and 
washed with water until the pH stabilised at 6.5. The resulting cryogel samples were 
named PVA-GA cryogels. 
2.4.1.2 PVA-AC composite cryogel preparation 
For the PVA-AC composite cryogel preparation, macroporous carbon A2 with 
particle size between 250 to 500 µm diameter and A6 with particle size smaller than 45 
µm diameter was selected. This candidate was chosen as a result of the preliminary 
investigations which suggested the use of AC with macroporous structures showed 
more efficient adsorption of middle to larger molecular weight and albumin bound 
toxins (Chapter 4). 
2.4.1.2.1 Composite preparation method 1 
In method 1, to avoid the pre-formation of the PVA-glutaraldehyde hydrogel, 3% 
(
w
/v) AC beads were mixed with 5% (
w
/v) PVA (pH=1.0) solution until a homogenous 
AC-PVA solution was achieved. Then 0.5% (
w
/v) glutaraldehyde was added to this 
homogenous solution and stirred for a further 30 seconds before 0.5 ml of the resulting 
mixture were transferred to the 7 mm diameter glass tubes and frozen at -12°C for 18 
hours. The composite cryogel samples were defrosted at room temperature and washed 
with water until the pH stabilised at 6.5. The resulting composite samples were named 
PVA-AC-GA cryogels representing the sequence of substances that were added into the 
precursor mixture. 
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2.4.1.2.2 Composite preparation method 2 
In this method, to avoid the adsorption of PVA or glutaraldehyde into the pores 
of the AC beads, composite materials were prepared by mixing the 5% (
w
/v) PVA 
(pH=1.0) solution with 1% (
w
/v) glutaraldehyde to encourage the interaction between 
PVA and glutaraldehyde. After 30 seconds of mixing, 3% (
w
/v) AC beads were added to 
the mixture. The resulting mixture was stirred until a homogenous solution was 
achieved before pipetting 0.5 ml into a 7 mm diameter glass tube and frozen at -12°C 
for 18 hours. The composite cryogel samples were defrosted at room temperature and 
washed with deionised water until the pH stabilised at 6.5. The resulting composite 
samples were named PVA-GA-AC representing the sequence of substances that were 
added in the precursor mixture. 
PVA cryogels were prepared using PVA1 (67000 molecular weight, 88% 
hydrolysis), PVA2 (89000 to 98000 molecular weight, >99% hydrolysis) and PVA3 
(130000 molecular weight, 88% hydrolysis) for analysis to identify the best PVA matrix 
for the haemoperfusion column. A series of composite PVA-AC cryogels were prepared 
as listed in Table 2-1. 
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Table 2-1 List of PVA cryogels and PVA-AC composite cryogels prepared 
PVA1, PVA2 and PVA3 are the poly (vinly) alcohols of different molecular weights; 
GA abbreviates for glutaraldehyde, A6 is a macroporous NovaCarb AC from Mast 
Carbon Ltd. 
Sample code 
PVA used 
Preparation sequence 
Molecular 
weight (
g
/mol) 
Degree of 
hydrolysis 
PVA1-A2 67,000 88% 5% PVA1+0.5% GA+1% A2 
PVA1-GA 67,000 88% 5% PVA1+0.5% GA 
PVA2-GA 89,000 > 99% 5% PVA2+0.5% GA 
PVA3-GA 13,000 88% 5% PVA3+0.5% GA 
PVA1-A6-GA 67,000 88% 5% PVA1+3% A6+0.5% GA 
PVA2-A6-GA 89,000 > 99% 5% PVA2+3% A6+0.5% GA 
PVA1-GA-A6 67,000 88% 5% PVA1+0.5% GA+3% A6 
PVA2-GA-A6 89,000 >99% 5% PVA2+0.5% GA+3% A6 
PVA3-GA-A6 130,000 88% 5% PVA3+0.5% GA+3% A6 
 
2.4.2 Imaging of the PVA and PVA-AC composite cryogels 
2.4.2.1 Scanning electron microscopy (SEM) 
For SEM imaging, the fully hydrated 0.5 ml cryogels were sectioned to a 
thickness of 1mm. To avoid ice formation altering the existing cryogel internal structure, 
prior to the freeze drying processes, low temperature instant freezing was employed to 
encourage the formation of smaller ice crystals [214]. Therefore, sections of cryogel 
samples were frozen at -80°C before being transferred to a Christ freeze dryer to 
remove the water from the cryogel matrix over night at 0.200 mbar vacuum pressures. 
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The freeze-dried cryogel slices were mounted on a sample holder and coated with a 4 
nm thick layer of platinum using a Quorum (Q150TES) coater. The sections were 
examined using a Zeiss Sigma field emission gun SEM (Zeiss NTS) at an accelerating 
voltage of 5 kv. 
2.4.2.2 Confocal microscopy  
Confocal microscopy was used to allow the imaging of the porosity and internal 
structure of cryogels in a hydrated state. For confocal imaging, the fully hydrated 0.5 ml 
cryogels were sliced into 1 mm thick sections and transferred into a 24 well-plate 
containing 1 ml of 100 uM rhodamine B. The cryogel slices were incubated with the 
rhodamine B dye in the dark for 30 mins before rhodamine B solution was removed and 
the sample slices were washed with water until no pink colour was observed. The 
cryogel slices were kept hydrated during the confocal (Leica TCS SP5, Wetzlar, 
Germany) imaging using an excitation wavelength of 562 nm and detected using an 
emission wavelength of 573 nm. The application of laser light however cannot penetrate 
the AC beads, therefore only PVA-GA cryogels were examined under the confocal 
microscope. 
2.4.3 Low temperature nitrogen adsorption analysis  
For nitrogen adsorption analysis, the PVA cryogels and PVA-AC composite 
cryogel samples were frozen at -80°C for 30 minutes before being transferred to the 
Christ freeze dryer overnight under 0.200 mbar vacuum pressure for the removal of 
water present in the cryogel pores.  The AC (A-6) and freeze dried cryogel samples used 
for low temperature nitrogen adsorption analysis were degassed for 24 hours at 80°C 
using an Autosorb-1 gas sorption analyser (Quantachome Instruments, USA). The 
relatively low temperature of 80°C was selected in order to preserve the PVA cryogel 
polymeric structure. The instrument was used to measure the adsorbed and desorbed 
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volumes of nitrogen by the test samples at relative pressures at 77.4 K. The data were 
analysed using Quantachrome data analysis software. The specific surface area was 
calculated using the BET method; the pore size distributions of the materials were 
estimated using both BJH and DFT methods. 
Total pore volume was obtained by converting the volume of nitrogen adsorbed 
at the highest relative pressure to the volume of liquid nitrogen using Equation 2-9. In 
this equation, the pore volume represented by the adsorbed liquid nitrogen volume (Vliq) 
is calculated by multiplying the adsorbed gas nitrogen volume by the ambient pressure 
(Pa), the molar volume of the liquid nitrogen (Vm=34.7cm
3
/mol) and divided by the 
ambient temperature (T). Assuming the cylindrical pore structure, an average pore 
radius rp was then calculated by dividing the total pore volume (Vliq) by the BET 
specific surface area (SBET) and multiply by two (Equation 2-10). 
 
 liq  
 a   ads   m
 
 Equation 2-9 
     
    
    
 Equation 2-10 
 
2.4.4 Mercury porosimetry analysis 
After the low temperature nitrogen adsorption analysis, the samples were used 
for mercury porosimetry analysis performed on the PoreMaster (Quantachome 
Instruments, USA). The meso- and macro- (diameter ≥50 nm) pore size distributions 
of samples were determined by mechanical intrusion of mercury. Data were analysed 
using PoreWin 6.0 software (Quantachome Instruments, USA). 
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2.4.5 Methylene blue adsorption onto solid surfaces of AC, PVA cryogels and 
PVA-AC composite cryogels 
To determine and compare the adsorption capacity of AC, PVA cryogels and 
PVA-AC composite cryogels, experiments to determine the adsorption of methylene 
blue from an aqueous solution were conducted. For methylene blue adsorption studies, 
fully hydrated PVA cryogel and PVA-AC composite cryogel monoliths were sliced into 
0.2 cm
2
 blocks and freeze-dried. The dry PVA cryogel, PVA-AC composite cryogels 
and naked AC beads were carefully weighed and incubated with methylene blue 
solutions for both adsorption kinetics and isotherm determination.  
A set of methylene blue standard solutions with concentrations ranging from 0.1 
to 35 µM (Figure 2-26) were used to obtain the linear regression graph of methylene 
blue concentration against UV adsorption using a UV-2401PC UV-VIS Recording 
Spectrophotometer (Shimadzu, Japan). 
2.4.5.1 Methylene blue adsorption kinetics of AC, PVA cryogels and PVA-AC 
composite cryogels 
To achieve same A6 or PVA-GA contents, adsorbents including 15 mg A6 
carbon beads, 27.5 mg of each PVA cryogels and 42.5 mg of each PVA-AC composite 
cryogels were separately incubated with 10 ml of 1 mM methylene blue solution for 5 
min, 15 min, 30 min, 60 min, 16 hours and 24 hours in a shaking incubator set at 37°C. 
At each time point 40 µl of solution was collected and diluted with 960 µl of water for 
UV spectrometer reading at the wavelength of 664.5 nm. The remaining methylene blue 
concentration in the aqueous solution was calculated from the linear regression model 
(Figure 2-26). The adsorption kinetics of the different materials were examined using 
Pseudo-first-order (Equation 2-7) and Pseudo-second-order (Equation 2-8) models. 
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2.4.5.2 Methylene blue adsorption isotherms of AC, PVA cryogels and PVA-AC 
composite cryogels 
Adsorbents including 15 mg A6, 27.5 mg of each PVA cryogels and 42.5 mg of 
each PVA-AC composite cryogels were separately incubated with 10 ml of methylene 
blue solution with varying concentrations of 1, 2, 4 and 5 mM for 24 hours in a shaking 
incubator at 37°C. Aliquots (1 ml) of solution were collected for each concentration and 
diluted into the 0.1 to 35 µM range for UV detection and quantification against the 
linear regression standard curve (Figure 2-26). The methyl blue adsorption isotherm 
was used for calculation of adsorption capacity using the Langmuir equation (Equation 
2-3) and surface area using the BET equation (Equation 2-4 & Equation 2-5). 
2.5 Results 
2.5.1 Material development 
In initial experiments, AC beads with 250 to 500 µm diameter particle size were 
used for composite preparation. Furthermore, 5% and 7% PVA precursor concentration 
were used with the aim of altering the viscosity of the liquid phase and therefore 
slowing the sedimentation of AC beads during the cryogelation process. However both 
attempts failed to produce a homogenous composite monolith (Figure 2-11). A dense 
black coloured layer at the bottom of all the resulting composite cryogel indicated that 
the large particle size AC failed to remain evenly dispersed in the PVA-glutaraldehyde 
mixture during the cryogelation process, suggesting that the use of smaller AC beads 
was a better alternative future composite production. Therefore AC beads with less than 
45 µm in diameter were used in all the later composite preparations. 
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Figure 2-11 PVA-AC composite cryogel prepared using large AC beads. 
PVA with increased concentration (5% to 7% 
w
/v) were used to increase the 
viscosity of liquid precursor (A). However, separation of the PVA and AC layer 
was seen when both concentrations of PVA were used (B). 
 
2.5.2 Theoretical solid contents in the PVA cryogel and PVA-AC composite 
cryogels 
During the cryogelation process, water acts as both solvent and porogen, 
therefore, the total water content has a direct effect on the total porosity. The 
introduction of AC beads into the PVA-GA cryogelation precursor mixture results in an 
increase of total solid weight and therefore a decrease of water to solid ratio which 
could affect the resulting cryogel porosity. Furthermore the adsorption of water by AC 
could also contribute to the reduction of water content. In addition, the coexistence of 
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A6 carbon beads and glutaraldehyde crosslinked PVA cryogel matrix resulted in a 
reduction of total carbon content when compared to A6 carbon beads alone.  
The polymer and AC content in the cryogelation precursor mixture is listed in 
Table 2-2. In the PVA-GA cryogelation precursor mixture PVA and glutaraldehyde 
accounted for a total of 5.5% (
w
/v) of the aqueous solution, with the remaining 94.5% 
(
w
/v) water content. The introduction of a 3% (
w
/v) A6 into the PVA-AC composite 
cryogel resulted in a decrease in water content to 91.5% (
w
/v). Assuming that the water 
content remained unchanged after cryogelation, the resulting cryogel in its dehydrated 
state would consist of 100% (
w
/w) polymer in the case of the PVA-GA cryogel. In the 
case of PVA-AC composite cryogel, the composition would be 65% (
w
/w) polymer and 
35% (
w
/w) A6 carbon beads. 
 
Table 2-2 Polymer and AC content in the PVA cryogel and PVA-AC composite 
cryogel 
The composition of the PVA, glutaraldehyde and A6 (
w
/v) used for cryogelation is 
listed under the hydrated state. The polymer and AC content in the PVA cryogel 
and PVA-AC solid content is listed under the dehydrated state (
w
/w). The polymer 
(PVA-GA) and A6 contents were calculated based on the composition of PVA, 
glutaraldehyde and A6 prepared for the cryogelation. 
 Hydrated state  Dehydrated State 
 PVA (%) GA (%) A6 (%) H2O (%)  PVA-GA (%) A6% (%) 
PVA-GA 5 0.5 0 94.5  100 0 
PVA-AC 5 0.5 3 91.5  65 35 
A6 N/A N/A N/A N/A  0 100 
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2.5.3 Morphology of the PVA and PVA-A6 composite cryogels 
All of the prepared cryogels were able to maintain their shape without additional 
support (Figure 2-12). PVA-GA cryogels were white coloured columns with no visual 
difference observed among the PVA-GA cryogels prepared from PVA with different 
molecular weights and degree of hydrolysis (Figure 2-12 A, B & C). With the 
incorporation of 3% (
w
/v) A6 beads, the PVA-A6 composite cryogels exhibited an 
evenly distributed intense black colour (Figure 2-12 A, B & C). There was no visual 
difference observed among the PVA-AC cryogels. All of the PVA cryogels and PVA-
A6 cryogel columns retained large amounts of water which upon application of pressure 
was squeezed out of the column, resulting in a flattened column with a reduced height. 
However, when the pressure was removed, the water re-entered the cryogel allowing the 
cryogels to re-swell back to their original shape and height. 
The A6 beads were responsible for the black colour of the PVA-AC composite 
cryogels. Illustrated in Figure 2-13 is an example of the observed increase of black 
colour intensity in the PVA-AC composite cryogel with the increase in A6 content. The 
PVA2-GA cryogel (0% A6) demonstrates a white colour, and with incorporation of 
increasing A6 content from 0.3% (
w
/v) to 2% (
w
/v), the black colour intensity increased. 
It was discovered that it was possible to incorporate up to 3% (
w
/v) into the 5% (
w
/v) 
PVA and 0.5% glutaraldehyde cryogel matrix without subsequent release of unattached 
A6 beads from the composite matrix. However, the black colour intensity did not 
increase visually when 3% A6 was incorporated into the PVA2-GA cryogel matrix 
compared to the composite with 2% A6. In addition, the PVA2-GA-A6 composite 
cryogel with only 0.3% A6 content appeared less homogenous than all the other 
composite cryogels.  
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Figure 2-12 Images of PVA cryogels and PVA-AC composite cryogels. 
A: PVA1-GA cryogel prepared by crosslinking of PVA1 polymer (88% hydrolysis, 
molecular weight =60,000); B: PVA2-GA cryogel prepared by crosslinking of 
PVA2 (>99% hydrolysis, molecular weight =89,000) long chain polymer with 
glutaraldehyde, C: PVA6-GA cryogel was prepared by crosslinking of PVA3 
polymer (88% hydrolysis, molecular weight =130,000) using glutaraldehyde, D: 
PVA1-GA-A6 was prepared by incorporating A6 beads into PVA1-GA cryogel, E: 
PVA2-GA-A6 was prepared by incorporating A6 beads into the PVA2-GA 
cryogels and F: PVA3-GA-A6 cryogels were prepared by incorporated A6 beads 
into the PVA3-GA cryogels. The PVA cryogels (A, B & C) prepared from different 
molecular weight were white coloured columns with no visible difference in their 
morphology from each other. The entire selection of PVA-AC composite columns 
(D, E &F) exhibited an evenly distributed black colour; no visual difference was 
observed among the PVA-A6 composite columns. 
A
D
CB
E F
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Figure 2-13 Morphology of hydrated PVA2-GA cryogel (0% A6) and PVA2-GA-
A6 (0.3 to 3% A6) composite cryogels. 
An increase in the A6 bead content from 0.3% (
w
/v) to 2% (
w
/v) resulted in an 
enhancement of the black colour intensity in the resulting composite PVA2-GA-A6 
cryogel columns. No visual difference in the black intensity was observed when the 
A6 content increased from 2% to 3% (
w
/v). 
 
2.5.4 SEM imaging of the PVA, A6 and PVA-A6 composite cryogels 
All SEM micrographs presented in this section are representative of a number of 
micrographs taken of replicates of each material. The SEM micrograph of PVA1-GA 
cryogel illustrates the presence of channels with a diameter of approximately 20 µm 
formed in the voids of the dense PVA polymeric walls (Figure 2-14 A). In addition, the 
channels do not have a uniform size or cylindrical shape. Instead, channels appear to 
narrow into smaller necks or widen into larger openings. The high magnification image 
(Figure 2-14 B) revealed the PVA cryogel wall consists of a dense centre with porous 
outer surface structure. The cross sectioned area revealed a smooth and regular 
polymeric internal wall structure. 
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Figure 2-14 Scanning electron micrograph of freeze-dried PVA1-GA cryogel. 
Image A illustrates the presence of large channels (indicated by red arrows) in the 
cryogel surrounded by a dense polymer wall. Image B is a close up view of PVA1-
GA cryogel wall where porous outer surface structures can be observed on the 
outer surface (circled) of the polymer wall, while a dense polymeric centre (blue 
arrow) can be observed in the cross section of wall structure. 
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The Scanning electron micrograph of PVA2-GA cryogel (Figure 2-15 A) shows 
this cryogel matrix consisted of a large number of narrow, elongated channels with 
porous polymer wall within the cryogel sample. A smooth thin polymer wall structure 
was also observed under high magnification (Figure 2-15 B).  
 
Figure 2-15 Scanning electron micrograph of freeze dried PVA2-GA cryogel. 
Image A demonstrates the presence of narrow channels (red arrows) in the cryogel, 
image B reveals the thin but dense wall structure (blue arrow).  
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The Scanning electron micrograph of PVA3-GA cryogel (Figure 2-16 A) 
indicated the presence of channels with greater than 20 µm widths. Similar to PVA1-
GA cryogel, the PVA3-GA cryogel sample structure was also supported by the dense 
PVA polymer wall with a porous outer surface structure (Figure 2-16 B). 
 
Figure 2-16 Scanning electron micrograph of freeze-dried PVA3-GA cryogels. 
Large channels (red arrows) are present in the PVA3-GA cryogel (A); the PVA3-
GA polymer wall consists of a porous outer surface (circled blue) with a dense 
smooth internal structure (blue arrow) (B). 
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The spherical beaded morphology of the A6 beads was revealed by their SEM 
micrograph (Figure 2-17 A). Figure 2-17 B illustrated that the A6 beads have a smooth 
outer shell with meso- and macro- pores, and a nanoscale internal structure consisting of 
aggregates of spherical AC beads, with the voids between the aggregates forming a 
large number of internal macropores.  
The addition of A6 carbon beads in the cryogel matrix appears to reduce the 
channel size of the PVA1-GA-A6 composite cryogel in Figure 2-18 A, when compared 
to the PVA1-GA cryogel SEM micrographs (Figure 2-14 A). The SEM micrographs in 
Figure 2-18 B also suggested that the A6 carbons were securely held in the PVA1-GA 
polymer matrix, exposing the A6 beads on the dense polymer wall. 
The SEM micrographs of PVA2-GA-A6 composite cryogel (Figure 2-19 A) 
demonstrated that the composite matrix consisted of channels less than 10 µm in width 
and A6 beads were embedded within the PVA polymer matrix. The size of the A6 beads 
appeared to be larger than the polymer matrix pore sizes; therefore, the beads were held 
in between the pores of the composite cryogel rather than exposed on the cryogel wall 
(Figure 2-19 B) potentially this could result in blocking of some of the channels in the 
composite matrix for whole blood passage. 
Clear, large channels of greater than 20 µm were observed in the PVA3-GA-A6 
composite cryogel SEM micrographs (Figure 2-20 A). The A6 beads were held on the 
polymer walls, while large carbon surfaces were exposed on the polymer wall matrix 
(Figure 2-20 B). 
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Figure 2-17 Scanning electron micrograph of A6 beads. 
A6 beads were spherical, with less than 30 µm diameter particle size (A). The 
beads exhibit a smooth outer surface (blue arrow) with a number of meso- and 
macro-pores (red arrows), and a nanoscale internal structural consisting of 
aggregates (circulated) of spherical carbon particles (B). 
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Figure 2-18 Scanning electron micrograph of freeze-dried PVA1-GA-A6 cryogel. 
Large channels (red arrows) remain present in the cryogel matrix with the 
spherical A6 beads (black arrows) scattered within the PVA3 cryogel matrix (A), 
the A6 beads (red arrow) are held on the PVA polymer wall (blue arrow) with 
exposed sites (B) 
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Figure 2-19 Scanning electron micrograph of freeze-dried PVA2-GA-A6 cryogel. 
Channels (red arrows) less than 10 µm width are rarely observed in the SEM 
images of freeze-dried PVA2-GA-A6 cryogels (A), the images also indicate that the 
spherical A6 beads (black arrows) were buried within the PVA cryogel (blue 
arrows) matrix (B) 
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Figure 2-20 Scanning electron micrograph of freeze-dried PVA3-GA-A6 cryogel. 
SEM images of freeze-dried PVA3-GA-A6 cryogels indicate that large channels 
(red arrows) remain present in the cryogel matrix, with the spherical A6 beads 
(black arrows) scattered in the PVA cryogel matrix (A), the A6 beads are held on 
the PVA polymer wall (blue arrow) with apparently exposed sites (circulated) (B). 
  
 86 
 
2.5.5 Confocal imaging of the PVA and PVA-A6 composite cryogels 
In order to examine the PVA-GA cryogel materials in their hydrated state, a 
confocal microscope was used to image the PVA cryogel prepared from three different 
grades of PVA polymers (refer to Table 2-1). Figure 2-21 illustrates that large pores 
were present in the PVA1-GA cryogel, and the glutaraldehyde crosslinked PVA1 
polymer wall structure was fluorescent blue under laser excitation.  
 
Figure 2-21 Representative confocal microscopy image of hydrated PVA1-GA 
cryogel stained with rhodamine B fluorescence dye 
The areas of blue fluorescence are the PVA-GA cryogel polymeric wall and the 
dark areas in the image are the channels of the cryogel filled with water which 
shows no fluorescence. 
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Figure 2-22 is a confocal microscopy image of PVA2-GA cryogel prepared by 
crosslinking 5% (
w
/v) greater than 99% hydrolysis degree, molecular weight 89,000 
PVA2 polymer using 0.5% (
w
/v) glutaraldehyde. Represented in Figure 2-22, PVA2-GA 
comprised a dense wall structure in blue fluorescence with a narrow and elongated dark 
coloured channel structure. The image illustrated the presence and morphology of the 
channels of this cryogel which were approximately 5 µm wide and 20 µm long and 
were smaller than both the PVA1-GA cryogel (Figure 2-21) and PVA3-GA cryogel 
(Figure 2-23).  
 
Figure 2-22 Confocal image of hydrated PVA2-GA cryogel stained with rhodamine 
B fluorescence dye. 
The blue colour of the hydrated PVA2-GA cryogel wall can be observed in the 
majority of the image; with small dark voids representing the channels within the 
matrix. 
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Figure 2-23 is a confocal microscopy image of hydrated PVA3-GA cryogel 
prepared by crosslinking 5% (
w
/v) 88% hydrolysed, 130,000 molecular weight PVA3 
polymers using 0.5 (
w
/v) glutaraldehyde. The image illustrated that the PVA3-GA 
cryogel consisted of a dense PVA3-GA wall structure visualised with blue fluorescence 
and large internal channels (approximately 50 µm width) comprised of dark voids 
surrounded by the walls. 
 
Figure 2-23 Representative confocal microscopy image of hydrated PVA3-GA 
cryogel stained with rhodamine B fluorescent dye. 
The blue fluorescence dye stains the PVA3-GA cryogel wall, and the dark areas 
are the channels within the matrix. 
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2.5.6 Nitrogen adsorption analysis of PVA, A6 and PVA-A6 composite 
cryogels 
Imaging techniques employed in this chapter including SEM have provided high 
resolution images of the internal structure of PVA cryogel, AC and PVA-AC composite 
cryogels. However, the heterogeneity in the channel size and shape of the cryogel 
materials revealed by the SEM micrographs and confocal images suggests that imaging 
techniques cannot be used to accurately quantify material porosity and surface area. 
Therefore, a nitrogen adsorption analysis technique was employed to quantify the 
surface area, pore volume and micro- and mesopore size distribution of A6 carbon, 
PVA cryogel and PVA-AC composite cryogels, by utilising mathematical models such 
as BET, DFT and BJH.  
The nitrogen adsorption textural analysis results in Table 2-3 list the total pore 
volume, BET surface area, micro- and meso-pore diameter and volume of AC alone 
(A6), PVA cryogels prepared by crosslinking of three different molecular weight and 
hydrolysis degree PVA polymers (Table 2-1) and AC bearing composite cryogels 
prepared using different methods described in section 2.4.1.2.  
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Table 2-3 Low temperature nitrogen adsorption analysis of selected AC beads, 
freeze-dried PVA cryogels and PVA-AC composite cryogels. 
The specific surface area (SBET) was calculated using the BET method; the total 
pore volume (Vp), the micropore diameter (D DFT micropore) and volume (V DFT micro) 
were calculated using the DFT method; the BJH method was used for mesopore 
diameter (D BJH meso) and volume (V BJH meso) calculation. A6 is a macroporous AC 
beads of less than 45 µm in diameter; PVA-GA cryogels are the glutaraldehyde 
crosslinked PVA cryogels prepared using three different grades of PVA (PVA1, 
PVA2 and PVA3); PVA-AC-GA are the AC bearing composite cryogel prepared 
by adding glutaraldehyde to the PVA-AC mixture prior to the cryogelation and 
PVA-GA-AC are the AC bearing composite cryogel prepared by adding the AC to 
PVA-GA mixture prior to the cryogelation. 
Adsorbents 
Vp 
(cm
3
/g) 
SBET 
(m
2
/g) 
D DFT mico 
(nm) 
V DFT micro 
(cm
3
/g) 
D BJH meso 
(nm) 
V BJH meso 
(cm
3
/g) 
PVA1-GA 0.38 68.62 == == 3.37 0.38 
PVA2-GA 0.30 70.68 == == 3.39 0.31 
PVA3-GA 0.20 78.70 == == 3.39 0.21 
A6 1.18 1070.15 0.70 0.95 3.10 0.74 
PVA1-A6-GA 0.51 407.65 0.60 0.47 6.52 0.41 
PVA2-A6-GA 0.44 315.79 0.60 0.37 3.37 0.33 
PVA1-GA-A6 0.56 356.98 0.62 0.51 3.38 0.44 
PVA2-GA-A6 0.33 321.70 0.60 0.28 3.38 0.21 
PVA3-GA-A6 0.39 432.08 0.68 0.34 3.78 0.23 
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2.5.6.1 Nitrogen adsorption by PVA cryogels 
PVA cryogels including PVA1-GA, PVA2-GA and PVA3-GA, were prepared 
by crosslinking different grades of commercially available PVA (PVA1- 67,000 Mw & 
88% hydrolysis degree; PVA2- 89,000 Mw & >99% hydrolysis degree and PVA3- 
130,000 Mw & 88% hydrolysis degree) with glutaraldehyde without the incorporation 
of AC. These PVA cryogels showed a relatively low total pore volume (Vp between 
0.1986 to 0.3817 cm
3
/g) and relatively low surface area (SBET between 24.79 and 70.68 
m
2
/g) measured by nitrogen adsorption analysis. In addition, no micropores were 
calculated in the PVA cryogels alone when the DFT method was used. The BJH method 
was used to calculate the presence of mesopores with a pore diameter below 4 nm in 
PVA-GA cryogels. The PVA1-GA cryogel has a mesopore volume of 3.84 cm
3
/g, 
which is the highest amongst all the PVA-GA cryogels studied. However, the PVA3-
GA cryogel showed the highest surface area of 78.683 m
2
/g determined by the BET 
method. 
2.5.6.2 Nitrogen adsorption by activated carbon  
A6 beads were used for the preparation of PVA-AC composite monoliths and 
therefore were tested as reference for the preservation of AC porosity in the composite 
materials. Among all the tested materials, the highest specific surface area (1070.15 
m
2
/g) was found for the A6 beads using nitrogen adsorption analysis calculated using 
the BET method described in section 2.4.3 
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2.5.6.3 Nitrogen adsorption by PVA-AC composite cryogels 
PVA-AC composite cryogels were prepared using two methods described in 
section 2.4.1.2. PVA-AC-GA composite cryogels were prepared by mixing the A6 
carbon beads with PVA polymers before the addition of cryogelation crosslinker-
glutaraldehyde. In contrast, PVA-GA-AC composite cryogels were prepared by 
incorporating the A6 beads into the PVA-GA mixture before the cryogelation. In order 
to select the most appropriate grade of PVA for the composite preparation, all three 
PVA with different degree of hydrolysis and molecular weight were all used for the 
composite preparation respectively. The introduction of A6 into the PVA-GA cryogel 
matrix increased the specific surface area in the composite material when compared to 
the PVA-GA cryogel alone, making the composite material specific surface area as high 
as 432.08 m
2
/g (Table 2-3).  
Although no micropores were observed in the PVA-GA cryogels, the volume of 
micropores found in the A6-containing composite material was as high as 0.508 cm
3
/g 
(PVA1-GA-A6). The micropore diameter and volume in the composite materials was 
smaller than those for the A-6 alone. The mean mesopore diameter for all of the 
materials was very similar ranging from 3.1 to 4.4 nm, apart from the PVA1-A6-GA 
which displayed a mean mesopore diameter of 6.5 nm, and the A6 material which 
possessed mesopores with a mean diameter of 3.1 nm and a pore volume of 0.740 cm
3
/g 
(Table 2-3). 
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2.5.7 Mercury porosimetry structural analysis 
The major advantage of nitrogen adsorption analysis is the utilisation of nitrogen 
molecules whose small size enables their penetration into materials with a pore size of 
less than 1 nm. However, this advantage also limits the use of nitrogen adsorption in the 
quantification of large mesopores, macropores and the large channels such as the ones 
found in cryogel materials. Therefore, quantification methods such as mercury 
porosimetry can be applied to quantify the pore diameters and internal porosities larger 
than 2 nm in diameter by assuming a uniform cylindrical pore structure in the tested 
materials. As demonstrated in the SEM and confocal images, PVA cryogels and PVA-
AC composite cryogels have internal channels in the micrometer size range (section 
2.5.4 and 2.5.5). This cannot be quantified by the nitrogen adsorption analysis; therefore, 
mercury porosimetry can be employed for their quantification. Thus, the mercury 
porosimetry technique was used after the materials were tested by nitrogen adsorption 
analysis, to gain a more comprehensive evaluation of material internal porous structure. 
The mercury porosimetry analysis results in Table 2-4 summarised the total pore 
volume, surface area, macropore diameter and volume of AC (A6), PVA-GA cryogels 
and AC bearing composite material PVA-A6 composite cryogels. In addition, the 
diameter of the large channels in the PVA cryogel and AC bearing composite cryogels 
prepared using different methods (described in section 2.4.1.2.) were determined (Table 
2-4) . 
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Table 2-4 Structural characteristics of the different PVA-GA cryogels, PVA-AC 
composite cryogels and AC beads used in the composite synthesis. 
Total intruded mercury volume was represented by VHg; S is the calculated surface 
area; Dmacro and Vmacro represent the diameter and total volume of the macropores. 
Dchannel and Vchannel are the diameter and volume of the channels in the cryogel 
materials. A6 is a macroporous AC bead with less than 45 µm in diameter; PVA-
GA cryogels are the glutaraldehyde crosslinked PVA cryogels prepared using 
three different grades of PVA (PVA1, PVA2 and PVA3); PVA-AC-GA are the AC 
bearing composite cryogel prepared by adding glutaraldehyde to the PVA-AC 
mixture prior to the cryogelation and PVA-GA-AC are the AC bearing composite 
cryogel prepared by adding the AC to PVA-GA mixture prior to the cryogelation. 
(N/P=not present) 
Adsorbents 
V Hg 
(cm
3
/g) 
S (m
2
/g) 
D macro 
(nm) 
V macro 
(cm
3
/g) 
D channel 
(µm) 
Vchannel 
(cm
3
/g) 
PVA1-GA 9.62 4.68 N/P N/P 17.90 45.52 
PVA2-GA 8.31 54.88 N/P N/P 5.83 16.64 
PVA3-GA 12.91 22.05 N/P N/P 17.80 65.41 
A6 3.52 84.50 96.94 10.76 N/P N/P 
PVA1-A6-GA 6.68 32.25 84.72 2.53 21.18 24.29 
PVA2-A6-GA 6.84 57.58 89.81 2.66 5.87 15.13 
PVA1-GA-A6 8.58 26.30 81.39 2.29 24.05 29.14 
PVA2-GA-A6 7.95 61.80 88.24 3.06 5.89 19.60 
PVA3-GA-A6 9.58 51.63 86.11 4.14 15.39 49.34 
 
  
 95 
 
2.5.7.1 Mercury porosimetry analysis of PVA cryogel alone 
The pore size distribution of PVA cryogels prepared from PVA1 (67,000 Mw & 
88% hydrolysis degree), PVA2 (89,000 Mw &>99% hydrolysis degree) and PVA 3 
(130,000 Mw & 88% degree of hydrolysis), were determined by mercury intrusion 
porosimetry analysis. The results calculated from the intruded mercury volume and 
pressure required for the intrusion indicated that a negligible amount of macropores 
smaller than 1000 nm were found in all three PVA cryogels (Table 2-4).In addition, the 
channels in the PVA2-GA cryogel sample were less than 6 µm in diameter, whilst the 
PVA1-GA and PVA3-GA cryogel which were produced from 88% hydrolysed PVA 
contained channels had a diameter of approximately 18 µm. The overlay of the pore size 
distribution of PVA-GA cryogels prepared from PVA1, PVA2 and PVA3 in Figure 
2-24 illustrated that the use of 88% hydrolysed PVA (PVA1 & PVA3) in the 
cryogelation process produced larger channels with a narrower size distribution and a 
mean diameter of 17µm.  
2.5.7.2 Mercury porosimetry analysis of AC beads and PVA-AC composite cryogel 
In order to determine the preservation of AC meso- or macroporosity after 
incorporation into the PVA cryogel matrix, A6 beads were analysed by mercury 
porosimetry. A total macropore volume of 10.76 cm
3
/g (mean diameter 96.94 nm) was 
found in the A6 beads (Table 2-4). The addition of A6 in the composite materials was 
responsible for the appearance of macropores in the range of 80-90 nm into the material 
matrix (Figure 2-25). However, a reduction in the macropore size and volume in the 
composite cryogels was observed in Figure 2-25 compared to the macropore volume of 
A6 beads alone. The addition of A6 into the cryogel also resulted in the reduction of 
total pore volume in the material calculated from the total intrusion of the mercury 
compared to the cryogel alone. Amongst all the composite materials PVA3-GA-A6 
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possessed the highest mesopore volume (4.1 cm
3
/g) and a narrower distribution of 
channel size (diameter 15.4 µm) compared to the composite cryogels prepared from 
PVA1 (24.0 µm diameter) and PVA2 (5.9 µm diameter) (Table 2-4). 
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Figure 2-24 Pore size distribution of PVA-GA cryogels determined by mercury 
porosimetry. 
Pore size distribution of PVA-GA cryogels prepared from PVA1 (67000 molecular 
weight, 88% hydrolysed), PVA2 (89’000 molecular weight, >99% hydrolysed) and 
PVA3 (130000 molecular weight and 88% hydrolysed) were calculated from the 
pressure required for the intrusion of mercury and the volume of intruded 
mercury. On the pore size distribution graph, the calculated cryogel channel 
diameter was plotted against the volume of the channels. 
 
 97 
 
10 100 1000 10000 100000 1000000
0
20
40
60
PVA2-GA-A6
PVA3-GA-A6
PVA1-GA-A6
A6
Cryogel channel
Pore diameter (nm)
d
v
/d
(l
o
g
d
) 
(c
m
3
/g
)
32 40 50 63 79 100 126 158 200 251
0
5
10
PVA2-GA-A6
PVA3-GA-A6
PVA1-GA-A6
A6
 
Figure 2-25 Pore size distribution of AC (A6) and AC bearing composite cryogels 
(PVA1-GA-A6, PVA2-GA-A6 and PVA3-GA-A6). 
On the pores size distribution graph, the calculated cryogel channel diameter was 
plotted against the volume of the channels. The incorporation of A6 beads into the 
PVA-GA cryogel matrix resulted in a shift of macropore size on the AC bead from 
100 nm to 80 nm. 
 
2.5.8 Methylene blue adsorption from aqueous phase 
The quantification of the porosity of the A6, PVA-GA cryogels and PVA-AC 
composite cryogels carried out by nitrogen adsorption and mercury porosimetry was 
carried out using dehydrated materials. However, cryogel materials such as PVA-GA 
cryogels and PVA-AC composite cryogels swell upon contact with water, therefore an 
alteration in the surface area and porosity may occur. In order to determine material 
adsorptive properties in the hydrated state, adsorption of methylene blue from an 
aqueous phase was carried out on the materials previously tested by nitrogen adsorption 
and mercury porosimetry. 
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As illustrated in Figure 2-26, a linear relationship (R
2
=0.9825) between the UV 
absorbance at 664.5 nm wavelength and methylene blue concentration up to 40 µM was 
observed. The linear regression equations obtained though this standard curve was were 
used for determination of methylene blue concentrations in the plasma samples before 
and after incubation with ACs. 
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Figure 2-26 Linear regression plot of methylene blue concentration against 
absorbance of ultraviolet light at a wavelength of 664.5 nm. 
This linear regression curve yields an intercept of 0.6762 and a slope of 0.05568, 
and the fitness of the curve to the experimental readings were 0.9825 (R
2
) (Mean 
n=3, ± SEM) 
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2.5.8.1 Adsorption isotherms 
2.5.8.1.1 Comparing the two composite preparation methods 
In order to investigate the influence of composite preparation methods on 
adsorptive porosity, methylene blue adsorption by PVA-AC prepared from different 
grades of PVA (PVA1 or PVA2) were compared. The methylene blue adsorption 
isotherms (Figure 2-27) illustrated that the PVA1-GA cryogel alone adsorbed negligible 
amounts of methylene blue in comparison to the A6 carbon bead bearing composite 
cryogels PVA1-A6-GA and PVA1-GA-A6. In addition, the isotherms demonstrated that 
the PVA1-A6 composite cryogel prepared by the addition of glutaraldehyde before AC 
bead addition (PVA1-GA-A6), had higher methylene blue adsorption capacity 
compared to the composite prepared by adding AC before glutaraldehyde (PVA1-A6-
GA).  
Similar methylene blue adsorption isotherms were observed when PVA2 
(89,000 Mw & >99% hydrolysis) was used for the preparation of PVA2 cryogel and 
PVA2-A6 composite cryogels. Illustrated in Figure 2-28 are the adsorption isotherms of 
PVA2-GA cryogel, PVA2-A6-GA composite cryogel prepared by premixing the A6 
with PVA2 polymer before the addition of glutaraldehyde for crosslinking cryogelation, 
and PVA2-GA-A6 composite cryogel prepared by mixing the PVA2 and glutaraldehyde 
prior to the addition of A6 carbon beads. The results demonstrated that the adsorption of 
methylene blue by PVA2-GA cryogel was close to base line at a value of 0.0068 g/g. In 
contrast, the methylene blue adsorption by AC bearing composite cryogels PVA2-A6-
GA and PVA2-GA-A6 reached 0.0780 and 0.08395 g/g respectively. Furthermore, the 
isotherms in Figure 2-28 demonstrated that the PVA2-A6 composite cryogel prepared 
by addition of glutaraldehyde before AC bead addition (PVA2-GA-A6), had higher 
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methylene blue adsorption capacity compared to the composite prepared by adding AC 
before glutaraldehyde (PVA2-A6-GA). 
 
0.0000 0.0005 0.0010 0.0015
0.00
0.05
0.10
0.15
PVA1-GA
PVA1-GA-A6
PVA1-A6-GA
Cqe (g/ml)
q
e
(g
/g
)
 
Figure 2-27 Methylene blue adsorption isotherms for PVA1-GA cryogel and 
PVA1-AC composites prepared using two different methods. 
Methylene blue adsorption was performed by incubating 42.5 mg freeze dried 
composite cryogels and 27.5 mg PVA1-GA cryogel with 10 ml of methylene blue 
aqueous solutions with concentration 1, 2, 4 and 5 mM at 37°C for 24 hours. The 
equilibrium methylene concentration (Cqe) was plotted against the methylene blue 
adsorption at the equilibrium (qe). (Mean n=4, ± SEM) 
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Figure 2-28 Methylene blue adsorption of PVA2-GA cryogel and PVA2-AC 
composites prepared using two different methods. 
Methylene blue adsorption was performed by incubating 42.5 mg freeze dried 
composite cryogels and 27.5 mg PVA2-GA cryogel with 10 ml of methylene blue 
aqueous solutions with concentration 1, 2, 4 and 5 mM at 37°C for 24 hours. The 
equilibrium methylene concentration (Cqe) was plotted against the methylene blue 
adsorption at the equilibrium (qe) (Mean n=4 ± SEM). 
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2.5.8.1.2 Comparing the PVA used for composite preparation 
To compare the influence of increasing PVA molecular weight towards the 
preservation of AC adsorptive capacity in the resulting PVA-AC composite cryogels, 
three PVA polymers with increasing molecular weight (PVA1-Mw=67,000, PVA2-
Mw=89,000 & PVA3-Mw=130,000) were used to prepare composite cryogels using the 
composite cryogel preparation method described in section 2.4.1.2.2. 
The adsorption isotherm of methylene blue by PVA cryogels (PVA1-GA, 
PVA2-GA and PVA3-GA) and AC bearing PVA-AC composite cryogels (PVA1-GA-
A6, PVA2-GA-A6 and PVA3-GA-A6) is illustrated in Figure 2-29. PVA cryogels alone 
including PVA1-GA, PVA2-GA and PVA3-GA showed methylene blue adsorption as 
low as 0.001 g/g. With the incorporation of A6 into the cryogel matrix, the resulting 
PVA1-GA-A6, PVA2-GA-A6 and PVA3-GA-A6 composite cryogel demonstrated a 
huge increase in the methylene blue adsorption to values as high as 0.1296 g/g (by 
PVA3-GA-A6). In addition, when higher molecular weight PVA polymer was used to 
prepare PVA-AC composites, an improved methylene blue adsorption capacity was 
observed (Figure 2-29). For example, composite cryogel prepared using PVA2 polymer 
showed a higher methylene blue adsorption of up to 0.1219 g/g compared to the 
composite cryogel prepared using PVA1 polymer which showed up to 0.08395 g/g 
methylene blue adsorption. Furthermore, when the PVA3 was used for composite 
preparation, the highest methylene blue adsorption of up to 0.1296 g/g was observed 
when compared to the composites prepared from PVA1 and PVA2. 
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Figure 2-29 Methylene blue adsorption of cryogel and composites prepared using 
PVA with increased molecular weight. 
Methylene blue adsorption was performed by incubating 42.5 mg freeze dried 
PVA-GA-A6 composite cryogels and 27.5 mg PVA-GA cryogel with 10 ml of 
methylene blue aqueous solutions with concentration 1, 2, 4 and 5 mM at 37°C for 
24 hours. The equilibrium methylene concentration (Cqe) was plotted against the 
methylene blue adsorption at the equilibrium (qe). (Mean n=4, ± SEM) 
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2.5.8.1.3 Methylene blue adsorption capacity and adsorbent surface area 
Listed in Table 2-5 is the summary of methylene blue adsorption isotherms 
obtained from the PVA-GA cryogels, A6 carbon beads alone and PVA-A6 composite 
cryogels when the Linewearver-Burk equation (Equation 2-6) was applied. Among all 
the tested materials, as may be expected, A6 carbon beads showed the highest capacity 
for methylene blue adsorption of 0.419 g/g of adsorbent, and PVA-GA cryogels showed 
limited adsorption of the methylene blue in the range of 0.001 to 0.008 g/g (Table 2-5). 
In addition, the methylene blue adsorption data of PVA1-GA, PVA1-A6-GA, PVA1-
GA-A6 cryogels and PVA2-GA cryogel had less than 20% probability of fitting into a 
linear regression model (Table 2-5). Therefore the Linewearver-Burk equation cannot 
be used for the calculation of maximum adsorption capacity and adsorption constant of 
these materials. The adsorption of methylene blue by the composite materials ranged 
from 0.075 to 0.188 g/g, with PVA1-A6-GA showing the lowest monolayer capacity 
(0.075 g/g) and PVA3-GA-A6 showing the highest monolayer capacity (0.188 g/g). 
The material specific surface area calculated by assuming the qm as the 
monolayer capacity indicated that the A6 beads had the highest specific surface area of 
1555.82 m
2
/g, the specific surface area of the composites ranged from 278.30 to 697.76 
m
2
/g. The methylene blue adsorption isotherms of materials prepared from PVA1 
polymer including PVA1-GA, PVA1-A6-GA and PVA1-GA-A6 did not fit the 
Linewearyer-Burk model, their surface area calculated from the monolayer capacity can 
only be used as an approximate indication. In addition, PVA-AC composite cryogels 
produced from PVA polymer with highest molecular weight (130,000 for PVA3) 
showed the highest methylene blue monolayer capacity of 0.1888 g/g, and therefore, 
resulted in a relatively higher surface area (697.76 m
2
/g) accessible by the methylene 
blue molecule from aqueous solution.  
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Table 2-5 Methylene blue adsorption of PVA cryogel, A6 carbon beads and PVA-
A6 composite cryogel and the material surface area calculated from BET equation. 
The methylene blue adsorption by PVA-GA cryogel prepared by crosslinking of 
three different grades of commercially available PVA polymers (PVA1, PVA2 and 
PVA3), A6 carbon beads and AC bearing PVA-A6 composite cryogels. The 
Lineweaver-Burk equation was applied to the methylene blue adsorption isotherm 
of the test materials to yield a linear regression plot with slope, intercept and 
fitness (R
2
) listed In addition, the methylene blue monolayer capacity (qm) was 
calculated from 
 
     
 and the adsorption isotherm constant (K) was calculated 
from 
 
 m
 The surface area (S) was then calculated using a BET equation based on 
the monolayer capacity qm. 
Adsorbent Slope Intercept R
2
 qm (g/g) K S (m
2
/g) 
PVA1-GA -1.18 309.77 0.00007* 0.003 -262.76 11.98 
PVA2-GA 49.94 121.81 0.77910* 0.008 2.44 30.47 
PVA3-GA 11.29 752.09 0.99450 0.001 66.59 4.93 
A-6 0.01 2.39 0.99340 0.419 188.14 1555.82 
PVA1-A6-GA 0.27 13.34 0.58090* 0.075 50.00 278.30 
PVA2-A6-GA 0.21 9.64 0.99000 0.104 45.37 384.95 
PVA1-GA-A6 0.02 12.16 0.32910* 0.082 669.29 305.32 
PVA2-GA-A6 0.18 8.22 0.99910 0.122 45.97 451.67 
PVA3-GA-A6 2.68 5.32 0.97530 0.188 1.98 697.76 
* R
2
 less than 0.9, therefore less than 90% chances of the experimental data fitting 
the Pseudo-first-order model 
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2.5.9 Methylene Blue Adsorption Kinetics 
Adsorption kinetic experiments are designed to gain an understanding of the 
adsorption rate of molecules from a liquid phase onto a solid surface. In order to 
determine the preservation of AC adsorptive rate and capacity before and after its 
incorporation into the PVA cryogel matrix, methylene blue was used as a model 
molecule in the adsorption kinetic studies. Furthermore, the use of different molecular 
weight PVA in the preparation of PVA-AC composite cryogels was also compared in 
this study.  
The adsorption of methylene blue over a 1440 minute (24 hours) period by A6 
carbon beads, PVA-GA cryogel prepared from three different grades of PVA polymers 
(PVA1, PVA2 and PVA3) and AC bearing PVA-A6 composite cryogels (PVA1-GA-A6, 
PVA2-GA-A6 and PVA3-GA-A6, as described in the methods section 2.4.1.2) are 
shown in Figure 2-30. Methylene blue adsorption by A6 carbon beads occurred in a 
time dependent manner over the 24 hour incubation period when the methylene blue 
adsorption reached 0.198 g/g. In contrast the PVA-GA cryogel sample prepared from all 
three different grades of PVA polymers showed negligible adsorption of methylene blue 
ranging between 0.0004 to 0.004 g/g over the 24 hour incubation period. The 
incorporation of A6 into the composite materials resulted in a much greater rate and 
capacity for methylene blue adsorption compared to the PVA-GA cryogels alone. For 
example, the PVA1-GA, PVA2-GA and PVA3-GA cryogel showed maximum 
methylene blue adsorption of 0.003, 0.003 and 0.005g/g respectively, however the A6 
carbon bearing PVA1-GA-A6, PVA2-GA-A6 and PVA3-GA-A6 composite cryogel 
showed the maximum methylene blue adsorption of 0.068, 0.064 and 0.068 g/g. In 
addition, when comparing the methylene blue adsorption curves of A6 carbon beads, 
PVA-GA cryogels alone and PVA-AC composite cryogels, a steeper adsorption curve 
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can be observed when A6 carbon beads were used compared to the PVA-AC composite 
cryogels.  
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Figure 2-30 Methylene blue adsorption kinetics of A6 carbon beads, PVA cryogels 
alone, and PVA-AC composite cryogels. 
Methylene blue adsorption was performed by incubating 42.5 mg freeze dried 
PVA-GA-A6 composite cryogels and 27.5 mg PVA-GA cryogel with 10 ml of 1 mM 
methylene blue aqueous solutions at 37°C for 5, 15, 30, 60 960 and 1440 minutes. 
The equilibrium methylene blue adsorption at each time point (qt) was plotted 
against the incubation time (t). (Mean n=4, ± SEM) 
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When Pseudo first order (Equation 2-7) was applied to the methylene blue 
adsorption data for the PVA1-GA, PVA2-GA, PVA3-GA, PVA1-GA-A6 and A6 
carbon beads, low regression coefficients (<0.95) were observed between the natural log 
of the equilibrium concentration (   t) and the incubation time (t) (Table 2-6). This 
suggests that the methylene blue adsorption experimental data have less than 95% 
chance of fitting to the Pseudo first order kinetic adsorption model. Therefore, the 
Pseudo first order kinetic adsorption model should not be used to predict the 
equilibrium methylene blue adsorption (qe) and the adsorption rate constant (Kp1). Since 
in Pseudo first order model, a negative slope is assumed, a positive slope will mean that 
the experimental data does not fit the model. Although the experimental data of 
methylene blue adsorption by PVA1-A6-GA showed a greater than 95% chance of 
fitting to the Pseudo first order model, the positive slope of 1.27 × 10
-4
 suggested that 
this experimental data does not fit to the Pseudo first order model The adsorption 
kinetics for PVA2-A6-GA, PVA2-GA-A6 and PVA3-GA-A6 indicate a linear 
relationship (R
2
 > 0.95) between    t and t, and a negative slope when Equation 2-7 
was applied, suggesting that the Pseudo-first-order model can be used for the 
calculation of equilibrium methylene blue adsorption (qe) and the adsorption rate 
constant (Kp1).  
As summarised in Table 2-6, among the data that fit to the Pseudo first order 
models, PVA2-A6-GA has the equilibrium methylene blue adsorption capacity of 
0.00009 g/g lower than the 0.00027 g/g observed in PVA2-GA-A6 and 0.00028 g/g 
observed in the PVA3-GA-A6 composite cryogel. The Pseudo first order rate constant 
of the methylene blue adsorption by PVA2-A6-GA was 0.00313, lower than the 
0.00364 by PVA2-GA-A6 and 0.00606 by PVA3-GA-A6. These data suggest that the 
PVA3-GA-A6 had the fastest methylene blue adsorption and PVA2-A6-GA had the 
slowest methylene blue adsorption among the three composites. 
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Table 2-6 The methylene blue adsorption kinetics of PVA cryogels, A6 carbon 
beads and PVA-A6 composite cryogels with Pseudo-first-order model calculation. 
By plotting the natural log of equilibrium methylene blue concentration at each 
time point (ln Ct) against the incubation time, the Pseudo-first-order model yields a 
linear regression equation with the slope equal to the Pseudo-first-order 
adsorption kinetic constant (Kp1) and the intercept representing the natural log of 
equilibrium adsorption capacity (qe). 
Adsorbent Slope Intercept R
2
 qe (g/g) Kp1 
PVA1 -9.94E-04 -8.12E+00 0.01369* 0.00030 0.00002 
PVA2 -1.36E-03 -8.13E+00 0.03647* 0.00029 0.00004 
PVA3 -8.36E-06 -8.14E+00 0.02667* 0.00029 -0.00003 
PVA1A6GA 1.27E-05 -8.14E+00 0.09660* 0.00029 0.00229 
PVA2A6GA -3.07E-03 -9.30E+00 0.95286 0.00009 0.00313 
PVA1GAA6 -2.22E-03 -8.11E+00 0.91912* 0.00030 0.00511 
PVA2GAA6 -1.58E-03 -8.21E+00 0.97329 0.00027 0.00364 
PVA3GAA6 -2.63E-03 -8.17E+00 0.99825 0.00028 0.00606 
A6 -1.53E-05 -8.15E+00 0.90189* 0.00029 0.00706 
* R
2
 less than 0.95, therefore less than 90% chances of the experimental data fitting 
to the Pseudo-first-order model  
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When the Pseudo second order equation (Equation 2-8) was applied to the 
methylene blue adsorption kinetics of all the tested materials, only the PVA1-A6-GA 
and PVA2-GA-A6 showed a low linear regression coefficient (< 0.95) between the 
t
qt
 
and the incubation time (t) suggesting that there was less than 95% probability of the 
experimental data fitting the Pseudo second order model (Table 2-6).  
The equilibrium methylene blue adsorption capacity (qe) and adsorption rate 
constant (K) calculated using Pseudo second order are summarised in Table 2-7. A6 
carbon beads showed the highest equilibrium methylene blue adsorption of 0.191 g/g 
and the highest adsorption rate constant of 0.03774. PVA-GA cryogels including 
PVA1-GA, PVA2-GA and PVA3-GA showed negligible methylene blue adsorption 
capacity of 0.00003, 0.00080 and 0 g/g respectively. The incorporation of A6 carbon 
beads into the PVA-GA cryogel resulted in an increase of equilibrium methylene blue 
adsorption capacity. For example, the PVA1-GA-A6 composite cryogel showed a 0.074 
g/g equilibrium methylene blue adsorption capacity, higher than the 0.00003 g/g 
observed in the PVA1-GA cryogel alone; the PVA2-GA-AC composite cryogel showed 
a 0.067 g/g methylene blue adsorption capacity at the equilibrium, higher than the 
0.00080 g/g found in PVA2-GA cryogel. PVA3-GA-A6 composite cryogel is capable of 
adsorbing 0.079 g/g methylene blue at equilibrium, rather than zero adsorption observed 
in the PVA3-GA cryogels. Although the methylene blue adsorption capacity of PVA-
AC composite cryogels remained lower than A6 carbon beads, an overall increase in 
methylene blue adsorption was observed compared to the PVA-GA cryogel alone. 
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Table 2-7 The methylene blue adsorption kinetics of PVA cryogels, A6 carbon 
beads and PVA-A6 composite cryogels using Pseudo-second-order model 
By plotting the time divided by the methylene blue adsorption at each time point 
(t/qt) against the incubation time (t), the Pseudo-second-order model yields a linear 
regression equation with a slope and intercept. The equilibrium adsorption 
capacity (qe) can be calculated by 
 
     
, and the Pseudo-second-order adsorption 
kinetic constant (Kp2) can be calculated by 
 
            
. 
Adsorbent Slope Intercept R
2
 qe (g/g) Kp2 
PVA1 4.62E+02 3.05E+04 0.99706 0.002 0.00003 
PVA2 2.81E+02 1.25E+03 0.97000 0.004 0.00080 
PVA3 2.68E+05 4.86E+07 0.99680 0.000 0.00000 
PVA1A6GA 1.41E+01 9.00E+03 0.77318* 0.071 0.00011 
PVA2A6GA 1.45E+01 5.03E+03 0.89207* 0.069 0.00020 
PVA1GAA6 1.36E+01 3.42E+03 0.95213 0.074 0.00029 
PVA2GAA6 1.50E+01 2.31E+03 0.97444 0.067 0.00043 
PVA3GAA6 1.27E+01 2.85E+03 0.97611 0.079 0.00035 
A6 5.24E+00 2.67E+01 0.99996 0.191 0.03744 
* R
2
 less than 0.9, therefore less than 90% chances of the experimental data fit to the 
Pseudo-second-order model 
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2.6 Discussion and conclusion 
In this chapter, PVA cryogel and PVA-AC composite cryogel preparation 
methods are described. In order to characterise the morphology, internal structure and 
AC porosity preservation in the PVA-AC composite cryogels; SEM, confocal 
microscopy, mercury intrusion, nitrogen adsorption, and methylene blue adsorption 
analysis were employed.  
The study determined that when glutaraldehyde is used as a crosslinker, PVA 
cryogels can be prepared using commercially available PVA polymer with either 88% 
or greater than 99% degree of hydrolysis (PVA1, PVA2 and PVA3) and with increasing 
molecular weights. The methods examined showed successful incorporation of AC 
beads (A6) with less than 45 µm diameter into the cryogel matrix, which resulted in the 
introduction of black colour into the usual white coloured PVA cryogel matrix. Results 
indicated that up to 3% 
w
/v A6 beads could be embedded into the 0.5% (
w
/v) 
glutaraldehyde crosslinked 5% 
w
/v PVA cryogel matrix.  
The SEM and Confocal microscopy imaging of the freeze dried PVA cryogels 
prepared from PVA with 88% hydrolysis degrees (PVA1 and PVA3) revealed the 
abundant presence of channels with greater than 20 µm diameter. However, the SEM 
and confocal images of freeze dried PVA cryogels prepared from PVA with greater than 
99% hydrolysis degree (PVA2) revealed narrow and elongated channels with a diameter 
of less than 10 µm. Furthermore, the SEM micrographs revealed that the A6 beads were 
attached onto the PVA polymeric walls with exposed carbon surfaces in the PVA1-A6 
and PVA3-A6 composite materials showing the potential of preserved AC porosity and 
adsorptive capacity. In contrast, the A6 beads appeared to be buried within the PVA2 
polymeric walls due to the small channel size of the PVA2 cryogels.  
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The introduction of AC in the PVA matrix resulted in the increase of the “solid” 
to water ratio. This reduction of total water content in the cryogelation system can result 
in the reduction of total pore volume in the PVA-AC composite cryogels. Therefore a 
reduction in the volume of channels in the PVA-AC composite cryogel was expected 
and observed from the experimental results. Results from the nitrogen adsorption 
analysis indicated that no micropores were present in the PVA cryogel. However, 
microporosity was observed in the PVA-A6 composite cryogels as a result of the 
introduction of the highly porous AC beads (A6) into the composite system.  
2.6.1 Morphology of PVA cryogels and PVA-AC composite cryogels under 
SE and confocal microscopy 
2.6.1.1 SEM micrographs of AC, PVA cryogels and PVA-AC composite cryogels 
Although images of the PVA cryogels (Figure 2-12) prepared using PVA 
polymers with differing degrees of hydrolysis (Table 2-1) look very similar visually, 
their internal structures were very different under SEM analysis (Figure 2-14 to Figure 
2-16). Irregularly shaped large channels with pore size greater than 20 µm were 
abundant in the PVA cryogels prepared using PVA with 88% hydrolysis (PVA1-GA 
and PVA3-GA). Narrow and elongated channels, with less than 5 µm in their narrowest 
points, were observed in the PVA cryogels prepared from greater than 99% hydrolysis 
degree polymer (PVA2). It appears that the increase of molecular weight of PVA 
polymer from 67,000 (PVA1) to 130,000 (PVA3) did not alter the size and shape of the 
channels in the PVA cryogels prepared from the 88% hydrolysis degree PVA polymers. 
In contrast, the increase in degree of hydrolysis from 88% to over 99% (PVA2) in the 
PVA polymer resulted in the reduction of channel size and shape. Lozinsky et al. (1996) 
suggested that PVA polymers with greater than 99% hydrolysis can undergo physical 
crosslinking resulting in a cryogel which possesses ~1 µm interconnected channels 
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[198]. They also reported that by controlling the PVA concentration in the precursor 
mixture and the thawing rate after cryogelation, those interconnected channels can be 
tailored within micrometer range. Plieva et al. [172] suggested the use of glutaraldehyde, 
which can act as a crosslinker of low hydrolysis degree PVA polymers, such as those 
prepared from PVA1 and PVA3. These two systems produced very different cryogel 
internal structures. When glutaraldehyde was added as a crosslinker during the PVA2 
cryogelation process, larger channel sizes were observed in the resulting PVA2 cryogel. 
The PVA2-GA cryogel displayed larger channels sizes than Lozinsky had suggested. 
This could be due to interaction between glutaraldehyde with the hydroxyl groups on 
the PVA2 polymer chains which may have obstructed the physical crosslinking of the 
hydroxyl groups. Compared to the PVA2-GA cryogel matrix, the larger channels that 
were observed in both PVA1-GA and PVA3-GA cryogels could reduce the flow 
resistance of the column. In addition, the dense wall structure observed in both PVA1-
GA and PVA3-GA cryogels is desirable allowing the cryogel to withstand high pressure 
liquid flow though, whilst retaining structural integrity. These properties have important 
implications in the cryogels’ suitability for the passage of whole blood in 
hemoperfusion applications. 
The addition of A6 beads into the PVA1-GA cryogel matrix appeared to distort 
the original smooth, round shaped channel wall structure, and resulted in an uneven wall 
structure (Figure 2-18 A), suggesting a successful incorporation of carbon beads (A6) 
into the PVA matrix. In addition, a decrease in channel size could be observed in 
PVA1-GA-A6 composite cryogel (Figure 2-18 A & B) compared to the SEM images of 
PVA1-GA (Figure 2-14). The incorporation of A6 in the PVA2-GA system turned its 
elongated channel structure into irregular shaped channels within which the A6 beads 
were incorporated (Figure 2-19). In the PVA3-GA-A6 composite cryogel (Figure 2-20), 
a similar phenomenon of incorporation of A6 beads into the PVA cryogel wall was 
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observed with the reduction of channel sizes compared to the PVA3-GA cryogel. The 
reduction in the sizes of PVA-AC composite cryogel internal channels compared to the 
corresponding PVA cryogels can be explained by the theoretical calculation of solid 
(PVA, glutaraldehyde and A6) to solvent (water) content listed in Table 2-2 Polymer 
and AC content in the PVA cryogel and PVA-AC composite cryogel. The addition of 3% 
(
w
/v) A6 beads increased the solid content in the PVA-AC composite cryogel precursor 
mixture, however the amount of water remained unchanged, therefore, the percentage of 
water in the resulting mixture was reduced. Since water acts as the porogen in the 
cryogelation process, the reduction in the resulting cryogel channel volume and size can 
be expected. The weight ratio between PVA and A6 beads at 13:7 allows enough PVA 
to secure the incorporation of A6 beads without completely masking the outer surfaces 
of the A6 beads as shown by SEM micrographs. These findings support a promising 
future for the PVA-AC composite cryogels in haemoperfusion applications. 
2.6.1.2 Confocal images of AC, PVA cryogels and PVA-AC composite cryogels 
The confocal images of the PVA1-GA and PVA3-GA cryogels in their hydrated 
state showed similar internal morphology compared to their equivalent SEM images, 
suggesting that the swelling PVA cryogel polymer walls when hydrated did not affect 
the channel sizes of the cryogel. However, the PVA2-GA cryogel viewed under 
confocal microscopy appeared to have smaller channel size and thicker polymer walls, 
suggesting that the swelling of polymer walls reduced the channel size to some extent. 
Due to the fact that the laser used in the confocal imaging technique was unable to 
penetrate the AC beads, this technique could not be used for imaging the PVA-AC 
composite cryogels.  
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2.6.1.3 Summary 
PVA cryogels can be prepared using different grades of commercially available 
PVA polymers. The internal structure of the cryogel matrix varies greatly depending on 
the use of high hydrolysis degree PVA (< 99%) or low hydrolysis degree PVA (88%). 
While low hydrolysis degree PVA (PVA 1 and PVA3) cryogels had pores with a width 
as large as 80 µm, the high hydrolysis degree PVA (PVA 2) cryogels had pores with a 
much smaller width of less than 20 µm. For applications such as haemoperfusion, larger 
interconnected pores are preferred for allowing free flowing whole blood passage. 
Therefore low hydrolysis degree PVA cryogels would be a more promising 
haemoperfusion matrix. 
The SEM and confocal images indicated that PVA-AC composite cryogels 
prepared from PVA1 and PVA3 (88% hydrolysis) possessed more suitable channel 
structure for haemoperfusion applications due to the large channel sizes observed. 
2.6.2 Porosity of the of AC, PVA cryogels and PVA-AC composite cryogels 
2.6.2.1 Nitrogen adsorption analysis 
BET analysis of the nitrogen adsorption data indicated that the PVA-GA cryogels 
have a low specific surface area of 69-79 m
2
/g (Table 2-3). Since no microporosity was 
estimated when the DFT method was applied, the low specific surface area could be 
explained by the fact that micropores are usually the main contributors to the large 
surface area of adsorbent materials. The BJH calculation suggested the presence of 
small mesopore (3.4 nm) volumes in the PVA-GA cryogels of between 0.21 to 0.38 
cm
3
/g. Cyrogel materials are associated with high porosity often with channels of 
greater than 20 µm in diameter, where only 3-5% of the total porosity was considered to 
be contributed by the pores with less than 100 nm in diameter [215]. Therefore the lack 
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of microporosity and low mesoporosity in the range measured by nitrogen adsorption 
analysis was expected in all three PVA-GA cryogel samples. 
The large specific surface area of A6 carbon beads (1070.153 m
2
/g) is mainly 
contributed by the micropores (0.951 cm
3
/g) in the sample. In addition to the high 
microporosity estimated by the DFT method, a high mesopore volume of 0.740 cm
3
/g 
was also estimated by the BJH method, indicating the coexistence of micro- and meso- 
pores in A6 carbon beads. The incorporation of A6 beads into the PVA cryogel matrix 
introduced this microporosity into the composite PVA-AC composite cryogel system, 
with a resultant more than five-fold increment of specific surface area (Table 2-3). 
Although compared to the A6 carbon beads, a reduction of surface area and 
microporosity was observed in the PVA-AC composite cryogel system, it was expected 
as a result of reduction of carbon weight content from 100% of A6 beads alone to 35% 
AC to 65% PVA-GA polymer (Table 2-2). The results obtained from nitrogen 
adsorption analysis indicated the successful introduction of microporosity from the A6 
beads into the composite cryogel systems when A6 were incorporated into the 
composite cryogel. Furthermore, the highest specific surface area was observed in the 
resulting composite cryogels prepared from the highest molecular weight PVA (PVA3) 
indicating the increase of molecular weight could have positive impact on the 
preservation of surface area of incorporated A6 beads. However, this was associated 
with the reduction in the composite mesopore volume possibly also due to the reduction 
of carbon weight content. The presence of high meso- and macro- porosity has been 
largely associated with the adsorptive capacity of the ACs towards middle to large 
molecular weight toxins, protein bound toxins and inflammatory mediators [139]. 
Therefore, the successful preservation of AC porosities after the incorporation into the 
composite matrix, will support the potential use of the PVA-AC composite in 
haemoperfusion applications 
 118 
 
The use of nitrogen adsorption analysis technique for porosity determination in 
compliant samples such as aerogels was questioned, due to the sample morphological 
distortion upon compression generated during analysis [216]. Although strong 
polymeric wall structures in cryogel materials have been reported, high compliance has 
also been reported in their hydrated state [201]. This high compliance is mainly 
attributed to the large volume (nearly 95%) of interconnected channels [217]. However, 
very little attention has been focused on cryogel compression in the dehydrated state 
due to the fact that the main applications of cryogel materials are in aqueous 
environments. This raised uncertainty in the porosity data on the PVA-GA cryogel 
matrix and PVA-AC composite cryogels generated by nitrogen adsorption analysis, 
especially in the mesopore size range, due to the high relative pressure used for 
estimating the pore size and volume within this range. Therefore, a technique that 
allows the estimation of composite cryogel porosity in the hydrated state was employed. 
2.6.2.2 Mercury porosimetry analysis  
The mercury porosimetry analysis revealed that the introduction of A6 in the 
PVA2-GA system using different methods didn’t influence the channel size of the 
resulting PVA2-A6 composite cryogels. Both PVA2-GA-A6 and PVA2-A6-GA were 
estimated with similar volume (15.1 to 19.6 cm
3
/g) of channels with a mean diameter of 
5.9 µm using mercury porosimetry. The PVA-GA cryogels prepared using 88% 
hydrolysis PVA was estimated with 17 µm channel sizes. Interestingly, the introduction 
of A6 carbon beads resulted in an increase in the channel size in the PVA1-GA matrix 
but a reduction in the pore size in the PVA3-GA matrix. The mercury porosimetry 
results indicated that after incorporating the A6 carbon beads into the PVA-GA matrix, 
macroporosity of A6 carbon beads in the resulting composite cryogels was preserved 
regardless of the composite preparation method and grades of PVA used. However, a 
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reduction of pore diameter of A6 was reduced from 100 nm to 80 nm when incorporated 
into the cryogel matrix. This could be an indication of the PVA polymer partially 
masking the A6 macropores. Interconnected channels with diameter greater than 20 µm 
would allow the passage of blood cells therefore, were more desirable for 
haemoperfusion applications and were studied further in chapter 5. However, mercury 
porosimetry results suggested that even the PVA1-GA-A6 composite cryogel with 
highest channel size among all the composite cryogels, only possessed 24 µm diameter 
channels. Due to the fact that mercury porosimetry analysis operates under the 
assumption that the test material possesses only cylindrical through pores, an under 
estimation of pore size could be expected [218]. In addition, during the cryogelation 
process, a certain amount of water was incorporated in the cryogel matrix, which is 
referred to as bound-water; the rest was frozen and ultimately responsible for the pore 
volume and shape of the resulting cryogel. Freeze drying of test samples required for 
nitrogen adsorption and mercury porosimetry analysis could result in the removal of the 
polymer bound water, and lead to shrinkage of cryogel samples and pore size reduction 
[170]. 
Although nitrogen adsorption and mercury porosimetry are two very powerful 
analytical techniques allowing the quantification of surface area and porosity of the 
materials, the use of these techniques to characterise materials such as cryogels has 
disadvantages. The requirement of using dehydrated samples in both techniques means 
the polymer-bound water is removed with a possible influence on the cryogel polymer 
matrix internal structural and texture. Although the small size of the nitrogen molecule 
allows its entry into very small pores allowing measurement of microporosity, the 
surface area accessible for nitrogen molecules might not be accessible for the larger 
biological toxins in biomedical applications, such as protein bound liver and uraemic 
toxins. The use of mercury porosimetry focused on the larger mesopores and 
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macropores of the test materials. However, the high pressure utilised in this technique to 
force the mercury into polymeric materials such as the PVA composites could 
potentially break any PVA film coating the outer surface of the AC beads, and result in 
the re-opening of the blocked pores in the AC, therefore, creating an over estimation of 
meso- and macro- porosity preserved in the AC contained within the composite 
materials. To understand the porosity and adsorption capacity of the wet state PVA-AC 
composite materials, adsorption from liquid phase was also studied. 
2.6.2.3 Summary 
Compared to the A6 carbon beads, the A6 embedded PVA cryogels prepared 
from different grades of commercially available PVA polymer showed a reduction in 
the specific surface area by nitrogen adsorption analysis and a decrease of meso- and 
macro- porosity from the mercury porosimetry analysis results. Those could be simply a 
result of a “dilution effect” due to the addition of PVA cryogel which have a low 
surface area, limited meso- and macro- porosity and negligible methylene blue 
adsorption capacity.  
2.6.3 Methylene blue adsorption by AC, PVA cryogels and PVA-AC 
composite s 
2.6.3.1 Methylene blue adsorption isotherm 
In order to understand the behaviour of PVA-GA cryogel, PVA-AC composite 
cryogel and AC beads in aqueous systems, the adsorption of methylene blue from liquid 
phase was used to monitor the adsorption isotherm of the adsorbents. The use of liquid 
allows the PVA-GA cryogel and PVA-AC composite cryogel to be tested under 
hydrated conditions. A clear increase of methylene blue adsorption when A6 was 
incorporated into the PVA-GA cryogel matrix indicated that the accessibility of A6 
surface and pores were successfully preserved for relatively small molecules such as 
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methylene blue with molecular weight of 319.85 
g
/mol. Furthermore, the methylene blue 
adsorption by composite cryogels produced by two different precursor preparation 
methods tested indicated that pre-mixing PVA solutions with glutaraldehyde resulted in 
an increase in methylene blue adsorption capacity (Figure 2-27 and Figure 2-28), 
suggesting a PVA-glutaraldehyde matrix might be formed prior to AC addition, which 
would limit the adsorption of PVA or glutaraldehyde by AC thereby preserving the AC 
porosity. In addition, the increase in the PVA molecular weight also indicated a positive 
influence on the methylene adsorption capacity in the resulting composite cryogel 
(Figure 2-29). The application of the Lineweaver-Burk equation suggested that the 
methylene blue adsorption isotherm data for the materials including PVA1-GA, PVA2-
GA, PVA1-A6-GA and PVA1-GA-A6 cannot be fitted to the Langmuir adsorption 
isotherm calculations; therefore the surface area calculated using the BET equation was 
disregarded. In addition, the surface area of A6 carbon beads and the PVA-A6 
composite materials determined by the methylene blue adsorption were higher than 
those determined by nitrogen adsorption analysis. This suggested that the compression 
of the material during nitrogen analysis could result in a under estimation of composite 
porosity. However, the increase of surface area calculated from methylene blue 
adsorption by non-compliant material A6, was also higher than estimated using nitrogen 
adsorption analysis, suggesting that the use of methylene blue absorption analysis could 
result in an over-estimation of material porosity. 
2.6.3.2 Methylene blue adsorption kinetics 
The adsorption kinetics of methylene blue by AC, PVA cryogel and PVA-AC 
cryogel revealed that although the introduction of A6 beads into the PVA cryogel 
matrix successfully increased the adsorption of methylene blue, the superior adsorption 
speed and capacity of AC was dimmed by its incorporation into PVA the cryogel matrix. 
In addition, Pseudo first order model could not be fitted to the methylene blue 
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adsorption kinetic data with the exception of; PVA2-A6-GA, PVA2-GA-A6 and PVA3-
GA-A6 composite cryogels. In contrast, Pseudo second order model could be fitted to 
most of the methylene blue adsorption data except PVA1-A6-GA and PVA2-A6-GA 
composite cryogels. These two chemical reaction based mathematical models are often 
used for the calculation of adsorbent capacity (qe) at fixed adsorbate concentration and 
the adsorption kinetic constant (K) for the comparison in the speed of adsorption. 
Although Pseudo first and second order was designed to describe the rates of chemical 
reactions, their applications in adsorption studies has gained increasing popularity 
recently. However, calculating the physical adsorption processes using  chemical 
reaction models remains controversial since they poorly describe the underlying 
adsorption mechanism [212]. The use of these two models in conjunctions with the 
other analysis techniques remains popular due to the valuable data on the material 
porosity characteristics can be estimated and compared. 
2.6.3.3 Summary 
The methylene blue adsorption isotherm and kinetics results suggested that 
higher methylene blue adsorption capacity of the embedded A6 beads could be better 
preserved when the composite cryogels were prepared by pre-mixing the PVA with 
glutaraldehyde before the addition of A6 carbon beads. Furthermore, the use of higher 
molecular weight PVA polymer for composite preparation could improve the methylene 
blue adsorption capacity in the composites. Among the PVA polymers used for the 
preparation of the PVA-AC composite cryogels, PVA3 with the highest molecular 
weight and low degree of hydrolysis, showed the greatest potential as a haemoperfusion 
column due to the relatively successful preservation of the desired porosity of the A6, 
and a high volume of macropores with uniformed AC pore size distribution. This 
discovery led to the preparation of a more useful composite material for continued 
 123 
 
testing, using PVA3 polymer by reacting PVA3 with glutaraldehyde before addition of 
AC. 
Chapter 3. Assessing the in vitro cytotoxicity of carbon and cryogel 
materials 
3.1 Introduction 
3.1.1 The need for in vitro cytotoxicity assessments 
Early ACs failed as haemoperfusion adsorbents due to their low biocompatibility 
(section 1.3.3). Although coating of AC using more biocompatible materials was 
believed to improve AC biocompatibility, the low adsorptive capacity of the coated 
carbons has stimulated research into the development of AC haemoadsorbents that can 
be used uncoated. The development of new AC adsorbents must involve confirmation 
of non-cytotoxicity. The use of polymer based materials for AC production became 
popular for the development of homogenous products compared to the naturally sourced 
AC that was used by Yatzidis [126]. In particular improving the mechanical strength of 
the AC can prevent leaching of carbon fines which makes them more suitable for 
haemoperfusion applications. In addition, the possibility of toxic leachate release by 
PVA and glutaraldehyde crosslinked PVA (PVA-GA) must be investigated if they are 
to be used as matrices for ACs in the hemoperfusion devices described earlier. 
During the development of adsorbents for blood purification, the evaluation of 
adsorbent biocompatibility is equally as important as determining adsorption capacity 
and efficacy. Biomaterials are required to perform during in vivo or ex vivo situations 
with no harmful effects on cell function since cytotoxicity caused by direct biomaterial 
contact or contact with biomaterial leachate may result in non-programmed-cell-death 
(necrosis) which may further trigger inflammation and an immune response [219]. 
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Cytotoxic effects can be measured using short-term in vitro cytotoxicity assays. 
However, inflammation and initiation of an immune response are more difficult to 
determine using in vitro studies due to the complex nature of these processes and the 
involvement of multiple tissue and organs requiring the use of more complex and 
expensive animal models [220]. The use of cell based cytotoxicity assays assessing 
biocompatibility of newly developed biomaterials has many advantages. For example, 
well designed cytotoxicity assays can provide reproducible results, are cost and time 
efficient compared to animal studies and allow early rejection of unsuitable biomaterials 
[221]. Although ongoing arguments over the coherence of in vitro cytotoxicity assays to 
animal studies remain unresolved, the popularity of cytotoxicity assays as a first check 
point for material biocompatibility remains. 
3.1.2 Modalities of in vitro cytotoxicity assessments 
The biomaterial cytotoxicity can be assessed by comparing cell morphological 
changes, measuring cell damage, cell growth, or specific aspects of cellular metabolism. 
Imaging techniques such as SEM and immunofluorescence labeling are often applied 
for the assessments of cell morphological changes [222, 223]. Methods such as total 
protein or DNA content and colony formation counts can also be used to determine if 
the material has any effect on cell proliferation [224, 225]. Of the available methods, 
assays such as LDH (lactic dehydrogenase) for determination of cell damage, and MTS 
(5- (3 - carboxymethoxyphenyl) - 2(4, 5 - dimethylthiazoly) – 3 - (4-sulfophenyl) 
tetrazolium, inner salt) assays for quantifying cell metabolism are commonly used due 
to their simple protocol and reliable results [223, 226, 227]. 
The International standard of biological evaluation of medical devices part 5 
tests for in vitro cytotoxicity (ISO-10993-5) suggests three categories for  cytotoxicity 
testing depending on the material, potential application site and nature of use of the 
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biomaterial [219]. These are direct contact, indirect contact and extract tests. Direct 
contact tests are performed by seeding the cells directly onto the test materials before 
examination of cell morphology, adhesion, viability or proliferation [228, 229]. Indirect 
contact tests involve separation of materials from the cells using a membrane or an agar 
gel which allows the diffusion of any possible toxic agents to the cell layer and the 
quantification of the toxic effects of the materials [225, 230]. For extract tests, test 
materials are incubated with culture medium to allow any possible harmful leachates to 
be eluted from the test materials into the culture medium. The cells are then treated with 
this extract medium to evaluate the cytotoxicity of the extract and the test materials [223, 
225]. The adsorptive nature of adsorbent materials can lead to the removal of nutrients 
from the cell culture medium, therefore this restricts the in vitro test methods which are 
suitable to either indirect contact or extract tests [225]. Although, by tailoring the pore 
size, MAST Carbon AC can be used for targeted removal of middle to large molecular 
weight molecules, the nonspecific adsorption of low molecular weight substances and 
ionic supplements and proteins from cell culture medium is still inevitable. The 
adsorption of these cell culture medium nutritional factors may result in a false 
indication of cytotoxicity during in-vitro conditions [225]. In addition, the adsorption of 
MTS and LDH by AC from the culture medium can also influence the results [231]. 
Despite the fact that the clinical use of haemoperfusion adsorbent requires the direct 
contact of human whole blood to the adsorbent material, the length of this contact is 
relatively short since there is constant blood flow during the EBP treatment. Therefore, 
prolonged direct contact in vitro testing is not required. Extract tests were therefore 
selected for the in vitro evaluation of haemoperfusion adsorbent cytotoxicity. As 
previously developed by Barnes et al. materials were conditioned in water for 24 hours 
before cell culture medium was used to extract any cytotoxic leachable contents in the 
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materials for a further 24 hours before a series of extract dilutions were tested on the 
cultured cells for their cytotoxicity assessments [225]. 
The LDH cytotoxicity assay is a colorimetric assay that is used to assess LDH 
release upon cell membrane lysis. LDH is a stable enzyme present in the cytoplasm of 
cells of all types. When cell plasma membranes are damaged in vitro, LDH is rapidly 
released into the cell culture supernatant [232]. Therefore, the amount of LDH measured 
in the culture supernatant reflects cell plasma membrane damage. The use of 
tetrazolium salts in conjunction with diaphorase, or alternate electron acceptors, to 
determine the LDH level have been used in the measurement of cell damage for several 
decades [233]. The method involves transforming LDH in cell culture supernatant into a 
red-coloured formazan product, the concentration of which is then determined by 
measuring light absorbance using a spectrophotometer at wavelength around 490 nm 
and comparing it to a standard curve of known LDH concentration against absorbance 
[234]. The MTS assay is an alternative colorimetric assay that can be used to determine 
cell viability [235]. MTS can be utilized by living cells, and transformed into a 
formazan product which is soluble in tissue culture media. The soluble MTS formazan 
concentration in the media supernatant can also be measured directly using UV 
spectrometry at 490 nm wavelength [235]. The formation of MTS formazan represents 
the mitochondrial metabolic rate which reflects the cell viability. The combination of 
LDH and MTS assays can be used to quantify damage to the cells when exposed to the 
newly developed materials or material extracts during in vitro conditions.  
3.2 Hypothesis and objectives 
The aim of this study was to determine whether the AC from Mast Carbon 
International and PVA cryogel materials leach cytotoxic contents into cell culture 
medium after incubation. Novacarb AC beads are manufactured using a range of 
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chemicals that in themselves are toxic (Chapter 2.1.1.1) and therefore it is important that 
after carbonisation and activation none of these components remain to be leached into 
solution and cause cytotoxic effects. Similarly, PVA cryogels are prepared from toxic 
monomers and crosslinking agents, and thus the final cryogel material needs to be tested 
to ensure it is not cytotoxic. To avoid the influence of nutrient adsorption by AC, the in 
vitro cytotoxicity assays used in this study were selected to determine the membrane 
integrity (LDH assay) and cellular mitochondrial activities (MTS assay) of V79 hamster 
lung cell line cells after their exposure to the material extracts for 8 and 24 hours. A 
selection of AC prepared from both steam and carbon dioxide activation (A7), steam 
activation (A8) and carbon dioxide activation (A9) were selected for the assessment to 
determine the influences of activation methods on the resulting AC’s possible 
cytotoxicity. Although the ISO standards suggested that material cytotoxicity should be 
determined with minimum 24 hours cell exposure, the V79 cell viability and membrane 
integrity was also monitored after 8 hours of exposure due to the complications arising 
from the adsorptive nature of the AC samples. 
3.3 Materials 
 V79 fibroblast type hamster lung cell line (ECACC No. 86041102)  
 Dulbecco's Modified Eagle Medium (DMEM) (PAA: E15-810) 
 Phenol red-free DMEM media (PAA: E15-877) 
 Fetal bovine serum (FBS) (PAA: A15-104) 
 Penicillin/Streptomycin (100x) (PAA: P11-010) 
 Trypsin/EDTA (PAA: L11-004) 
 A 0.57% Dibutyltin maleate containing PVC polymer (Hydro polymers Ltd) 
 CytoTox 96 Non-Radioactive Cytotoxicity Assay kit (Promega Corporation: G1780) 
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 CytoTox 96 Non-Radioactive Cell Proliferation Assay kit (Promega Corporation: 
G3580) 
 PVA1-GA cryogel (preparation described in section 2.4.2.1)  
 ACs listed in Table 3-1 (tailor made macroporous NovaCarb S, Mast Carbon Ltd) 
 
Table 3-1 ACs used for the in vitro cytotoxicity assay and their activation method 
and particle sizes. 
ACs 
Activation 
methods 
Particle size 
range (µm) 
Macropore 
size (nm) 
SBET (m
2
/g) 
A7 
Steam and 
Carbon dioxide 
250 to 500 70 861.48 
A8 Carbon dioxide 250 to 500 72 1030.05 
A9 Steam 250 to 500 78 832.37 
 
3.4 Methods 
3.4.1 Cytotoxicity Assay validation 
Due to the variation in cell LDH content and MTS utilisation rates in different 
cell types, optimisation of target seeding density was carried out in order to provide 
reproducible results when using the LDH and MTS assays. In this set of experiments, 
fibroblast type hamster lung cell line V79 were chosen as they are a cell line considered 
to be sensitive to cytotoxic effects [219]. The V79 cells were maintained in 10% FBS 
supplemented DMEM medium with 1% Penicillin/Streptomycin and passaged by 
trypsinisation at 80% confluence approximately every two days. To optimise the cell 
seeding density for the LDH and MTS assays, a series of cell seeding densities in 100 µl 
medium (5.00 x 10
4
, 2.50x10
4
, 1.25x10
4
, 0.63x10
4
, 0.31x10
4
, 0.16x10
4
, and 0.08x10
4
 
cells/well) were added to each well of a 96 well plate and incubated for 24 hours. The 
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utilisation of MTS and the release of LDH by the cultured cells were determined using 
MTS and LDH assay kits following the manufacturer’s protocol briefly described below 
in section 3.4.2.1 (MTT assay) and 3.4.2.2 (LDH assay).  
3.4.2 Extract preparation and cell extract treatment 
Material extracts were prepared by incubating 0.5 g of AC and freeze-dried PVA 
cryogel (prepared by crosslinking of 5% 
w
/v PVA1 with 0.5% 
w
/v glutaraldehyde at -
12 °C cryogelation process as described in section 2.4.2.1) in 5 ml of 10% FBS 
supplemented phenol-red free DMEM medium at 37°C for 24 hours. A positive control 
of dibutyltin maleate containing PVC polymer and a negative control containing neither 
AC nor PVA were also included. The extracts were sterilized by filtering through a 0.2 
µm syringe filter before being used undiluted (100%). In addition, a 50% dilution of the 
sterilised extracts was also prepared for cell treatment by adding 50% of fresh culture 
medium to compensate the nutrients removed by the AC. V79 cells were seeded into a 
96-well-plate at a density of 6 x 10
3
 cells per well and incubated at 37˚C in a humidified 
5% CO2 atmosphere for approximately 18 hours prior to extract treatment. The 18-hour 
incubation period was selected to allow the cells to settle onto the culture plate but also 
to avoid prolonged incubation resulting in over populated culture conditions. Medium 
was removed and extracts were introduced in quintuplicate. The cells were incubated 
with extract samples for a further 8 or 24 hours before the MTS and LDH assays were 
performed. 
3.4.2.1  MTS assay 
After the extract incubation time, the culture medium was aspirated and 100 µl 
of 20% (
v
/v) MTS reagent in phenol red free medium was added to each well of the plate 
followed by a further 2 hours incubation at 37˚C in a humidified 5% CO2 atmosphere. 
The MTS formazan intensity was measured at 492 nm using a Biotech ELISA plate 
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reader. The cell viability was calculated according to Equation 3-1, where I0 represents 
the intensity of MTS formazan produced by V79 cells exposed to the culture medium; I1 
represents the intensity of MTS formazan produced by V79 cells exposed to the sample 
extracts; B is the media blank. 
 
           
 1   
 0
       Equation 3-1 
 
3.4.2.2 LDH assay 
After the extract incubation period, 50 µl aliquots of culture medium were 
transferred to a fresh 96-well plate, and 50 µl of LDH substrate solution was added to 
react with the LDH released by the V79 cells in the culture medium. The plates were 
left in the dark at room temperature for 30 min before 50 µl of stop solution was added 
to each well of the plate. The intensity of LDH formazan product was measured at 492 
nm using a Biotech ELISA plate reader. The cytotoxicity was calculated according to 
Equation 3-2, where I0 represents the intensity of LDH formazan released by V79 cells 
when the cells were lysed; I1 represents the intensity of LDH formazan released by V79 
cells exposed to the sample extracts; B is the medium blank. 
 
              
 1   
 0
       Equation 3-2 
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3.5 Results: 
3.5.1 Assay validation 
The effect of changes in cell seeding density on the MTS assay results is shown 
in Figure 3-1. The x-axis represents the seeding densities of V79 cells, and the y-axis 
represents the absorbance of MTS formazan at a wavelength of 492 nm. The results 
indicate a linear relationship (R
2
=0.9169) between MTS formazan (optical density) 
(absorbance) in the culture medium and cell seeding density up to 1.25 x 10
4
 cells per 
well after 18 hours incubation of cells in the culture medium. The MTS formazan 
optical density (OD) in the blank (when cell seeding density is zero) media only was 
0.24 and the MTS optical density reading (OD=0.45) was nearly doubled when the 
seeding density was increased to 0.31x10
4 
cell per well compared to the blank. 
The results of the validation of the LDH assay (cell seeding density vs. optical 
density of LDH) on V79 cells following 18 hours of incubation are shown in Figure 3-2. 
Data on the x-axis represent the seeding densities of the V79 cells, and data on y-axis 
represent the LDH released by V79 cells as a result of loss of their cell membrane 
integrity. The results indicate a linear correlation (R
2
=0.9679) between released LDH 
optical density and V79 cell density up to 1.25 x 10
4
 cells per well after 18 hours 
incubation of cells in the culture medium. The LDH optical density of the blank (when 
cell seeding density is zero) media was 0.18 and the MTS optical density reading 
(OD=0.38) was nearly doubled when the seeding density was increased to 0.16x10
4
 cell 
per well compared to the medium control. 
According to the manufacturer’s guidance, the optimal target cell seeding 
density should be when the target cells yield absorbance values at least two times the 
background absorbance of the media control [235-237]. Therefore, the optimal V79 cell 
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seeding density for MTS and LDH assays for 18 hours incubation period was between 
0.3x10
4
 to 1x10
4
 cells per well. 
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Figure 3-1 Optimisation of V79 cell seeding density for MTS assay. 
V79 cells were seeded onto 96-well-plates with the density of 5.00 x 10
4
, 2.50 x 10
4
, 
1.25 x 10
4
, 0.63 x 10
4
, 0.31 x 10
4
, 0.16 x 10
4
, and 0.08 x 10
4
 cells per well, and MTS 
assays were performed after 24 hours incubation. (Mean n=4, ± SEM) 
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Figure 3-2 Optimisation of V79 cell seeding density for LDH assay. 
V79 cells were seeded onto 96-well-plates with the density of 5.00 x 10
4
, 2.50 x 10
4
, 
1.25 x 10
4
, 0.63 x 10
4
, 0.31 x 10
4
, 0.16 x 10
4
, and 0.08 x 10
4
 cells per well, and LDH 
assays were performed after 24 hours of incubation. (Mean n=4, ± SEM) 
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3.5.2 Cytotoxicity assessments of PVA and AC 
The LDH assay results of sample extract cytotoxicity following 8 hours of 
extract treatment is displayed in Figure 3-3. Following 8 hours of 50% and 100% 
extract treatment, the positive controls (dibutyltin maleate extracts) displayed 
cytotoxicity (35% cytotoxicity) ten times higher than that of the negative, culture 
medium control (3% cytotoxicity). The LDH assay revealed that, after 8 hours of 
incubation, the 100% AC extract induced up to 10% cytotoxicity towards V79 cells and 
the 50% AC extract induced as low as 3% cytotoxicity. Although the cytotoxicity of the 
100% AC extracts was two to three times higher than the 100% negative control, the 
cytotoxicity of the AC extracts was only 29% of the cytotoxicity of the positive control. 
The MTS results in Figure 3-4 show that the addition of extracts from the AC 
bead (A7, A8 and A9) materials had no negative effect on cell metabolism after 8 hrs of 
cell incubation with 100% and 50% carbon extract. In fact, the V79 cells maintained 
viability up to 137% after 8 hours of incubation in the 100% AC extracts compared to 
the positive control after 8 hours of treatment. The high viability of the cells might be an 
indication of cell proliferation or a signal that the  cells are under stress [238]. To 
identify the reason for this 37% increase in cell viability, prolonged extract treatments 
were also carried out. If the increase of V79 cell viability after 8 hours extract treatment 
was due to cell stress, after 24 hours extract treatment, this stress should result in a cell 
death hence a reduction in the measured MTS levels. If this increase was caused by cell 
proliferation, the cell viability should increase further after 24 hours of AC extract 
treatments. Therefore, extract treatments were prolonged from 8 hours to 24 hours. 
The results of the MTS assay in Figure 3-5 revealed that after 24 hours contact 
with undiluted AC extract, V79 cell viability was reduced to as low as 32%. However, 
when the cells were exposed to 50% dilution of AC extracts diluted in fresh culture 
medium, very little reduction in cell viability was observed compared to the negative 
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control in which cells were treated with culture media alone. The LDH assay results in 
Figure 3-6 indicate that the 100% AC extract induced up to 53% cytotoxicity in V79 
cells after 24 hour incubation. This cytotoxic effect was decreased by ten times after a 
50% dilution with the culture medium, making the cytotoxic level of the 50% AC 
extracts comparable to that of the negative control. This may suggest that, in the 100% 
AC extracts the nutrients in the media were absorbed by the AC during the 24 hr 
incubation as previously identified by Barnes et al. [225]. The remaining nutrients in the 
culture medium were sufficient for the cells to survive for 8 hours incubation, but not 
enough to support cell survival for 24 hours. When the cells were treated with a 50% 
dilution of the extract in culture medium, an increase in cell survival was observed. The 
cells treated with both 50% and 100% PVA extracts for 24 hours showed more than 135% 
of cell viability measured using the MTS assay. The LDH assay also indicated that both 
50% and 100% PVA extracts showed apparent cytotoxicity of less than 5% for V79 
cells. 
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Figure 3-3 The cytotoxicity of activated carbon extracts determined by LDH assay. 
AC extracts (cell culture medium incubated with A7, A8 and A9), Positive control 
(24-hour extraction of dibutyltin maleate containing PVC polymer in cell culture 
medium) and negative control (cell culture medium) on V79 cell viability were 
determined by LDH assay after 8 hours of extract incubation. (Mean n=3, ± SEM) 
 135 
 
A7 A8 A9 Positive Negative
0
50
100
150
200
100%
50%
C
e
ll
 v
ia
b
il
it
y
 (
%
)
 
Figure 3-4 V79 cell viability were determined by MTS assay after 8 hours 
incubation with  AC-7, AC-8 and AC-9 activated carbon extracts. 
Positive control (24-hour extraction of dibutyltin maleate containing PVC polymer 
in cell culture medium) and negative control (cell culture medium). Media blank 
absorbance was subtracted. (Mean n=3, ± SEM) 
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Figure 3-5 V79 cells viability were determined by the MTS assay after 24 hours 
treatment with AC-7, AC-8 and AC-9 activated carbon extracts. 
Positive control (24-hour extraction of dibutyltin maleate containing PVC polymer 
in cell culture medium) and negative control (cell culture medium). Media blank 
absorbance was subtracted. (Mean n=3, ± SEM) 
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Figure 3-6 The cytotoxicity of activated carbon extracts determined by LDH assay. 
AC extracts (cell culture medium incubated with A7, A8 and A9), Positive control 
(24-hour extraction of dibutyltin maleate containing PVC polymer in cell culture 
medium) and negative control (cell culture medium) on V79 cell cytotoxicity were 
determined by LDH assay after 24 hours treatment. (Mean n=3, ± SEM) 
 
3.6 Discussion and conclusions: 
After the cell number optimisation for both MTS and LDH assays, a seeding 
density of 0.6 x 10
4
 cells/well was selected for the in vitro cytotoxicity assessments of 
the material extracts prepared by incubating 0.5 g materials in 5 ml 10% FBS 
supplemented with phenol red free DMEM medium at 37°C for 24 hours. ACs prepared 
from different activation processes were selected to determine the effects of steam and 
carbon dioxide activation methods on the potential cytotoxicity of resulting AC beads. 
In addition, the cytotoxicity of PVA1-GA cryogel prepared by crosslinking PVA1 
(67,000 molecular weight, 88% hydrolysis) with glutaraldehyde via cryogelation 
processes was also measured. 
Due to the adsorptive nature of AC beads, their cytotoxicity was monitored 8 
hours after the cells were exposed to the extracts to ensure any cytotoxic effects 
observed were not due to the depletion of nutrients during the extraction process. In 
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contrast, the PVA1-GA cryogel material does not exhibit this nutrient adsorption 
characteristic. Therefore, the PVA1-GA extract cytotoxicity was only monitored after 
the standard 24 hours of cell exposure.  
The MTS and LDH assay results showed that the viability and membrane 
integrity of V79 cells after 8 hours of 100% and 50% AC extract treatments were very 
similar to the control treatments in which cells were exposed to the cell culture medium, 
indicating that the AC extracts did not cause cytotoxic effect during the 8 hours 
exposure time. When the exposure time was increased to 24 hours, reduction in cell 
viability and membrane integrity were observed in the 100% AC extracts treated V79 
cells. However, this reduction was not observed in the 50% AC extracts treated V79 
cells.  
3.6.1 Cell number optimisation for MTS and LDH in vitro cytotoxicity 
assessments 
The optimisation of MTS and LDH assay was performed by altering the initial 
V79 cell seeding density. In the assay validation, a linear (R
2
>0.98) relationship 
between absorbance optical density of both MTS and LDH formazan and V79 cell 
seeding density was observed when the cells were seeded below 1.25 x 10
4
 cells per 
well within the 24 hours incubation period. Although a lower seeding density was 
preferred, in order to eliminate the influences of culture medium on the assay results, 
the cell seeding density (0.6 x 10
4
 cells/well) which yields at least three times higher 
MTS or LDH formazan optical density than the blank (culture medium without cells) 
was selected for the experiments.  
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3.6.2 Cytotoxicity of PVA cryogel and AC extracts 
The results obtained from the LDH cytotoxicity assays demonstrate that when 
undiluted AC extracts were incubated with the V79 cells for 8 hours, low cell lysis 
occurred in the treated cells. In addition, a slight increase of cell mitochondrial activity 
could be observed in the MTS assay results. The increase in the cell mitochondrial 
activity after 8 hours of AC extract treatment was possibly caused by environmental 
stress therefore prolonged 24 hour treatments were used in further investigation. When 
the treatment time was extended to 24 hours, a significant increase in cell lysis was 
observed in the undiluted extract treated cells, this was also associated with a significant 
reduction in cell viability after 24 hours of undiluted extract treatment. This suggested 
that the high mitochondrial activities observed in MTS assay of V79 cells after 8 hours 
undiluted AC extract treatments could be due to the environmental stress, this cell 
survival mechanism however, failed to support the cell survival after 24 hours of 
incubation. A 50% dilution of all extracts did not alter the cytotoxic effect of the 
positive control extract, however a significant increase in AC extract treated cell 
viability and a significant decrease in LDH release was observed. This indicated that by 
supplying the cells with 50% of fresh medium could boost the cell survival after 24 
hours of AC extract treatment. The AC used in this study exhibits high BET specific 
surface area and abundant meso- and macro-pores (Table 3-1). These characteristics 
were suggested to increase their adsorption for a range of larger molecular weight 
molecules [136, 139]. This indicating that the ACs are capable for removing nutrients 
essential for cell survival, therefore, could result in cell starvation. 
Studies published by Barnes et al. [225] on in vitro cytotoxicity evaluation of 
porous phenolic resin derived AC with less than 27 nm diameter mesopore sizes, 
utilizing a colony count method showed an initial inhibition of colony formation which 
is an indicator of material cytotoxic effects. Further studies on ions and protein content 
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in the cell culture medium extract using atomic adsorption spectrophotometry and the 
Bradford total protein assay revealed a 71% loss of calcium, 52% loss of magnesium 
and 47% loss of total protein after each millilitre of FCS supplemented DMEM culture 
medium was incubated with 0.1g AC samples for 24 hours. The loss of these essential 
ions and proteins was believed to be the real cause of the cytotoxic effect seen in the 
colony count results. When AC to medium ratio was reduced and supplementary FCS 
was added after the AC-medium incubation, an increase of colony formation was 
observed, therefore, Barnes et al. suggested that the adsorptive nature of the AC 
samples should be taken into account when an in vitro cytotoxicity assay is conducted 
to avoid a false positive cytotoxic effect [225].  
Recently an in vitro cytotoxicity study of porous carbon material for drug 
delivery was conducted by Zhao et al. utilising the MTT assay to assess the cytotoxicity 
of carbon spheres with 500-800 nm diameter particle size range [239]. In their study 10 
to 800 µg/ml of carbon nanospheres were incubated with cells for 24 hours before the 
MTT assay was performed to determine the cell mitochondrial activity. Although a low 
cytotoxicity was exhibited by the carbon nanospheres, an increasing cytotoxicity trend 
was observed as the carbon nanosphere concentration increased [239]. This could again 
be an effect caused by nutrient depletion in the culture medium due to carbon adsorption. 
In the study presented in this chapter, a selection of ACs prepared from different 
activation methods, with larger mesopore sizes were used. However, a similar pattern 
was observed in the cytotoxicity of ACs used in this chapter in comparison to those in 
Barnes’ study [225]. The 100% undiluted AC extract appeared to have a cytotoxic effect 
towards V79 cells, whilst a 50% dilution of this extract with fresh culture medium 
increased V79 cell survival as evidenced by both the MTS and LDH results. The same 
type of dilution didn’t alter the cytotoxic effect caused by V79 cells treated with the 
positive control extract. This suggested that the cytotoxic effect of the 100% AC extract 
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treatment seen in V79 cells was simply adsorption of nutrients which are important for 
cell survival rather than leaching of cytotoxic elements from the AC. 
3.6.3 Conclusions 
Based on the in vitro LDH and MTS assay results, it can be concluded that the 
AC beads and PVA1-GA cryogel samples did not leach cytotoxic components into the 
cell culture medium after 24 hours of incubation. No complications were observed 
during the standard MTS and LDH assessments of PVA1-GA cryogel cytotoxicity. In 
contrast, the determination of AC cytotoxicity was more challenging because of its 
nutrient adsorbing characteristics.  
ACs from Mast Carbon International Ltd did not show any cytotoxic effect 
towards V79 cells after 8 hours incubation. However, the nutrient depletion caused by 
AC adsorption resulted in cell starvation, and led to a cytotoxic effect in the cells 
exposed to 100% AC extracts. This cytotoxic effect disappeared when 50% fresh 
culture medium was used to supply the essential nutrients required by cell survival. 
Furthermore, the results indicated that the different activation methods used for AC 
bead preparation did not influence the results obtained by the MTS and LDH assays. As 
discussed previously in chapter 2, different activation methods can produce different 
surface chemistry on the AC beads. Although this could influence the internal structure 
of the AC beads and surface interaction with molecules, no difference in their 
cytotoxicity was observed; suggesting that those different activation methods used 
during AC production all managed to produce adsorbents that do not leach toxic 
elements when incubated with culture medium. These findings and those by previous 
authors suggest that these AC’s are potentially safe for use as haemoperfusion 
adsorbents. The PVA-GA cryogels prepared from the cryogelation processes also 
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showed low cytotoxicity suggesting that they had not leached any residues of 
glutaraldehyde or monomers which are toxic, into the culture medium 
The in vitro cytotoxicity assessments suggested that cryogels prepared by 
crosslinking of PVA using glutaraldehyde and AC beads prepared by Mast Carbon 
International Ltd using different activation methods are suitable materials for biological 
applications due to their inherent low cytotoxicity.  
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Chapter 4. In vitro Protein Bound Toxin Removal by AC and PVA-
AC composite cryogel 
4.1 Introduction 
4.1.1 Albumin bound liver toxins 
The main challenge in the management of liver failure whether acute, acute-on-
chronic liver failure or chronic decompensation of end-stage liver disease, is the 
removal of accumulated substances which the malfunctioned liver failed to process [73]. 
Those accumulated substances are often referred to as liver toxins and they are 
commonly classified into three different groups: 1) small molecular weight water-
soluble toxins such as ammonia, lactate, urea; 2) middle and high molecular weight 
water soluble toxins such as amino acids, peptides, and interleukins; 3) albumin-bound 
toxins such as bilirubin, bile acids, aromatic amino acids, indoles, mercaptans, nitric 
oxide, middle- and short-chain fatty acids, phenols, tryptophan and manganese [240]. 
The removal of small molecular weight, water soluble toxins can be achieved using 
conventional haemodialysis. Although the reduction of some middle molecular weight 
molecules and albumin bound toxins in a patient’s blood circulation can be achieved 
through albumin dialysis (MARS system) or albumin containing plasma filtration 
(Prometheus system), the relatively low removal of albumin bound toxins and the high 
cost associated remain the main limiting factors of these techniques. Liver toxins 
including bilirubin, cholic acid, tryptophan and phenol exhibit different levels of 
albumin binding affinity (Table 4-1), consequently they are often chosen for the 
evaluation of new adsorbents for EBP hepatic support systems. 
Bilirubin (Figure 4-1) is a classic liver failure bio-marker. In mammals, 
degradation of haem-containing proteins such as haemoglobin are the main source of 
bilirubin in blood [241]. After formation, bilirubin presents in the circulation either in 
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its unconjugated or conjugated forms. The unconjugated bilirubin exhibits low 
solubility in aqueous solution such as blood. Therefore, unconjugated bilirubin is 
transported in the form of a reversible albumin-bilirubin complex in the blood. When 
entered the liver, unconjugated bilirubin is released by albumin, and transformed into its 
conjugated, water soluble form, hence leaving albumin molecules free to bind and 
transport other molecules. The conjugated bilirubin is transported from the liver and 
recycled via liver - small intestine - liver enterohepatic circulation [242]. The impaired 
liver fails to carry out bilirubin conjugation and results in the accumulation of albumin 
bound unconjugated bilirubin in the circulation. Although toxicity of unconjugated 
bilirubin has been reported, binding to plasma albumin, is believed to remove bilirubin 
toxicity [242]. Normally the concentration of albumin in plasma is in excess of 
unconjugated bilirubin, so that little free bilirubin remains. However, it has been 
reported that during hyperbilirubinemia the concentration of unconjugated bilirubin may 
increase from the normal 3- 17 µmol/l range to over 103-428 µmol/l [73].  
 
 
Figure 4-1 Chemical structure of bilirubin [243]. 
 
  
 144 
 
Cholic acid (Figure 4-2 A) is one of the most important bile acids converted 
from cholesterol in the liver and stored in the gallbladder. As with most of the bile acids, 
the main function of cholic acid is for lipid transportation and for assisting adsorption in 
the small intestine [244]. Under normal healthy conditions, the enterohepatic circulation 
can recycle the bile acids efficiently, which results in their low serum concentration 
[244, 245]. However, when the liver function is compromised, leakage of bile acids into 
the blood circulation occurs and increases the plasma bile acid concentration from the 
normal 3-7 µM to 500-600 µM [246]. At lower serum cholic acid concentrations, cholic 
acid binds to high affinity sites on albumin [247], when the serum cholic acid level 
exceeds the capacity of the albumin high affinity sites, serum lipoproteins also exhibit 
high binding affinity towards cholic acid [248]. The binding of cholic acid to 
lipoprotein may assist the cellular uptake of cholic acid by crossing the cellular 
membrane via lipoprotein receptors and channels on the cell membrane [248]. The 
dramatic increase of bile acid levels in the bloodstream and tissues under hepatic 
distress has been proven to cause a wide variety of pathophysiological conditions such 
as elevated plasma cholesterol levels and impaired biosynthesis transport and may have 
severe cytotoxic effects [249]. 
 
 
Figure 4-2 Chemical structure of cholic acid (A), tryptophan (B) and phenol (C).  
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Tryptophan (Figure 4-2 B) is an essential amino acid acquired via the diet. 
However, abnormal blood levels in liver disease makes it one of the more important 
biomarkers for the study of liver associated diseases. The circulation of tryptophan in 
the bloodstream is facilitated by albumin binding due to its low water solubility [250]. 
Elevated tryptophan levels found in the blood of liver failure patients is believed to be 
the main causal factor of hepatic encephalopathy [251] and a promoter of hepatic 
steatosis [252]. 
Although phenol is a small-water-soluble compound, its binding to proteins has 
been reported in rat and dog plasma [253]. The presence of phenol in the blood is very 
rare and usually only occurs upon exposure to large amounts of phenol via inhalation or 
ingestion. However, its neurotoxicity, nephrotoxicity and ability to induce liver failure 
means its removal is essential.  
4.1.2 Albumin bound uraemic toxins 
Uraemic toxins, are a group of substances that accumulate in the bloodstream 
and interact negatively with biologic functions during kidney failure [254]. Generally 
the uraemic toxins are classified into three categories which are 1) free water soluble 
low molecular weight (< 500 D) solutes; 2) protein bound solutes and 3) middle 
molecules (> 500 D) [44]. The levels of free water soluble low molecular weight 
uraemic toxins creatinine and urea have not only been used as biomarkers for uraemic 
syndrome, but are also used as important indicators of the effectiveness of renal 
replacement therapy. However, increasing clinical evidence suggests that the toxicity of 
these two compounds is relatively low compared to albumin bound uraemic retention 
solutes such as p-cresyl sulphate and indoxyl sulphate [35, 48]. P-cresyl sulphate and 
indoxyl sulphate have attracted much attention due to their toxic effects and poor 
removal using current renal replacement therapies [255]. Studies have also suggested 
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the inclusion of serum p-cresyl sulphate and indoxyl sulphate levels for the prediction of 
the progression of chronic kidney disease and related clinical complications [48, 256]. 
P-cresyl sulphate (Figure 4-3 A) is a conjugated form of p-cresol which is a 
bacterial fermentation product of tyrosine in the large intestine [257]. Indoxyl sulphate 
(Figure 4-3 B) is derived from tryptophan, which is metabolised by intestinal bacteria 
into indole and further converted to indoxyl sulphate in the liver. The in vitro 
cytotoxicity and clinical adverse effect of p-cresyl sulphate and indoxyl sulphate are 
well established [258]. Furthermore, both toxins are reported to bind to albumin on 
Sudlow’s site II of the molecule. Since the average molecular weight of albumin is 67 
kDa, when albumin bound, these molecules are poorly removed by conventional renal 
replacement therapies [259]. 
 
 
Figure 4-3 Chemical structure of p-cresyl sulphate (A) and indoxyl sulphate (B). 
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Table 4-1 A description of the binding of selected liver and kidney toxins to 
albumin. 
Compound molecular weight (Mwt), albumin-compound binding constant (KA) 
and their primary binding sites on albumin are listed. 
Compounds MWt (g/mol) KA (M
-1
) Primary binding site Ref 
Phenol 94.11 -- -- -- 
Tryptophan 204.23 1.0×10
4
 
Sudlow’s site II , 
subdomain IIA, loop 7-8 
[260] 
Cholic acid 408.57 0.33×10
4
 
Sudlow’s site II, 
subdomain IIA, loop 4-5 
[248, 261] 
Bilirubin 584.66 9.5×10
7
 
Sudlow’s site II, 
subdomain IIA, loop 4 
[262] 
P-cresyl sulphate 188.20 1.0×10
5
 
Sudlow’s site II, 
subdomain IIA 
[259, 263] 
Indoxyl sulphate 213.21 0.98×10
5
 
Sudlow’s site II, 
subdomain IIA 
[259, 263] 
 
The albumin bound liver toxins and uraemic toxins listed above pose a huge 
challenge in their removal using conventional dialysis [9]. Their interaction with 
albumin demonstrated in Table 4-1 indicates the strongest binding between albumin and 
bilirubin (9.5 × 10
7) at Sudlow’s site II subdomain IIA, loop 4 [262]. Cholic acid binds 
to albumin at the Sudlow’s site II subdomain IIA loop 4-5, and demonstrates the lowest 
binding constant of 0.33 × 10
4
 [262].  
4.1.3 AC adsorption of protein bound toxins 
Although the adsorptive properties of AC are well studied, the mechanism of AC 
adsorption of albumin bound molecules remains largely unclear. Studies suggested that 
the efficient removal of albumin bound toxins by HemoSorbent Granulated Deliganding 
(HSGD) ACs could be due to the deliganding effects of AC, leading to the purification 
of albumin from high affinity toxins such as unconjugated bilirubin [264]. Furthermore, 
the HSGD carbon also demonstrated efficient removal of relatively low affinity uraemic 
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toxins including 3-carboxy-4-methyl-5-propyl-2-furanpropionate (albumin association 
constant 130 ×10
5
 M
-1
), indoxyl sulphate (albumin association constant 16 ×10
5
 M
-1
) 
and hippuric acid (albumin association constant 0.1×10
5
 M
-1
) [265]. Mesoporosity of 
the HSGD ACs was reported to be assisting the AC deliganding and adsorption of 
albumin bound toxins [266].  
Similar to HSGD carbons, NovaCarb S (Mast Carbon International Ltd, UK) are 
also prepared by the pyrolysis of synthetic resins and possess a large surface area. 
Furthermore, a study conducted by Tripisciano et al. suggested the removal of albumin 
bound liver toxins including bilirubin, cholic acid, tryptophan and phenol was 
dependent on the degree of burn off during the AC pyrolysis process [135]. However, 
there is currently a lack of comprehensive understanding regarding the dependence of 
albumin bound toxin adsorption efficiency on the pore size distribution of NovaCarb S 
ACs. 
4.2 Aims and objectives 
This chapter aims to investigate differences in the ability of a series of ACs from 
Mast Carbon International Ltd, with a range of different pore size distributions, to 
remove marker albumin bound toxins  in order to select an AC with optimum pore size 
characteristics for composite preparation. NovaCarb S ACs (code A1 to A5) with 
similar particle sizes (250 to 500 µm diameter), large specific surface are (> 1200 m2/g), 
abundant micropores and increasing pore sizes in the meso- macropore range (Table 4-2) 
were selected for this study. Furthermore, this chapter also aims to identify if the AC 
beads selected for optimal albumin bound toxin adsorption can be incorporated into the 
PVA cryogel matrix whilst maintaining adsorption capacity for protein bound uraemic 
toxins.  
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A selection of albumin bound liver and uraemic toxins with a wide range of 
albumin binding affinities were used to select the appropriate AC beads by evaluating 
the adsorption efficacy of ACs with different porous characteristics for these toxins. 
Removal of the albumin bound uraemic toxins indoxyl sulphate and p-cresyl sulphate 
by the PVA3-GA-A6 composite cryogels was investigated in order to evaluate the 
incorporation of AC beads into the cryogel matrix and maintenance of porosity. In 
addition, methods for the preparation of p-cresyl sulphate and quantification of the 
concentration of indoxyl sulphate and p-cresyl sulphate in plasma were also developed 
as part of this study. 
4.3 Materials 
4.3.1 Liver toxin removal 
 Bilirubin (Sigma-Aldrich: B-4126),  
 Cholic acid (Sigma-Aldrich: C1129) 
 Tryptophan (Sigma-Aldrich: T9753) 
 Phenol (Sigma-Aldrich: P1037) 
 Bile acids test reagent (Trinity Biotech: 450) 
 Total Protein analysis reagent (Roche Diagnostic GMBH: 1553836-316) 
 Albumin BCG assay reagent (Roche Diagnostic GMBH: 11970569 216) 
 Total Bilirubin assay reagent (Roche Diagnostic GMBH: 11822730 190) 
4.3.2 Uraemic toxin removal 
 Chlorosulphonic acid (Fisher Scientific: 30449-5000) 
 Naphthalenesulfonic acid (Fisher Scientific: 18140-250) 
 P-cresol (Fisher Scientific: 40574-5000) 
 P-cresyl sulphate prepared in house 
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 Sodium caprylate (Fisher Scientific: 33460-1000) 
 Acetonitrile (Fisher Scientific: A-0627-17) 
 HPLC grade water (Fisher Scientific:W/0106/17) 
 Potassium 3-indoxyl sulphate (Sigma-Aldrich: 374245) 
4.3.3 Adsorbents 
 Carbon dioxide activated AC beads details listed in Table 4-2 (Mast 
Carbon International) 
 PVA3-GA, PVA3-GA-A6 cryogel (prepared according to Chapter 2) 
 
Table 4-2 Characteristics of the ACs used in the liver and kidney toxin removal 
studies 
d is pore sizes (diameter) determined by mercury porosimetry; D is the AC bulk 
density; Vmicro is the volume of pores less than 2 nm diameter; SBET is the BET 
specific surface area determined by nitrogen adsorption. (Data obtained from the 
manufacturer) 
 
d 
(nm) 
D  
(g/ml) 
V micro 
(cm
3
/g) 
V micro 
(cm
3
/ml) 
SBET 
(m
2
/g) 
SBET 
(m
2
/ml) 
A1 < 2 nm 0.56 0.69 0.39 1204 674 
A2 30 0.38 1.30 0.49 1559 592 
A3 70 0.27 1.75 0.47 1493 403 
A4 80 0.21 1.80 0.38 1548 325 
A5 120 0.18 1.61 0.29 1235 222 
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4.4 Methods 
4.4.1 Liver toxin removal 
The liver toxin removal test was carried out according to the method published 
by Weber et al. [267]. Total of 2 ml AC samples were washed three times using 10 ml 
sterile 0.9% NaCl solution. Aliquots of wet AC samples (0.6 ml) were then transferred 
to fresh 15 ml centrifuge tubes. Frozen plasma was defrosted in a 37 °C water bath 
before being spiked with 300 µM bilirubin, 100 µM cholic acid, 100 µM tryptophan and 
2 mM phenol to mimic the level of liver toxins in clinical applications. 
To each 0.6 ml aliquot AC sample, 5.4 ml of spiked plasma was added. The 
mixtures were then incubated in a rotating incubator at 37 °C for 5 min, 15 min, 30 min 
and 60 min. At each time point, 1 ml carbon/plasma mixture was collected and the 
plasma was separated from the carbon by centrifugation. The plasma supernatant (400 
µl) were transferred to fresh 1.5 ml microcentrifuge tubes and stored at -20 °C prior to 
the analysis. The remaining total protein, albumin, bilirubin and cholic acid in the 
plasma samples were quantified colourmetrically using an automated Roche/Hitachi 
902 Chemistry Analyzer, while the remaining phenol and tryptophan concentrations 
were determined using High Pressure Liquid Chromatography (HPLC). Prior to HPLC 
analysis, the plasma samples were de-proteinated by addition of 500 µl methanol 
(chilled to – 20 °C) per 50 µl of plasma sample. The mixtures were then vortex-mixed 
and stored at -80 °C for 30 min. The precipitated plasma proteins were separated from 
the aqueous content by centrifugation. Then 10µl of the supernatant was injected into a 
Waters 600 HPLC system equipped with a Varian C18 reversed phase HPLC column 
and Waters 2487 dual absorbance detector (UV λ=280 nm) running with a mobile phase 
of 50% (
v
/v) methanol. 
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4.4.2 Uraemic toxin removal 
4.4.2.1 Synthesis of p-cresyl sulphate 
Since P-cresyl sulphate is not commercially available, it was synthesised 
according to a method that was adapted from Feigenbaum and Neuberg’s preparation of 
aromatic sulphuric acid esters [268]. Firstly, 11 ml of p-cresol was dissolved in 40 ml of 
pyridine in a three-neck round bottom flask. The solution was cooled to – 15 °C using 
an ethanol/dry ice bath. A pressure equalising dropping funnel containing 8.56 ml 
chlorosulphonic acid in 20 ml chloroform was connected to the flask. The reaction was 
carried out by adding the chlorosulphonic acid to the p-cresol solution drop wise and the 
temperature of the reaction was controlled at under -5 °C. To avoid moisture collection, 
the reaction system was dried under a nitrogen atmosphere.   
After the reaction, the chloroform was evaporated by rotary evaporation and the 
remaining mixture was adjusted to pH 7 by adding saturated potassium hydroxide. The 
p-cresyl sulphate product was extracted from the mixture using 300 ml water which was 
later removed by heated rotary evaporation. The p-cresyl sulphate crystals were then 
washed under vacuum using ethyl acetate in order to remove any remaining pyridine. 
Nuclear magnetic resonance spectroscopy was used to determine the structure of the 
synthesised p-cresyl sulphate. 
4.4.2.2 Plasma sample collection 
A set of standards were prepared by spiking the plasma sample standards STD 1 
to 6 with increasing indoxyl sulphate and p-cresyl sulphate concentrations according to 
Table 4-3. The samples were used to prepare a standard curve for the calculation of 
unknown concentrations of both indoxyl sulphate and p-cresyl sulphate from plasma 
samples collected after incubating with ACs. 
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Table 4-3 Concentrations of spiked p-cresyl sulphate and indoxyl sulphate in the 
standard plasma samples 
 Standards 
 STD 1 STD 2 STD 3 STD 4 STD 5 STD 6 
p-cresyl sulphate 
conc. (µM) 
0 15.625 31.25 62.5 125 250 
Indoxyl sulphate 
conc. (µM) 
0 7.8125 15.625 31.25 62.5 125 
 
4.4.2.2.1 Batch test of p-cresyl sulphate and indoxyl sulphate removal by AC beads 
Prior to the test, 0.5 g carbon adsorbents were equilibrated with 800 µl sterile 
PBS in a shaking incubator at room temperature overnight. On the day of the test, 
frozen plasma was defrosted at 37 °C before 250 µM p-cresyl sulphate and 150 µM 
indoxyl sulphate were added to the plasma samples. The spiked plasma was incubated 
at 37 °C in a shaking incubator for 30 min in order to assist the binding of p-cresyl 
sulphate and indoxyl sulphate to the plasma albumin. Prior to the batch test, the carbon 
adsorbents were separated from the PBS solution by centrifugation. The PBS solution 
was then removed and 800 µl of spiked plasma was added to the equilibrated carbon 
adsorbent. The plasma/carbon mixtures were incubated at 37 °C in a shaking incubator 
for 10, 30 and 60 min; a negative control of non-spiked plasma without adsorbent and a 
positive control of spiked plasma without adsorbent were also included in the study. At 
the timed intervals the carbon adsorbents were separated from the plasma by 
centrifugation and the 600 µl of supernatant plasma top layer was collected and stored 
at – 20 °C. 
 154 
 
4.4.2.2.2 P-cresyl sulphate and indoxyl sulphate removal by PVA cryogel and PVA-
AC composite cryogel in circulating system 
In order to mimic the actual EBP system, a circulating assay system was set up 
according to Figure 4-4 for the p-cresyl sulphate and indoxyl sulphate removal studies. 
Three different test columns were prepared as follows; 1 ml PVA3-GA cryogel, 1 ml 
PVA3-GA-A6 cryogel and 30 mg of A6 (equal to weight of A6 in the PVA3-GA-A6 
cryogel column). One control column with no material was also included in the study to 
observe any removal effect of the tubing system. An ISMATEC (IPC8) multi channel 
peristaltic pump was used to ensure a stable circulating flow at a speed of 1 ml/min. 
Four reservoirs containing 20 ml of plasma spiked with 250 µM p-cresyl sulphate and 
150 µM indoxyl sulphate were connected to the inlets of the four columns via different 
channels of the peristaltic pump (Figure 4-4 B). The same silicon based tubing was used 
to connect the outlets of these columns back to the plasma reservoirs. 
 
 
Figure 4-4 Circulating system experimental set up for the removal of p-cresyl 
sulphate and indoxyl sulphate from the spiked plasma.  
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4.4.2.3 HPLC analysis sample preparation for p-cresyl sulphate and indoxyl 
sulphate 
The HPLC analysis methods were adapted from de Loor et al [46]. In order to 
monitor the efficiency of the sample preparation, 20 µl of 0.50 mM 1-
naphthalenesulfonic acid was added to 400 µl of plasma samples in 15 ml centrifuge 
tubes, to act as an internal standard. To allow the release of p-cresyl sulphate and 
indoxyl sulphate from albumin binding, 250 µL of 0.25 mol/l sodium caprylate was also 
added to the plasma to act as a binding competitor.  
Plasma proteins were precipitated by addition of 4 ml cold acetone. The 
acetone/plasma was vortex mixed and the protein precipitates were separated from the 
mixture by centrifugation at 5000 g for 10 min and the supernatant was transferred to a 
fresh 15 ml centrifuge tube. The acetone in the supernatant was then extracted from the 
aqueous phase by addition of 4 ml cold dichloromethane. The mixtures were then 
vortex-mixed and the aqueous layer was separated from the dichloromethane/ acetone 
mixture by centrifugation at the speed of 7000 g for 5 min. 200 µl of the top layer 
aqueous solution was collected and added to 20 µl of 1M hydrochloric acid, before the 
samples were injected into the HPLC system. For the HPLC analysis, 15 µl of the final 
mixture was injected into the HPLC for analysis. 
4.4.2.4 HPLC analysis of p-cresyl sulphate and indoxyl sulphate 
The HPLC analysis method used for the detection and quantification of indoxyl 
sulphate and p-cresyl sulphate was modified from Henriette et al. [46] and briefly 
described in this section. A C-18 reverse phase column was used in the HPLC system 
with mobile phase A; 0.2% trifluoracetic acid in HPLC grade water and mobile phase B; 
0.2% trifluoracetic acid in HPLC grade acetonitrile. The mobile phase was pumped 
through the column with six programmed steps listed in Table 4-4. A gradient change 
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from 85% mobile phase A and 15% mobile phase B to 80% mobile phase A and 20% 
mobile phase B in step 2 was used to separate the p-cresyl sulphate, indoxyl sulphate 
and the 1-naphthalenesulfonic acid in the mixture. The remaining substances were 
eluted by 100% mobile phase B in steps 3 and 4. After the elution, the system was re-
equilibrated to the 85 % mobile phase A and 15% mobile phase B environment.  
Indoxyl sulphate and 1-naphthalenesulfonic acid were detected by the Waters 
fluorescence detector at the wavelength of 234 nm and p-cresyl sulphate by the same 
detector at 298 nm. Concentrations of p-cresyl sulphate and indoxyl sulphate were 
calculated with reference to standard curves (Figure 4-14). 
 
Table 4-4 Solvent gradient experimental set up on the HPLC pump. 
Step Time (min) Solvent A  Solvent B Flow rate(ml/min) 
1 5.0 85% 15% 0.6 
2 5.0 80% 20% 0.6 
3 5.0 0% 100% 0.6 
4 1.0 0% 100% 0.6 
5 2.0 85% 15% 0.8 
6 5.0 85% 15% 0.6 
 
4.4.3 Data analysis 
The removal of toxins by each ml of adsorbent from spiked plasma was 
calculated using Equation 4-1, where C0 represents toxin concentration at time zero, Ct 
is the toxin concentration at the different time points, v is the volume of adsorbent used. 
Due to the different adsorbent densities, toxin removal data collected was also 
normalised using adsorbent weight according to Equation 4-2, where C0 represents 
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toxin concentration at time zero, Ct is the toxin concentration at the different time points, 
w is the weight of adsorbent used. 
 
                        
 0   t
 
 Equation 4-1 
                       
 0  t
 
 Equation 4-2 
 
Computer software Prism 5 (Version 5.03 from GraphPad) was used for graph 
plotting and statistical analysis. Two-way ANOVA (repeated measures -mixed model) 
was applied to the grouped data to determine if the difference in adsorbents and/or 
incubation time had a significant influence on toxin removal. In addition, one-way 
ANOVA analysis of variance was selected for the determination of influence of 
increasing incubation time on the removal of toxins from the spiked plasma for each 
adsorbent. The adsorption kinetics of albumin, bilirubin and cholic acid were also 
determined using Pseudo second order evaluation (Equation 2-8). 
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4.5 Results 
4.5.1 Removal of liver toxin by ACs with increase meso- to macropore sizes 
4.5.1.1 Phenol removal 
The results of phenol removal by each millilitre of A1 to A5 carbon beads 
showed a complete removal of phenol by all the ACs within 5 minutes of incubation 
period (Figure 4-5). Therefore, there was no significant difference in the removal of 
phenol when different AC samples (P = 0.9948) or different incubation time (P > 0.9) 
were used.  
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Figure 4-5 Amount of phenol removed from the spiked human plasma samples. 
Samples were collected after the 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) 
incubated with 5.4 ml of phenol (2 µmol/ml) spiked fresh frozen human plasma for 
5, 15, 30 and 60 min, and analysised HPLC. Phenol removal calculated based on 
the weight of AC beads used. (Mean n=4, ± SEM) 
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4.5.1.2 Tryptophan removal 
The results illustrated that complete tryptophan removal by each millilitre of 
ACs was achieved by all the test adsorbents within the 60 minutes incubation period. 
Therefore, no significant difference (p = 0.9949) was observed in the adsorption of 
tryptophan by A1 to A5 carbon beads (Figure 4-6). In addition, there was no significant 
difference in the tryptophan removal by all the AC used when the incubation time 
increased (Appendix 1. 10). 
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Figure 4-6 Amount of tryptophan removed from the spiked human plasma. 
Samples were collected after the 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) 
incubated with 5.4 ml of tryptophan (0.1 µmol/ml) spiked fresh frozen human 
plasma for 5, 15, 30 and 60 min, and analysised using HPLC. Tryptophan removal 
was calculated based on the volume of the AC beads. (Mean n=4, ± SEM) 
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4.5.1.3 Cholic acid removal 
The removal of cholic acid by ACs with micropores only (A1), meso-
/micropores (A2) and increasing macro-/micropores (A3, A4 and A5) from spiked 
plasma is illustrated in Figure 4-7. When the adsorbent weight was used in the 
calculations, adsorbent A4 and A5 showed a significantly higher (P<0.001) cholic acid 
removal from the spiked plasma, compared to A1 and A2 adsorbents (Figure 4-7 A). 
Although the removal of cholic acid by A3 carbon beads was higher than the A1 and A2 
carbon beads; lower than the A4 and A5 carbon beads, these difference were not 
significant (p<0.05) (Appendix 1. 1).  
However, when the adsorbent volume was used in the calculations, all the 
carbon beads removed similar amount of cholic acid after 60 minutes of incubation 
(Figure 4-7 B). In addition, A1 carbon beads showed significantly higher cholic acid 
removal after 5 and 15 minutes of incubation compared to A5 carbon beads. A4 carbon 
beads also showed significantly (p<0.05) higher cholic acid removal after 5 minutes of 
incubation compared to A3 carbon beads (Appendix 1. 2).  
With the increase of AC-plasma incubation time, significant improvement (p < 
0.05) in the amount of cholic acid removed by A2, A3 and A5 carbon beads was 
observed (Appendix 1. 10). Whereas there was no significant difference (p > 0.05) in 
the amount of cholic acid removed by A1 and A4 carbon beads with different 
incubation times (Appendix 1. 10). 
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Figure 4-7 Amount of cholic acid removed from the spiked human plasma. 
Samples were collected after 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) were 
incubated with 5.4 ml of cholic acid (0.1 µmol/ml) spiked fresh frozen human 
plasma for 5, 15, 30 and 60 min, and analysed using Roche/Hitachi 902 Chemistry 
Analyzer. (A) Cholic acid removal calculated based on the weight of AC beads 
used; (B) Cholic acid removal calculated based on the volume of the AC beads. 
(Mean n=5, ± SEM) 
* represents p<0.05 and *** represents p< 0.001 in Bonferroni post-test of two-way-
ANOVA statistical analysis (Appendix 1 1and 2) 
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4.5.1.4 Unconjugated bilirubin removal 
The results of bilirubin removal by ACs with micropores only (A1), meso-
/micropores (A2) and increasing macro-/micropores (A3, A4 and A5) from spiked 
plasma are shown in Figure 4-8. Similarity was observed between the results of 
bilirubin removal calculated based on adsorbent volume (Figure 4-8 B) and results 
normalised with adsorbent weight (Figure 4-8 A). A1 and A2 carbon beads removed 
least bilirubin over time, A3 adsorbent showed a slight but not significant (p>0.05) 
increase of bilirubin removal over time compared to A1 and A2 carbon beads 
(Appendix 1. 3 and 4). 
A significantly higher (P<0.001) bilirubin removal over time was observed when 
A4 and A5 carbon were used. In addition, there was no significant (P<0.05) difference 
in the adsorption of bilirubin by A1, A2 and A3 carbon beads when their incubation 
time was varied between 5, 15, 30 and 60 minutes (Appendix 1 11). In contrast, the 
adsorption of bilirubin by A4 and A5 carbon beads very significantly increased (p < 
0.0001) with increasing incubation time (Appendix 1 11). 
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Figure 4-8 Amount of bilirubin removed from the plasma sample. 
Samples were collected after 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) were 
incubated with 5.4 ml of bilirubin (0.3 µmol/ml) spiked fresh frozen human plasma 
for 5, 15, 30 and 60 min, and analysed using Roche/Hitachi 902 Chemistry 
Analyzer. (A) Bilirubin removal calculated based on the weight of AC beads used; 
(B) Bilirubin removal calculated based on the volume of the AC beads. (Mean n=5, 
± SEM) 
*** p< 0.001% Bonferroni post-test of two-way-ANOVA statistical analysis (Appendix 
1 3 and 4). 
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4.5.1.5 Albumin removal 
The results of albumin removal by different ACs calculated by both adsorbent 
weight and volume illustrated that A4 and A5 carbon beads removed significantly more 
(p< 0.001) plasma albumin than A1, A2 and A3 carbon beads (Figure 4-9 A and B). In 
addition, when calculated by adsorbent weight, A3 carbon beads also removed a 
significantly (P<0.05) larger amount of plasma albumin compared to A1 and A2 carbon 
beads (Figure 4-9 A). When calculated by adsorbent volume, the amount of plasma 
albumin removed by A3 carbon beads was only significantly higher than the A1 carbon 
beads after more than 15 minutes of incubation. No significant difference between the 
amount of plasma albumin removed by A1 and A2 carbon beads (p>0.05) regardless of 
whether the adsorbent weight or the volume was used in the calculation (Appendix 1. 5 
& 1. 6). 
There was no significant difference in the removal of plasma albumin by A1 
(p=0.2588), A2 (p=0.2552) and A5 (p=0.2311) carbon beads along the increase of 
incubation time (Appendix 1. 11).  
4.5.1.6 Total protein removal 
When calculated using the adsorbent weight, the total protein removal by the 
five AC beads in Figure 4-10 A indicated that A4 and A5 adsorb significantly (p<0.001) 
higher amounts of total protein within the 60 min incubation period compared to A1, A2 
and A3 carbon beads. However, this significance was not observed in A5 carbon when 
the adsorbent volume rather than weight was taken into consideration (Figure 4-10 B). 
In addition, there was no significant difference in the removal of total plasma albumin 
by all the ACs (p>0.05) along the increase of incubation time (Appendix 1. 11). 
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Figure 4-9 Amount of human serum albumin removed from the plasma sample. 
Samples were collected after the 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) 
were incubated with 5.4 ml of fresh frozen human plasma for 5, 15, 30 and 60 min, 
and analysed using Roche/Hitachi 902 Chemistry Analyzer. (A) Albumin removal 
calculated based on the weight of AC beads used; (B) Albumin removal calculated 
based on the volume of the AC beads. (Mean n=5, ± SEM) 
*** represents a less than 0.1% probability and * represents a less than 5% 
probability of the data set having the same variance as the other data sets determined 
by Bonferroni post-test of two-way-ANOVA statistical analysis (Appendix 1. 5 and 6) 
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Figure 4-10 Amount of total protein removed from the human plasma samples. 
Samples were collected after the 0.6 ml of AC beads (A-1, A-2, A-3, A-4 and A-5) 
were  incubated with 5.4 ml of fresh frozen human plasma for 5, 15, 30 and 60 min, 
and analysed using Roche/Hitachi 902 Chemistry Analyzer. (A) Total protein 
removal calculated based on the weight of AC beads used; (B) Total protein 
removal calculated based on the volume of the AC beads. (Mean n=5, ± SEM) 
*** represents a less than 0.1% probability of the data set having the same variance 
as the other data sets determined by Bonferroni post-test of two-way-ANOVA 
statistical analysis (Appendix 1 8) 
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4.5.1.7 Adsorption kinetics of cholic acid, unconjugated bilirubin, and albumin 
removal by ACs 
To examine the adsorption kinetics of the tested microporous only AC (A1), 
meso-/microporous AC (A2) and macro-/microporous AC (A3, A4 & A5) in plasma 
samples, Pseudo first order (Appendix 2) and Pseudo second order model was used. The 
adsorption kinetics of albumin by the ACs were fitted using one phase exponential 
association model using Prism 5 computing software (Figure 4-11). A4 and A5 carbon 
beads showed higher adsorption albumin over time compared to the A1, A2 and A3 
carbon beads. The adsorption of albumin from the plasma samples reached a plateau 
after 5 minutes of incubation when A1, A2 and A4 carbon were used. The adsorption of 
albumin by A3 and A5 did not reach a plateau until 15 minutes of incubation.  
Over 95% (R
2
>0.95) probability of fitness was observed when Pseudo second 
order model was used for all the AC used in the test (Table 4-5). In contrast, when 
Pseudo first order model was used for the calculation of albumin adsorption data, a less 
than 0.45 linear regression coefficient (R
2
) was obtained (Appendix 2. 1). Therefore, the 
albumin adsorption by all the tested ACs at equilibrium (qe) calculated using Pseudo 
first orders were not valid. An increase in the amount of albumin adsorbed at the 
equilibrium (qe) along the increase of meso- to macropore seizes was observed (Table 
4-5). However, A4 carbon beads showed a higher albumin adsorption of 81.10 mg/g at 
the equilibrium compare to the A5 carbon beads (73.48 mg/g). 
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Figure 4-11 Adsorption kinetics of albumin by AC1-5 from human plasma. 
The adsorption kinetics of albumin by 0.4 ml microporous carbon (A1), 
mesoporous carbon (A2) and macroporous carbon (A3, A4 and A5) from 5.6 ml 
plasma was observed at 4 time points over 60 min of incubation period. The data 
were fitted using one phase exponential association model for mimicking the 
adsorption curve using Prism 5 computing software). (Mean n=5, ± SEM) 
Table 4-5 Pseudo-second order model of albumin adsorption kinetics from the 
spiked plasma using microporous beads with increasing meso- to macropore sizes. 
A linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the equilibrium adsorption at equilibrium (qe) for each AC used, and 
the intercept was used for the calculation of Pseudo-second-order constant (Kp2). 
AC Slope Intercept R
2
 qe (mg/g) qe (mg/l) Kp2 
A1* 0.1171 0.2513 0.9778 8.54 4.78 0.0546 
A2* 0.06553 0.1082 0.9869 15.26 5.80 0.0397 
A3 0.02673 0.1402 0.9651 37.41 10.10 0.0051 
A4 0.01233 0.03846 0.9951 81.10 17.03 0.0040 
A5 0.01361 0.02021 0.9929 73.48 13.23 0.0092 
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The adsorption kinetics of bilirubin from spiked plasma in Figure 4-12 indicated 
that the bilirubin adsorption by A1, A2 and A3 reached a plateau after 5 minutes of 
incubation. The bilirubin adsorption by A4 and A5 showed a time dependent increase; 
this increment did not reach a plateau throughout the 60 minutes of the time course of 
this experiment. Higher bilirubin adsorption was observed in A4 and A5 macro-
/microporous carbon beads compared to A1, A2 and A3 carbon beads. 
The bilirubin adsorption at equilibrium of the ACs (qe) estimated using Pseudo 
second order showed a pore size dependent increase (Table 4-6). The introduction of 
macropores with greater than 80 nm mean diameter in A4 and A5 carbon beads resulted 
in at least five-fold-increase in the estimated bilirubin adsorption at equilibrium (qe) 
calculated based on adsorbent weight compared to A1, A2 and A3 carbon beads. 
Although this increase was partially due the difference of the AC carbon beads used in 
this study, a more than four times higher qe was estimated for A5 compared to A3 
carbon beads when an equal volume was used in the calculation. However, when 
Pseudo second order equation was used to predict the plasma bilirubin adsorption curve, 
less than 0.95 linear regression coefficient (R
2
) was observed in data of bilirubin 
adsorption by all the tested AC beads (Table 4-6). Similarly, less than 0.75 of linear 
regression coefficient (R
2
) for the bilirubin adsorption data was obtained when Pseudo 
first order model was used. Due to the low fitness of both models in mimicking the 
bilirubin adsorption by AC over 60 minutes of incubation, the qe estimated should only 
be used as indications of actual bilirubin adsorption capacity of the ACs. 
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Figure 4-12 Adsorption kinetics of bilirubin by AC1-5 from spiked plasma. 
The adsorption kinetics of bilirubin by 0.4 ml microporous carbon (A1), 
mesoporous carbon (A2) and macroporous carbon (A3, A4 and A5) from 5.6 ml 
300 µM bilirubin spiked plasma was observed at 4 time points over 60 min of 
incubation period. The data were fitted using one phase exponential association 
model for mimicking the adsorption curve using Prism 5 computing software). 
(Mean n=5, ± SEM) 
Table 4-6 Pseudo-second order model of bilirubin adsorption kinetics from the 
spiked plasma using microporous beads with increasing meso- to macropore sizes. 
A linear regression equation was fitted to each data set. The fitness of the 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the equilibrium adsorption at equilibrium (qew) for each AC used, the 
adsorption capacities were corrected by AC density (qev), and the intercept was 
used for the calculation of Pseudo-second-order constant (Kp2). 
AC Slope Intercept R
2
 qew (mg/g) qev (mg/ml) Kp2 
A1 23.62 77.98 0.4397 0.04 0.02 7.1568 
A2 12.54 28.97 0.8534 0.08 0.03 5.4287 
A3 4.078 49.27 0.7618 0.25 0.07 0.3376 
A4 0.7937 15.76 0.7755 1.26 0.26 0.0400 
A5 0.6294 10.36 0.9056 1.59 0.29 0.0382 
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4.5.2 Removal of uraemic toxins by ACs and PVA-AC composite cryogels 
4.5.2.1 Validation of the p-cresyl sulphate and indoxyl sulphate removal study 
4.5.2.1.1 NMR spectrum of p-cresyl sulphate prepared 
To confirm the successful preparation of p-cresyl sulphate, the products prepared 
according to section 4.4.2.1 were analysed by NMR spectroscopy. As illustrated in 
Figure 4-13, the quartet at 7.2 to 7.3 ppm chemical shift corresponds to the aromatic 
ring structure and the singlet at 2.3 ppm chemical shift corresponds to the methyl group 
of the p-cresyl sulphate molecules (Figure 4-3 A). The singlet peaks at the chemical 
shifts of 4.5 and 3.7 ppm correspond to the protons from water and sodium hydrogen 
phosphate in the PBS solution respectively. The singlet peak at the 0 ppm chemical shift 
corresponds to the protons from external standard sodium-3-trimethylsilylpropionate. 
 
Figure 4-13 The NMR spectrum of p-cresyl sulphate prepared in house 
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4.5.2.1.2 Standard curve of indoxyl sulphate and p-cresyl sulphate 
As illustrated in Figure 4-14, a linear relationship (R
2
=0.9974) between the 
normalised fluorescence intensity and indoxyl sulphate concentration up to 150 µM was 
observed. In addition, the relationship (R
2
=0.9967) between p-cresyl sulphate 
concentration up to 250 µM and its normalised fluorescence intensity was also 
illustrated in Figure 4-14. The linear regression equations obtained through these two 
standard curves were used for determination of p-cresyl sulphate and indoxyl sulphate 
concentrations in the plasma samples before and after incubation with ACs. 
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Figure 4-14 Standard curve of indoxyl sulphate and p-cresyl sulphate against the 
normalised fluorescence intensity. (n=4 ± SEM) 
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4.5.2.1 Indoxyl sulphate and p-cresyl sulphate removal by batch testing 
The study of liver toxin removal by AC with different pore sizes indicated a 
dependence of the albumin bound bilirubin removal with an increasing AC pore size up 
to 80 nm in diameter. When the AC pore size reached 120 nm, no improvement in the 
bilirubin removal was observed. Therefore in the uraemic toxin removal study, only a 
selection of ACs with pore size up to 80 nm diameter was used. 
Efficient indoxyl sulphate removal by all the tested AC beads over 60 minutes of 
incubation were observed (Figure 4-15). The removal of indoxyl sulphate by 
microporous AC (A1), mesoporous AC (A2) and macroporous AC (A3) were not 
significantly (P>0.05) different over the 60 min incubation period (Figure 4-15). The 
only exception was the indoxyl sulphate adsorption by A4 macroporous AC, which was 
significantly (p<0.05) different from the A1 after 5 minutes of incubation and A3 after 
15 minutes of incubation. In addition, the removal of indoxyl sulphate by A1 (p=0.0257) 
and A2 (p=0.0259) showed a significant time dependent increase, with one exception of 
A2 after 15 min incubation. No significant difference was observed in the removal of 
indoxyl sulphate by A3 (p=0.3711) or A4 (p=0.1330) at increasing incubation time. 
When Pseudo second order model was applied to the indoxyl sulphate adsorption data, 
over 99% fitness was observed in each AC used (Table 4-7). Due to the efficient 
adsorption of indoxyl sulphate by each gram of all the ACs (0.8 mg/g), very little 
difference was observed at its equilibrium adsorption by ACs with different meso- to 
macropore sizes when adsorbent weight was used in the calculation.  
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Figure 4-15 Amount of indoxyl sulphate removed by AC1-4 from spiked plasma. 
The removal of indoxyl sulphate by 0.5 g microporous carbon (A1), mesoporous 
carbon (A2) and macroporous carbon (A3 and A4) from 10 ml 150 µM (0.15 
µmol/ml) indoxyl sulphate spiked plasma was observed at 4 time points over 60 
min incubation period. (Mean n=4, ± SEM) 
* represents a less than 5% probability of the data set have same variance as the other 
data sets determined by Bonferroni post-test of two-way-ANOVA statistical analysis. 
 
Table 4-7 Pseudo-second order model of indoxyl sulphate adsorption kinetics from 
the spiked plasma using four AC beads (A1 to A4) with increasing pore sizes. 
A linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the indoxyl sulphate adsorption at equilibrium (qe) and the intercept 
was used for the calculation of Pseudo-second-order constant (Kp2). 
AC Slope Intercept R
2
 qe (mg/g) Kp2 
A1 1.212 2.521 0.9985 0.83 0.5827 
A2 1.203 1.834 0.999 0.83 0.7891 
A3 1.28 1.629 0.9986 0.78 1.0058 
A4 1.206 0.6675 0.9999 0.83 2.1789 
 175 
 
The results of p-cresyl sulphate removal using ACs in the shaking batch tests are 
illustrated in Figure 4-16. Although efficient removal of p-cresyl sulphate was observed 
in all the ACs tested, A4 carbon beads showed a significantly higher (P<0.01) p-cresyl 
sulphate removal than A1, A2 and A3 carbon beads (Appendix 1 9). One-way-ANOVA 
statistical analysis showed no significant difference (p>0.05) in the removal of p-cresyl 
sulphate removal of each AC at different incubation time points. 
Greater than 0.99 of linear regression coefficient (R
2
) was observed in data of p-
cresyl sulphate adsorption by all the tested AC beads when Pseudo second order model 
was used (Table 4-8). When Pseudo second order was used to predicting the p-cresyl 
sulphate adsorption at equilibrium (qe), A4 carbon beads demonstrated the highest qe of 
1.6 mg/g. 
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Figure 4-16 Amount of p-cresyl sulphate removed by AC1-4 from spiked plasma. 
The removal of p-cresyl sulphate by 0.5 g microporous carbon (A1), mesoporous 
carbon (A2) and macroporous carbon (A3 and A4) from 10 ml 250 µM (0.25 
µmol/ml) p-cresyl sulphate spiked plasma was observed at 4 time points over 60 
min incubation period. (Mean n=4, ± SEM) 
*** represents p< 0.001 in Bonferroni post-test of two-way-ANOVA statistical 
analysis (Appendix 1 1and 2) 
Table 4-8 Pseudo-second order model of p-cresyl sulphate adsorption kinetics from 
the spiked plasma using four AC beads (A1 to A4) with increasing pore sizes. 
A linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the p-cresyl sulphate adsorption at equilibrium (qe), and the intercept 
was used for the calculation of Pseudo-second-order constant (Kp2). 
AC Slope Intercept R
2
 qew (mg/g) Kp2 
A1 0.7222 1.71 0.9968 1.38 2.11 
A2 0.6774 2.313 0.9952 1.48 8.88 
A3 0.8215 1.377 0.9974 1.22 1.56 
A4 0.6248 1.133 0.9985 1.60 0.80 
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4.5.2.2 Indoxyl sulphate and p-cresyl sulphate removal in the circulating system 
The removal of plasma indoxyl sulphate and p-cresyl sulphate by PVA cryogel 
and PVA-AC composite cryogels was determined in a circulating system. The AC 
bearing PVA-AC (PVA3-GA-A6) composite cryogel showed significantly higher 
(P<0.5) removal of indoxyl sulphate at each of four time points monitored compared to 
the PVA-GA cryogel (Figure 4-17). However, more than 100 µM out of 150µM spiked 
indoxyl sulphate remained in the plasma sample after 60 minutes circulation through the 
PVA-GA-AC composite cryogel. 
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Figure 4-17 Indoxyl sulphate removal in the circulating system. 
The removal of indoxyl sulphate by 1 ml plain PVA cryogel (PVA-GA) and AC 
bearing cryogel composite cryogel (PVA3-GA-A6) from the circulating 20 ml 150 
µM indoxyl sulphate spiked plasma was observed at 4 time points over a 60 min of 
incubation period. (Mean n=3, ± SEM) 
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The results also revealed that there was no significant difference (p=0.4549) in 
the removal of p-cresyl sulphate when PVA3-GA or PVA-GA-A6 were used (Figure 
4-18). In addition, the prolonged circulation time from 5 to 60 minutes did not improve 
the p-cresyl sulphate adsorption significantly (p=.0.6391) in both PVA-GA cryogel and 
PVA-GA-A6 composite cryogels. 
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Figure 4-18 p-cresyl sulphate removal kinetics in the circulating system. 
The removal of p-cresyl sulphate by 1 ml plain PVA cryogel (PVA-GA) and AC 
bearing cryogel composite cryogel (PVA3-GA-A6) from the circulating 20 ml 250 
µM p-cresyl sulphate spiked plasma was observed at 4 time points over a 60 min 
incubation period. (Mean n=3, ± SEM) 
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4.6 Discussion 
4.6.1 Removal of albumin bound liver toxins by ACs with increasing meso- to 
macroporosity 
Five ACs with increasing pore sizes (Table 4-2) were tested for the adsorption of 
a selection of albumin bound liver toxins with various molecular weights and albumin 
binding constants (Table 4-1) including; bilirubin, cholic acid, tryptophan and phenol. 
A4 and A5 the two macroporous ACs showed greatest adsorption for all tested albumin 
bound toxins. Among the selected liver toxins, results indicated nearly 100% removal of 
cholic acid (Figure 4-7) and complete removal of tryptophan (Figure 4-6) and phenol 
(Figure 4-5) by all the AC tested regardless of their pore size. An increase in bilirubin 
(Figure 4-8) albumin (Figure 4-9) and total plasma protein (Figure 4-10) removal was 
observed alongside the increase in meso- to macropore size in the AC beads. 
Despite the difference in the particle density, the bilirubin removal by A1 to A5 
carbons illustrated similar patterns when calculated based on adsorbent volume or 
weight (section 4.5.1.4). This indicated that the removal of bilirubin by AC from plasma 
was due to the increase in AC pore sizes and/or specific surface area rather than 
differences in density. Although A1 and A5 carbon beads shared similar specific surface 
area (SBET> 1,200 m
2
/g), A5 carbon beads are also macroporous AC possessing 
macropores (120 nm mean diameter) compared to A1 carbon beads which are 
microporous carbon beads (Table 4-2). The presence of additional macropores in the A5 
carbon beads could be responsible for the significant increase in bilirubin adsorption 
when compared to A1 carbon beads. Similarly, both A2 and A4 carbon beads displayed 
greater than 1,500 m
2
/g specific surface area. However, A4 carbon beads showed 
significantly higher bilirubin removal over time compared to A2 carbon beads. This 
could be due to the presence of larger pores within A4 carbon beads (80 nm mean 
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diameter) compared to A2 carbon beads (20 nm diameter). Compared to A4, A5 carbon 
beads had a larger macropore size but smaller specific surface area. This could be the 
reason for the similarity in bilirubin removal observed in both carbon beads (Figure 4-8 
A and B).  
The adsorption of bilirubin by A4 and A5 carbon beads did not reach a plateau 
throughout the 60 minute incubation period, and results thus indicate that the adsorption 
equilibrium was not reached (Figure 4-12). This suggests that with an increase in 
incubation time, A4 and A5 carbon beads could potentially adsorb more bilirubin from 
the spiked plasma. In contrast, the A1, A2 and A3 carbon beads already had reached 
bilirubin adsorption equilibrium after 5 minutes of incubation, and no further increase in 
bilirubin adsorption occurred. Current results suggest that AC removal of bilirubin was 
mainly influenced by the increase in the size of macropores in the AC beads, whilst a 
decrease in AC specific surface area could be a limiting factor in their adsorption of 
bilirubin. In addition, A4 and A5 macroporous AC beads could potentially adsorb more 
bilirubin if an increased incubation time was used to allow the adsorption to reach 
equilibrium. 
The removal of albumin by ACs showed a similar pattern as bilirubin removal 
(Figure 4-9 and Figure 4-8). In addition, the results of albumin adsorption by all the 
tested AC beads illustrated that the adsorption of albumin reached equilibrium after less 
than 15 minutes of incubation at 37 °C (Figure 4-11). The fast saturation of the albumin 
adsorption by all the tested ACs could indicate that the adsorption of albumin mainly 
occurred on the outer surface of the AC beads. This was expected due to the large 
molecular weight (average 67 kDa) of the albumin molecule. Although increases in the 
AC pore sizes appeared to hugely increase the albumin adsorption at equilibrium 
calculated by weight of the adsorbent, this huge increase was magnified by the 
difference in the AC densities. Therefore when adsorbent volume was used in the 
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calculation, a relatively smaller but notable difference was observed in the albumin 
adsorption at equilibrium by ACs with increasing pore sizes (Table 4-5). This suggested 
that the adsorption of albumin molecules possibly takes place predominantly on the 
outer surface of the carbon beads. The introduction of macropores greater than 50 nm in 
A3, A4 and A5 carbon beads appeared to at least double the albumin adsorption 
compared to the microporous only A1 and meso-/microporous A2 carbon beads (Table 
4-5). This suggested that an increase in the macropore size could improve the amount of 
albumin adsorbed. Despite the smaller mean macropore sizes that A4 possesses 
compared to A5 carbon beads, higher albumin adsorption at the equilibrium was 
observed in the A4 carbon beads compared to A5 carbon beads. This could be due to the 
higher surface areas of the A4 carbon beads compared to A5 carbon beads (Table 4-2). 
The experimental set up used a relatively low toxin to albumin ratio (<1) this 
ensured the clinical relevance of the assay and the binding of all the toxins to albumin at 
their primary binding sites (Table 4-1). In loop 4 of Sudlow site II subdomain IIA of the 
albumin molecule, bilirubin binds tightly with a binding constant of 9.5 × 10
7
 M
-1
 [262]. 
When comparing albumin and bilirubin adsorption, each gram of A5 adsorbed an 
average of 2.3 µmol bilirubin and an average of 1.1 µmol/g albumin at equilibrium 
(Table 4-5 & Table 4-6). The binding site of cholic acid on albumin is in the loop 4-5 of 
Sudlow’s site II subdomain IIA, which is very close to the bilirubin binding site. 
Compared to bilirubin-albumin interaction, albumin shows lower affinity towards cholic 
acid (KA= 0.33 ×10
4
 M
-1
). A study by Tripisciano et al suggested that the co-existence 
of high levels of bilirubin (300 µM) and cholic acid (100 µM) could result in the 
competition of the neighbouring binding site in albumin, and result in a higher than 
expected free cholic acid concentration [269]. Therefore, the adsorbed cholic acid could 
largely consist of the non-albumin-bound cholic acid. Although tryptophan has a higher 
binding affinity for albumin (1.0 × 10
4
) in comparison to cholic acid, its low molecular 
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weight could be one of the reasons for its efficient removal from spiked plasma samples. 
Efficient adsorption of small molecular weight substances by AC were already 
demonstrated in the A6 carbon adsorption of methylene blue described in Chapter 2 
(section 2.5.8). In addition, carbon materials such as activated carbons and carbon 
nanotubes have been regularly reported to show efficient adsorption of phenolic organic 
compounds [267, 270, 271]. The efficient removal of phenol and tryptophan from the 
plasma samples could be due to their phenolic ring structure. AC adsorption of liver 
toxins with different binding affinity towards albumin indicated that a decrease in toxin 
albumin binding affinity resulted in an increase in toxin adsorption efficiency by AC.  
The Tripisciano et al study investigated the adsorption of albumin bound liver 
toxins (including unconjugated bilirubin, cholic acid, tryptophan and phenol) and 
cytokines (including TNF-α and IL-6) by macroporous ACs (50 - 100 nm in diameter)  
from MAST Carbon Ltd with increasing degrees of burn off [269]. Their results 
illustrated that efficient phenol and tryptophan removal from spiked plasma samples 
was also observed in ACs with different degrees of burn off. Furthermore, the increase 
in the degree of burn off in the macroporous ACs used in their study resulted in an 
increase in micro- and meso- porosity, which is believed to contribute to the 
improvement of cholic acid adsorption. However, the increase in microporosity in the 
ACs failed to improve the bilirubin adsorption. This suggested that the reduction in the 
cholic acid level in plasma could be due to the AC adsorption of free cholic acid since 
the free cholic acid was allowed to enter the smaller micropores of the AC. In contrast, 
the removal of bilirubin could be largely attributed to the AC adsorption of the 
bilirubin-albumin complex, which was unable to penetrate into the AC micropores 
therefore was not significantly affected by the increase of microporosity. Similar to the 
ACs used in Tripisciano’s study, all the ACs tested in this study possess high 
microporosity, and therefore showed efficient removal of cholic acid. In addition to the 
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high microporosity, A4 and A5 carbon used in this study have a larger macropore size 
when compared to the AC with 45% and 62% burn off degree in Tripisciano’s study. 
These macroporous AC beads A4 & A5 exhibited a better removal of bilirubin, possibly 
as a result of improved albumin-bilirubin-complex adsorption. Comparison of the 
findings in this chapter and the above study suggests that the AC adsorption of albumin 
bound liver toxins is not only influenced by the AC pore size but also the increase of 
microporosity and progressive broadening of micropores introduced by increasing 
degree of burn off during AC preparation. 
Privalov et al suggested that when toxins bind to albumin, the resulting albumin-
toxin complex exhibits a double peaked melting curve compared to the pure albumin 
single peaked-melting curve [272]. Therefore by monitoring the melting curve of 
albumin-toxin complex before and after albumin was perfused through a carbon column, 
Sarnatskaya et al., aimed to investigate the AC removal mechanism of high affinity 
albumin bound toxins, including removal of high affinity albumin bound liver toxins 
such as bilirubin, deoxycholic acid and phenol [264, 266]. Their study suggested that 
the removal of albumin bound toxins such as bilirubin by AC were due to the 
deliganding of toxins from albumin rather than the adsorption of the albumin-toxin 
complex [266]. 
The results of the liver toxin adsorption study described in this chapter indicated 
the efficient removal of albumin bound toxins with relative low albumin binding 
affinity (phenol, tryptophan and cholic acid). Furthermore, it also exhibits a positive 
correlation between the AC macropore sizes and increasing removal of high albumin 
bound affinity substances such as bilirubin. However, the complex mechanism of 
albumin bound toxin removal by AC requires further investigation.  
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4.6.2 Albumin bound uraemic toxin removal by ACs and PVA-AC composite 
In the AC adsorption of albumin bound liver toxin study, five ACs with 
increasing pore size range from > 2 nm to 120 nm mean diameters were used. All the 
ACs exhibited efficient removal of toxins with lower albumin binding constants such as 
phenol and tryptophan. An increase in the adsorption of toxins with higher albumin 
binding constants was associated with the increase in AC pore size. However, this 
positive influence of AC pore size towards bilirubin removal reached a plateau when the 
AC pores were greater than 80 nm. This could also be influenced by the fact that A5 
carbon beads exhibit a lower specific surface area (SBET of 1235 m
2
/g) compared to A4 
carbon beads (SBET of 1548 m
2
/g) (Table 4-2). Four of the five ACs used in the liver 
toxin removal were also tested for the adsorption of albumin bound uraemic toxins; p-
cresyl sulphate and indoxyl sulphate. All the tested ACs showed efficient removal of 
indoxyl sulphate and p-cresyl sulphate (Figure 4-15 and Figure 4-16). No significant 
difference was observed in ACs with increasing pore size despite the relatively high 
albumin binding affinity that was reported for both indoxyl sulphate (KA=0.98×10
5
) 
and p-cresyl sulphate (KA=1.0×10
5
) [259]. Similar to tryptophan and phenol, the 
efficient AC adsorption of indoxyl sulphate and p-cresyl sulphate could be the result of 
the stronger interaction between AC and the phenolic ring structure in indoxyl sulphate 
and p-cresyl sulphate. However, the adsorption of indoxyl sulphate by the tested ACs 
was lower than p-cresyl sulphate (Table 4-7 & Table 4-8). This may simply be 
explained by the lower concentration of indoxyl sulphate that was used in these 
experiments compared to the p-cresyl sulphate concentration (section 4.4.2.2). Thus, the 
amount of indoxyl sulphate and p-cresyl sulphate adsorbed did not saturate the ACs. 
Suggesting that those ACs could possess greater indoxyl sulphate and p-cresyl sulphate 
adsorption capacity within 60 minutes of incubation period.  
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Both liver and uraemic toxin removal studies suggested that the most efficient 
adsorbent was carbon A4, with the combination of large surface area (1548 m
2
/g) and 
macroporous structure (80 nm mean diameter). However, as discussed in Chapter 2 
section 2.5.1, ACs with particle size 250 to 500 µm were not suitable for incorporation 
into the PVA cryogel matrix. Therefore, A6 carbon with similar porous characteristics 
as A4, and a smaller particle size (< 45 µm) was selected for the composite cryogel 
preparation. In the circulating system, it could be observed that addition of A6 
macroporous AC into the PVA cryogel composite resulted in a slight but significant 
(p<0.05) increase in the removal of indoxyl sulphate (Figure 4-17). However, limited 
indoxyl sulphate removal was observed even when the AC bearing PVA composite 
cryogel (PVA3-GA-A6) was used in the circulation system. Compared to the indoxyl 
sulphate, PVA3-GA-A6 composite showed poor adsorptive capacity towards p-cresyl 
sulphate. There was no significant difference observed between plain PVA-GA cryogel 
and PVA-GA-A6 composite cryogel in the removal of p-cresyl sulphate. 
In the circulating system, 1ml of PVA3-GA-A6 composite cryogel with an 
estimated 30 mg of A6 carbon beads (Table 2-2) was used to remove the toxins from 20 
ml of spiked plasma (section 4.4.2.2.2). The large total amount of indoxyl sulphate/p-
cresyl sulphate and the relatively low AC content could be the main reason for the 
limited indoxyl sulphate removal in the circulating system when the PVA3-GA-A6 
composite cryogel was used. Furthermore, during the incorporation of A6 carbon beads 
into the PVA matrix, masking of the A6 outer surface area could be another 
contributing factor to the limited removal of indoxyl sulphate and p-cresyl sulphate. 
Although internal pore surfaces of the ACs are the main contributors of the large 
specific surface area, the outer surface of ACs, as a first point of contact between the 
carbon surface and solutes, are also important in adsorption kinetics (Chapter 1 section 
1.4.1). SEM images of the PVA3-GA-A6 composite cryogel revealed that the A6 beads 
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were held in the system by the PVA polymer walls (section 2.5.4). This possibly led to 
the reduction of accessible A6 outer surface areas and thus resulted in the limited 
removal of indoxyl sulphate and p-cresyl sulphate seen in the circulating system.  
In the AC batch tests, AC p-cresyl sulphate adsorption was 0.88 mg/ml, this was 
less than the adsorption for indoxyl sulphate, yet over 80% of p-cresyl sulphate was 
removed from the plasma samples. However, in the circulating system PVA3-GA-A6 
failed to remove clinically relevant amounts of p-cresyl sulphate. Watanabe et al. 
reported a possible binding competition between indoxyl sulphate and p-cresyl sulphate 
towards albumin [259]. Their experiment revealed that under constant albumin 
concentration, the increase of free indoxyl sulphate was associated with the increase of 
p-cresyl sulphate concentration and vice versa [259]. In the study described in this 
chapter, a higher p-cresyl sulphate concentration (250 µM) was used compared to 
indoxyl sulphate (150 µM). This difference could result in the higher than expected 
level of unbound indoxyl sulphate, which was easily absorbed into the limited amount 
of AC pores exposed in the composite cryogel walls, whereas the limited amount of AC 
pores surface failed to absorb the p-cresyl sulphate -albumin complex.  
As discussed in Chapter 2 section 2.6.3, after incorporating the A6 carbon beads 
into the PVA cryogel matrix, the A6 porosity remained accessible for methylene blue 
molecules. In addition, the adsorption of indoxyl sulphate by the composite cryogel 
described in this chapter suggested the AC porosity also remained accessible for the 
possibly free indoxyl sulphate molecule with lower molecular weight than methylene 
blue. However, the modality of the indoxyl sulphate adsorption by the A6 beads in the 
composite system remains unclear. Further work using higher adsorbent amounts of AC 
in the composite in the circulating system is required to fully understand the AC 
adsorption of albumin bound toxins.  
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4.7 Conclusions 
The batch adsorption studies by AC adsorption of albumin bound hepatic and 
uraemic toxins revealed the efficient removal of toxins such as tryptophan, phenol, 
cholic acid, indoxyl sulphate and p-cresyl sulphate by all the tested ACs. In addition, to 
their high adsorption capacity particularly for the phenolic toxins, ACs with pore mean 
diameter of 80 nm showed an ability to remove bilirubin from the spiked plasma 
samples. The results suggested the potential of ACs for the removal of liver and uraemic 
toxins. A4 carbon with a mean pore diameter of 80 nm and 1548 m
2
/g specific surface 
area is the most efficient in liver toxin removal, and therefore A6 with tailored porosity 
similar to A4 but a smaller particle size was used for the development of PVA-AC 
composite cryogels. 
When the PVA-AC composite adsorbent was used in a circulating system, a 
reduction in the total indoxyl sulphate adsorption was observed. This reduction could be 
explained by the reduced AC content in the composite compared to the study with the 
AC beads alone. In addition, the limited p-cresyl sulphate adsorption by the PVA-AC 
composite in a circulating system could be the result of a reduction in accessible AC 
pores in the composite materials to the p-cresyl sulphate-albumin complex. 
Adsorption of albumin bound toxins by ACs could involve complex mechanisms 
such as binding competition among toxins in binding to albumin and possible 
deliganding of toxins from albumin by AC surfaces. These mechanisms could result in 
unexpected levels of unbound toxins and/or competition between AC and albumin in 
toxin binding. The primary aim of this study was to investigate the albumin bound toxin 
adsorption efficacy of ACs. Therefore limited evidence was obtained into the 
underlying mechanism of the toxin removal by AC. Further investigations are required 
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to gain a deeper understanding of the mechanisms of AC adsorption of albumin bound 
toxins. 
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Chapter 5. Preliminary ex vivo Blood perfusion Study of PVA-AC 
composite Materials 
5.1 Introduction 
The composite material described in this thesis is intended to act as a supporting 
matrix for the AC beads to provide appropriate blood flow for the removal of toxins 
inadequately removed by current methods of haemodialysis. Studies described in 
pervious chapters of this thesis detailed the PVA-AC composite cryogel preparation 
method which allows successful preservation of desirable AC porosity (Chapter 2) and 
the selection of appropriate AC to be used as a haemoperfusion adsorbent (Chapter 4). 
Although the low cytotoxicity of ACs and PVA cryogels was established in the in vitro 
study described in Chapter 3, the haemocompatibility of the PVA-AC composite 
cryogel needs to be tested for the safe use of this newly developed haemoadsorbent. 
Following the optimisation and in vitro assessment of the novel composite system, it is 
important to assess the device in a clinically relevant setting. A preliminary ex vivo 
system was designed using haemodialysis patient blood to assess impact that PVA-AC 
composite cryogel has towards blood biochemistry and blood cell behaviour. ESRD 
patient’s blood urea and electrolyte (U&E) levels are monitored following 
haemodialysis to assess the adequacy of the treatment. In addition, whole blood counts 
(WBC) are also carried out in order to monitor patient’s blood cell loss and detect 
inflammation and/or infections that may occur. Therefore, U & E and WBC levels were 
employed in this study to assess the effectiveness and possible side effects that the 
composite cryogels may impose. 
U & E test is commonly used to determine the levels of blood electrolytes that 
the dysfunctional kidney fails to remove. Sodium, potassium, bicarbonate and calcium 
levels are monitored in the patients’ blood before and after receiving haemodialysis 
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treatment (Table 5-1) in addition to urea and creatinine levels. C-reactive protein levels 
are also monitored as an indication of inflammation in CKD patients. Imbalanced 
electrolyte levels, toxins and inflammatory regulatory protein production in CKD 
patients have been associated with complications such as cardiovascular disorder [273] 
and bone diseases [274]. The build up of electrolytes including sodium, potassium and 
phosphate have adverse affects on patients’ health. Despite the accumulated evidence 
suggesting the relative low toxicity of urea and creatinine, these two substances remain 
important markers for haemodialysis efficacy due to the lack of widely accepted 
alternative CKD markers [35]. Accumulation of phosphate in ESRD has been 
associated with complications such as mineral and bone metabolism abnormalities and 
increased cardiovascular morbidity and mortality [275, 276]. In addition to the removal 
of disease exacerbating substances, monitoring the beneficial substances such as 
bicarbonates and calcium in the patient’s blood can provide guidance in improving the 
management of ESRD. Reduced plasma bicarbonate levels are often found in CKD 
patients. However, bicarbonate helps to neutralise the high acidity resulting from CKD 
associated metabolic acidosis [277]. Low bicarbonate concentrations (<23 mmol/L) in 
CKD patient blood have been associated with high mortality risk [278], therefore 
bicarbonate supplemented medications are recommended for CKD patients. In addition 
to bicarbonate, calcium supplements are also prescribed for boosting the calcium level 
in CKD patients to prevent bone complications [279, 280]. By monitoring the removal 
of unwanted electrolytes and preservation of health beneficial substances, the U & E test 
provides an insight into the quality of haemodialysis treatment and information on 
supplementary treatments for better management of ESRD. 
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Table 5-1 Normal range of selected plasma electrolytes, toxin and proteins contents 
in healthy individuals. 
Tested Parameters Normal range 
Sodium (Na) 135-146 mmol/L 
Potassium (K) 3.2-5.1 mmol/L 
Urea 1.7-8.3 mmol/L 
Creatinine 62-106 μmol/L 
Bicarbonate 22-29 mmol/L 
C-reactive protein (CRP) <5 mg/L 
Calcium (Ca) 2.15-2.55 mmol/L 
Phosphate 0.87-1.45 mmol/L 
Total protein (TP) 66-87 g/L 
Albumin 34-48 g/L 
Globulin 18-36 g/L 
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Despite the successful removal of uraemic toxins such as urea and creatinine by 
haemodialysis, 80% of patients suffer from ESRD induced anaemia (haemoglobin level 
below 12.0 ± 1.1 g/dL) [281]. In addition, ESRD complications such as albuminuria 
result in a reduction in patient immunity. This, coupled with an increased risk of 
infection in the use of haemodialysis treatment results in an increase in infection 
associated mortality [282]. Therefore, in addition to the U&E test, WBC is also 
performed for the detection of any haemolysis and infection in patients on 
haemodialysis (Table 5-2). Abnormalities in the leukocyte and platelet counts are 
associated with an inflammatory response [283, 284]. An increase in the number of 
neutrophils which target bacteria and fungi could indicate a possible bacterial or fungal 
infection. Viral infections can be recognised by elevated lymphocyte number; and 
increased monocyte, eosinophil, or basophil cell numbers are associated with 
inflammation [285]. In addition, the activation of platelets caused by poor material or 
device haemocompatibility can be detected as platelet aggregation or platelet loss after 
blood-material contact.  
 
Table 5-2 Normal range of different blood components in healthy individuals 
Blood components Normal range 
Haemoglobin  11.5-18.0 g/dL 
Leukocytes 4.0-11.0 x 10
9
/L 
Platelets 150-450 x 10
9
/L 
Erythrocytes 3.8-6.5 x 10
12
/L 
 
  
 193 
 
In this chapter, the blood samples of ESRD patients on haemodialysis treatment 
were selected for the ex vivo perfusion through the newly developed adsorbent materials 
(PVA3-GA-A6) for the determination of material haemocompatibility and adequacy 
using WBC and U & E tests. WBC was used to determine the possibility of whole cell 
passage through the cryogel composite column, and detect any haemolysis. U & E test 
was used to monitor the efficiency in marker electrolyte removal of the test materials. 
Although the toxins and electrolytes routinely tested in ESRD patients on haemodialysis 
treatment were not the target substances that the AC aimed to eliminate, the U & E test 
provides an insight into the patient’s blood electrolyte composition and the impact of 
filtration through the prototype composites. Therefore the U & E tests were used to 
determine any alterations in the electrolyte balance in the blood samples after ex vivo 
perfusion experiments.   
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5.2 Materials 
 BD Vacutainer® spray-coated k2 EDTA tubes (BD: 366643) 
 BD Vacutainer® Heparin Tubes (BD:367886) 
 BD Vacutainer® Citrate Tubes (BD: 369714) 
 PVA3: Poly (vinyl) alcohol (Mowiol® 18-88) (Sigma Aldrich: 81365) 
 Glutaraldehyde (GA) 25% w/v solution (Agar Scientific R1012)  
 Hydrochloric acid (Fisher Scientific)  
 Glutaraldehyde (GA) 25% solution (Sigma-Aldrich G6257) 
 A6 (tailor made macroporous NovaCarb S with particle size smaller 
than 45 µm in diameter, Mast Carbon International Ltd) 
 Silicon Tubing (Fisher Scientific: FB68857) 
 Syringes (Fisher Scientific: 12044717- 20 ml and 12039817-2 ml) 
 Sodium cacodylate trihydrate (Acros Organics: S/2660/48) 
5.3 Methods 
An ex vivo study of adsorbent material efficacy and haemocompatibility was 
carried out in collaboration with Brighton and Sussex University Hospital NHS Trust, 
Clinical Investigation and Research Unit (BSUH-CIRU). The study was approved by 
the National Research Ethics Service (NRES) Committee East Midlands from 
Northampton, reference number 11/EM/0124 (Appendix 3).  
5.3.1 Adsorbent column preparation 
PVA3-GA cryogel and PVA3-GA-A6 composite cryogel were prepared 
according to the method described in Chapter 2. In brief, PVA3-GA cryogels were 
prepared by crosslinking 5% (
w
/v) PVA3 with 0.5% (
w
/v) of glutaraldehyde at -12°C for 
18 hours before the gel was thawed and washed with water until a pH of 7 was reached. 
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The PVA3-GA-A6 composite was prepared by adding 3% (
w
/v) dry A6 carbon beads 
into the 5% (
w
/v) PVA3 with 0.5% (
w
/v) of glutaraldehyde mixture before the system 
was frozen at -12°C for 18 hours. After composite gel formation, the gels were thawed 
and washed with water until a pH of 7 was reached as for the PVA3-GA gels. The 
PVA3-GA cryogels and PVA3-GA-A6 cryogel were then transferred to sterile 2 ml 
syringes before they were packed into polymer bags and sterilised using 29.9 kGy of 
gamma-irradiation.  
5.3.2 Patient blood collection 
In the BSUH-CIRU, patients with stage 5 CKD (ESRD) on haemodialysis were 
identified and selected for the study. Fifteen patients were recruited and consents were 
obtained following NRES ethical approval. In this study, 50 ml of patient’s blood was 
taken in addition to WBC and U&E routine blood sampling. For WBC and U&E 
sampling blood was collected into ethylenediaminetetraacetic acid (EDTA) and heparin 
containing blood collection tubes respectively. 
5.3.3 Blood perfusion experiment 
To avoid artificial haemolysis and platelet activation, a syringe pump rather than 
a peristaltic pump was used for a single pass blood perfusion experiment through the 
adsorbent (Figure 5-1). A 20 ml blood sample in a 20 ml syringe was loaded onto a 
Univentor 802 syringe pump (RoYem Scientific Ltd) and pumped through the adsorbent 
columns via connecting tubing at a flow rate of 0.25 ml/min. Blood samples were 
collected after perfusion through the test column. Control blood samples were collected 
by pumping 20 ml of the same patient’s blood though the tubing without the adsorbent 
column. The remaining 10 ml blood sample was used as a non-perfused control. All 
collected blood samples were tested in the biochemistry lab at BSUH for U&E and WB 
count. 
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Figure 5-1 Image of the ex vivo single blood perfusion test system 
A blood sample in the syringe was pumped through the PVA3-GA cryogel column 
and PVA3-GA -A6 composite cryogel column, and collected into centrifuge tubes 
before being sent for the U&E test and WB count. 
 
The percentages of remaining blood components were normalised by non-
perfused control WB count data as indicated in Equation 5-1, where Nnon is the number 
of blood components without perfusion, and Npost is the number of blood components 
after perfusion. The percentages of electrolytes and protein removal were calculated 
according to Equation 5-2. 
 
                      (
 post
 non
)       Equation 5-1 
                     
 non  post
 non
      Equation 5-2 
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5.3.4 SEM sample preparation 
After blood perfusion, the columns were rinsed using PBS to remove the patient 
blood from the cryogel pores, prior to their removal from the syringe column. One of 
the cryogel columns was washed with PBS to remove the remaining blood components. 
The other cryogel column was not only washed with PBS but also manually squeezed to 
assist removal. The AC bearing PVA3-GA-A6 composite cryogel column was also 
washed either with PBS alone or washed with PBS then squeezed before preparation for 
SEM imagining. After washing, the cryogel monoliths (1ml) were then incubated with 
5ml 2.5% glutaraldehyde for 1 hour before the monolith gels were sliced into 3mm 
thick slices. Slices were then transferred to the wells of a 24 well plate, and washed with 
2ml PBS three times, then with 2ml of cacodylate buffer (0.1 M) three times. The 
samples were frozen at -80°C and freeze-dried overnight. For SEM imaging, the freeze-
dried cryogel slices were mounted on the sample holder, coated with a 4 nm thick layer 
of platinum using a Quorum Q150TES (Quorum) coater and examined using a Zeiss 
Sigma field emission gun SEM (Zeiss NTS) at an accelerating voltage of 5 kv. 
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5.4 Results 
5.4.1 Removal of urea and creatinine by PVA-AC composite cryogels 
The urea and creatinine concentration in the blood samples was monitored 
before and after the ex vivo perfusion experiment to determine their removal by the AC 
bearing PVA3-GA-A6 composite cryogel and the PVA3-GA cryogel. After a single 
perfusion passage of blood samples over the PVA3-GA-A6, PVA3-GA and control, the 
reduction of urea and creatinine levels in the blood samples are illustrated in Figure 5-2, 
and the average urea and creatinine levels are summarised in Table 5-3. A nearly 30% 
reduction of urea concentration level was achieved after a single perfusion of patient 
blood samples through PVA3-GA-A6 composite columns. This significantly (p < 0.001) 
reduced the urea concentration in the blood samples from an average of 24.3 mmol/l to 
16 mmol/l.  
In addition, a nearly 80% reduction of creatinine levels was achieved after a 
single perfusion of patient blood through PVA3-GA-A6 composite columns, resulting 
in a significant (p < 0.0001) reduction in creatinine levels compared to the control. This 
reduced the creatinine concentration in the blood samples from 636 to 146 µmol/l and 
returned the creatinine level closer to the healthy patient level of 62 to 106 µmol/l.  
After the single pass perfusion was carried out using PVA3-GA cryogel, a less 
than 10% reduction of urea and creatinine were observed. Almost no reduction in the 
control blood sample was found. Compared to the control, the use of PVA3-GA-A6 
composite columns significantly (p < 0.0001) reduces the urea and creatinine 
concentration in the patients’ blood samples.  
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Figure 5-2 The percentage reduction in urea and creatinine levels in the patient 
blood samples after a single pass perfusion experiment. 
PVA3-GA-A6 composite cryogel and PVA3-GA cryogel columns were used in the 
perfusion experiment. Control blood samples were collected for each patient’s 
blood by passing the blood through the single passage syringe system without 
connecting to the test samples. 
*** represents p<0.001 
 
Table 5-3 Urea and creatinine concentration in the ESRD patient’s blood before 
(non-perfused) and after ex vivo single pass perfusion through PVA3-GA-A6 
composite cryogel (Composite) and perfusion through empty tubing (Control). 
Electrolytes Non-perfused Composite Control Healthy 
Urea (mmol/l) 24.3 ± 0.4 16 ± 3.4 24.3 ± 5.8 1.7-8.3 
Creatinine (µmol/l) 636 ± 74 146 ± 51 633 ± 81 62-106 
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5.4.2 Removal of electrolytes 
The concentration of electrolytes in the blood samples was monitored before and 
after the ex vivo perfusion experiment to determine their removal by the PVA3-GA-A6 
composite cryogel and the PVA3-GA cryogel. After a single perfusion passage of blood 
samples over the PVA3-GA-A6, PVA3-GA and control, the reduction in the level of 
health beneficial electrolytes including bicarbonate and calcium in the blood samples is 
illustrated in Figure 5-3, and the average bicarbonate and calcium levels are listed in 
Table 5-4. The PVA3-GA-A6 composite cryogel column removed 34% calcium from 
the blood samples after single perfusion passage. This reduced the blood calcium 
concentration from 23.15 mmol/l to 1.520 mmol/l, which is lower than the healthy level 
of 2.15 to 2.55 mmol/l. Reduction of bicarbonate levels were observed in both test 
materials and even control blood samples. After blood was perfused through the PVA3-
GA-A6 composite cryogel columns, the bicarbonate concentration reduced from 22.2 
mmol/l to 13.5 mmol/l which is lower than the normal range of 22 to 29 mmol/l. 
However, the bicarbonate concentration after perfusion through the control set up 
reduced to 19.35 mmol/l which is also lower than the normal level. The removal of 
calcium from blood samples by the PVA3-GA-A6 column was significantly (p=0.0111) 
higher than the control. However, no significant difference in the removal of 
bicarbonate was observed in the tested materials compared to the control.  
The level of sodium, potassium and phosphate in the blood samples increased 
from 139 (sodium), 4.9 (potassium) and 1.55 (phosphate) mmol/l to 141, 5.2 and 4.37 
mmol/l respectively after single perfusion through the PVA3-GA-A6 column (Table 
5-4).  
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Figure 5-3 Removal of bicarbonate (CHO3
-
) and calcium (Ca) from the blood 
samples after ex vivo single perfusion experiment. 
The removal of CHO
3-
 and Ca by the PVA3-GA-A6 composite cryogel and the 
PVA3-GA cryogel are expressed as a percentage. A control blood sample was 
collected from each patient’s blood by single pass perfusion through the system 
without connection to the test PVA or PVA-AC cryogels. 
* represents p<0.05  
Table 5-4 Electrolyte concentration in the ESRD patient before (non-perfused) and 
after ex vivo single pass perfusion through PVA3-GA-A6 composite cryogel 
(Composite) and through empty tubing (Control). 
Electrolytes Non-perfused Composite Control Healthy 
Ca (mmol/l) 2.315 ± 0.035 1.520 ± 0.28 2.30 ± 0.07 2.15-2.55 
CHO3
-
 (mmol/l) 22.2 ± 0.1 13.5 ± 0.8 19.35 ±2.65 22-29 
Na (mmol/l) 139 ± 1 141 ± 7 138 ± 3 135-146 
K (mmol/l) 4.9 ± 0.2 5.2 ± 0.1 4.7 ± 0.3 3.2-5.1 
Phosphate (mmol/l) 1.55 ± 0.9 4.37 * 1.535 ± 0.105 0.87-1.45 
* n=1 
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5.4.3 Removal of proteins 
In order to monitor the adsorption of transporting proteins from the blood, 
albumin and globulin levels were monitored along with the total protein (TP) level in 
blood. Around a 20% reduction of TP, C-reactive protein (CRP), albumin and globulin 
were observed after the blood samples were passed through the PVA3-GA-A6 
composite cryogel columns (Figure 5-4). The adsorption of proteins from blood samples 
resulted in a reduction of total protein concentration from 63 to 49 g/l. In particular, the 
albumin concentration reduced from 39 to 30g/l, while the globulin concentration 
reduced from 24 to 20 g/l.  
The concentration of CRP in the blood samples was monitored for the detection 
of any inappropriate immune response. In one of the patients, the concentration of CRP 
was reduced from 6.1 mg/l to less than 5 mg/l after single pass perfusion through a 
PVA3-GA-A6 composite cryogel column, which is within the healthy level. However, 
in the other patient’s blood sample, an initial CRP concentration of 54 mg/l was 
detected, and the control perfusion process resulted in a nearly 100 fold-increase in the 
CRP concentration to 5232 mg/l, however, perfusion through PVA3-GA-A6 resulted in 
a reduction of the CRP concentration to 47.2 mg/l (Table 5-5).  
The reduction of all the concentrations of the proteins measured in the blood 
after perfusion through the PVA3-GA-A6 columns were found not to be significant 
(p>0.05) compared to the protein removed in the control set up. Compared to the AC 
bearing composite cryogel (PVA3-GA-A6), the reduction in the protein concentration 
was lower in the blood samples perfused through the PVA-GA cryogel. 
Among five patients’ blood samples used for the U & E test before and after the 
ex vivo haemoperfusion, one patient’s blood sample showed the presence of haemolysis 
after passage over the PVA3-GA-A6 column.  
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Figure 5-4 Removal of proteins from blood samples after ex vivo perfusion. 
Plasma total protein (TP), albumin and globulin concentrations in the blood 
samples after single perfusion through a PVA3-GA-A6 composite cryogel and a 
PVA3-GA cryogel are expressed as a percentage. A control blood sample was 
collected for each patient’s blood passed through the single passage syringe system 
without connection to the test PVA or PVA-AC cryogels. 
 
Table 5-5 The concentration of total protein (TP), albumin, globulin and C-
reactive protein (CRP) in the blood samples before and after ex vivo single pass 
perfusion through PVA3-GA-A6 composite cryogel (Composite) and perfusion 
through empty tubing (Control). 
Proteins Non-perfused Composite Control Healthy 
TP (g/l) 63±6 49±3.5 62±6.5 66-87 
Albumin (g/l) 39±1 30±4 39±1 34-48 
Globulin (g/l) 24±5 20±9 24±6 18-36 
CRP (mg/l) * 6.1 <5.0 6.1 <5.0 
* one of two patients blood sample showed a 54 mg/l CRP concentration without 
perfusion experiment, after perfusion, the CRP concentration increased to 5232 mg/l 
in the control while after perfusion through the composite cryogel, the CRP level 
reduced to 47.2 mg/l. 
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5.4.4 Whole blood count (WBC) pre- and post- blood perfusion 
To monitor the retention of blood components during the ex vivo perfusion 
experiment using PVA3-GA-A6 composite cryogel and PVA3-GA cryogel, blood 
components including leukocytes, platelets, erythrocytes and haemoglobin levels were 
determined. Figure 5-5 illustrates that after passing the patient’s whole blood through 
the PVA3-GA-A6 adsorbent column, a nearly 80% loss of leukocytes and platelets were 
observed compared to the pre-perfusion blood samples. Over 80% of erythrocytes and 
haemoglobin remained in the blood samples after the perfusion through the PVA3-GA-
A6 adsorbent. Over 55% of leukocyte and platelet reductions were observed in the 
blood samples after perfusion over PVA3-GA cryogel column. Interestingly an increase 
in erythrocyte count and haemoglobin was observed in the blood samples after 
perfusion through the PVA3-GA cryogel column and the control (erythrocyte count of 
112% and 108% respectively). When the blood samples were passed through the single 
passage perfusion system without the adsorbent columns (control), over 90% of 
leukocytes and platelets remained in the blood samples, while over 112% of 
erythrocytes and haemoglobin were detected in the blood samples similar to the PVA-
GA samples. Compared to the control, perfusion of blood samples over PVA3-GA 
cryogel resulted in a significant reduction of leukocytes (P<0.01) and platelets (P<0.05), 
while no significant difference was observed in the erythrocytes and haemoglobin 
(P>0.05). Only one WBC was conducted in the ex vivo perfusion study of PVA3-GA-
A6 composite column, therefore, statistical significance was not determined. 
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Figure 5-5 The percentages of blood components remaining in the blood samples 
after ex vivo perfusion experiment. 
PVA3-GA-A5 composite cryogels and PVA3-GA cryogels were used in the 
perfusion test. Control blood samples were collected for each patient’s blood 
passed the single passage syringe system without connecting to the test PVA or 
PVA-AC cryogels. The remaining blood components were normalised using the 
WB count before perfusion.  
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5.4.5 SEM images of PVA3-GA cryogel and PVA3-GA-A6 composite 
cryogels after blood perfusion 
In addition to the WB count, an SEM imaging technique was also employed for 
the determination of blood component retention during the ex vivo perfusion experiment 
using the PVA3-GA-A6 composite cryogel and PVA3-GA cryogel columns.  
5.4.5.1 SEM images of PVA3-GA cryogels after whole blood perfusion 
When the gel was only washed using PBS, cryogel channels were partially 
covered by a fibrous net possibly created by glutaraldehyde crosslinked plasma proteins 
during sample fixing for SEM (Figure 5-6 A). In addition clusters of erythrocytes can be 
seen on the cryogel walls (Figure 5-6 B). In contrast, when the PVA3-GA cryogel was 
compressed during its washing in PBS, the fibrous net coverage on the cryogel channels 
was rarely seen (Figure 5-7 A). In addition, a very limited number of erythrocytes were 
found in the examined sample (Figure 5-7 B). The compression force applied during the 
washing step before the PVA3-GA cryogels were fixed with glutaraldehyde, appeared 
to assist in the release of blood components from the cryogel matrix, and resulted in a 
reduction in the number of erythrocytes and plasma proteins retained in the PVA3-GA 
cryogel matrix, suggesting the cells were not attached to the PVA cryogel walls. 
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Figure 5-6 Scanning electron micrograph of PVA3-GA cryogel after whole blood 
perfusion. 
The PVA3-GA cryogel was washed with PBS, before glutaraldehyde was used for 
cell fixation, followed by cacodylate buffer washing before the samples were freeze 
dried and examined under SEM. Erythrocytes (indicated by arrows) and plasma 
proteins (indicated in circles) can be found in the PVA3-GA cryogel channels (A) 
under x500 magnification. At a higher magnification of 2,530 (B), the erythrocytes 
can be visualised near the PVA3-GA cryogel channel openings.  
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Figure 5-7 Scanning electron micrograph of PVA3-GA cryogel after whole blood 
perfusion. 
The PVA3-GA cryogel was washed with PBS, and compressed in order to remove 
the blood samples from the cryogel column before glutaraldehyde was used for cell 
fixation. The fixed sample was then washed using cacodylate buffer before being 
freeze dried and examined under SEM. After washing the gel with squeezing, 
majority of the blood components were removed from the cryogel channels (A). A 
high magnification view of the samples revealed one erythrocyte (indicated by red 
arrow) and one leukocyte (indicated by blue arrow) retained (B).  
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5.4.5.1 SEM images of PVA3-GA-A6 composite cryogels after whole blood 
perfusion 
As illustrated in Figure 5-8, A6 carbon beads in the PVA3-GA-A6 composite 
cryogel remained securely held within the PVA polymer walls after the whole blood 
perfusion process. Although patches of crosslinked plasma proteins and a large number 
of erythrocyte clusters can be found in the channels of the PVA3-GA-A6 composite 
system (Figure 5-8 A), the surfaces of the AC beads appeared to be largely uncovered 
by PVA polymer, with very few erythrocytes attached and the channels remaining 
largely clear (Figure 5-8 B). 
When PVA3-GA-A6 composite cryogel was compressed during its washing 
with PBS after the whole blood perfusion, the A6 beads remained in the PVA matrix. 
The combination of pressure caused by whole blood perfusion and compression force 
during the washing step did not result in the detachment of A6 beads from the PVA 
cryogel matrix. Furthermore, fewer aggregated erythrocytes were found in the 
composite matrix (Figure 5-9 A) compared to the un-compressed PVA3-GA-A6 
composite cryogel sample (Figure 5-8). However, compared to the PVA3-GA cryogel 
samples, compressing the PVA3-GA-A6 sample during the washing step did not release 
the majority of the blood components from the cryogel matrix, leaving clusters of 
aggregated erythrocytes and crosslinked plasma protein within the composite matrix 
(Figure 5-9 B).  
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Figure 5-8 Scanning electron micrograph of PVA3-GA-A6 cryogel after whole 
blood perfusion 
The PVA3-GA-A6 cryogel was washed with PBS, before glutaraldehyde was used 
for cell fixation, followed by cacodylate buffer washing before the sample was 
freeze dried and examined under SEM. At x500 magnification, A6 beads (indicated 
by green arrows) remained held in the cryogel matrix, while clusters of 
erythrocytes can be seen on the cryogel walls (A). A higher magnification view of 
the sample revealed the presence of plasma protein (indicated by circles) and 
erythrocyte clusters (indicated by red arrows) (B). 
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Figure 5-9 Scanning electron micrograph of PVA3-GA-A6 cryogel after whole 
blood passage. 
PVA3-GA-A6 cryogel was compressed during washing in order to remove the 
blood from the cryogel column before glutaraldehyde was used for cell fixation. 
The fixed sample was then washed using cacodylate buffer before it was freeze 
dried and examined under SEM. A6 beads (indicated by green arrows) were 
securely held in the PVA polymer walls (A), while sheets of plasma proteins 
(indicated by circles) and small numbers of erythrocytes (indicated by red arrows) 
can be observed over the cryogel channels (B). 
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5.5 Discussion 
5.5.1 Adsorption of electrolytes and proteins by PVA3-GA and PVA3-GA -
A6 composite cryogels 
The use of AC bearing PVA3-GA-A6 composite cryogels in the ex vivo model 
of single pass haemoperfusion produced almost a 30% reduction of urea and 80% 
reduction of creatinine in the haemodialysis patient blood samples (Figure 5-2). In 
contrast, negligible amounts of urea and creatinine were removed by the PVA3-GA 
cryogel. This indicated that the urea and creatinine was predominantly removed by AC 
adsorption in the composite material rather than adsorption onto the PVA cryogel 
matrix.  
Similar findings were observed for the increase of PVA-GA-A6 composite 
cryogel specific surface area and methylene blue adsorption compared to the PVA-GA 
cryogels described in Chapter 2 section 2.6.2 and 2.6.3. These results suggest that 
although A6 beads were embedded in the PVA cryogel matrix, their porosity remains 
accessible for small molecules including nitrogen, methylene blue and urea and 
creatinine. Furthermore, the p-cresyl sulphate and indoxyl sulphate removal study 
described in Chapter 4 section 4.5.2 indicated that the PVA3-GA-A6 composite 
cryogels were capable of efficient removal of indoxyl sulphate from the plasma samples 
in a circulating system. In both studies, only 1 ml of PVA3-GA-A6 composite cryogels 
containing 30 mg A6 carbon beads were used for the perfusion of 20 ml blood or 
plasma samples. With an increase of adsorbent content, a better removal of toxins could 
be achieved, suggesting the potential use of PVA3-GA-A6 composite cryogels in the 
removal of a wide spectrum of toxins in haemoperfusion applications. 
In this study, when the PVA3-GA and PVA3-GA-A6 columns were prepared for 
ex vivo perfusion experiments, PBS was used to condition the columns and therefore, 
 213 
 
create a pH stable system suitable for biological testing. The use of PBS was the only 
source of additional phosphate, sodium and potassium in the study, therefore, the 
increase of phosphate (Table 5-4), potassium and sodium post perfusion was a result of 
the use of PBS in the composite pre-conditioning stage. Despite the removal of the 
toxins and unwanted electrolytes, removal of beneficial electrolytes including calcium 
and bicarbonate (Figure 5-3); and proteins such as albumin and globulin (Figure 5-4) 
were a side effect of perfusion over the composite adsorbent columns. However, the 
adsorption of those molecules indicated the accessibility of AC beads in the PVA 
cryogel matrix. 
 
5.5.2 Retention of blood components by PVA3-GA cryogel and PVA3-GA -
A6 composite cryogel 
The WBC results indicated a large number of leukocytes and platelets could be 
retained by the PVA3-GA-A6 column tested (Figure 5-5). When the PVA3-GA 
columns were used in the perfusion test, nearly triple the number of leukocytes and 
platelets were eluted from the column compared to the AC bearing column. Whereas, 
very little or no reduction of the erythrocyte number was observed in all the samples 
tested. Interestingly, no leukocytes were observed in the SEM images of the cryogels 
after whole blood perfusion. In addition, the sizes of the cryogel channels appeared to 
be sufficient for the unrestricted passage of the blood components. The loss of 
leukocytes and platelets could possibly be due to their activation during perfusion, and 
thus they could be attaching to the tubing before reaching the cryogel matrix.  
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5.6 Conclusions and future work 
The results of the ex vivo haemoperfusion study suggest that the AC bearing 
PVA3-GA-A6 composite cryogel is capable of adsorbing small uraemic toxins such as 
urea and creatinine. Although the unselective nature of AC adsorption resulted in a 
small reduction (< 25 %) of health beneficial electrolytes such as calcium and 
bicarbonate and desirable proteins such as albumin, supplementation of these substances 
after the haemoperfusion could overcome this problem. However, the use of PBS in 
cleaning and conditioning the test materials may have led to an increase in the levels of 
phosphate, sodium and potassium in the blood samples, and resulted in a increase in the 
measurement of these three electrolytes. Therefore, in future studies, other buffers 
should be used for material pre-conditioning.  
This preliminary study showed the potential of using PVA-AC composite 
cryogels in the removal of small toxins and unwanted electrolytes from CKD patient’s 
blood with post addition of beneficial electrolytes. However, the retention of leukocytes 
and platelets in the column could potentially be linked to clinically adverse affects. 
Therefore, further studies would be required to investigate the cause of the leukocyte 
and platelet retention. Unfortunately, the use of CKD patient blood and hospital 
procedure resulted in prolonged experimental preparation time and a possible 
detrimental effect on the activation of the blood cells. Coupled with time limitations and 
patient numbers in the ex vivo study, a limited amount of data was collected. Future 
studies could focus on optimizing the column size and haemocompatible design to 
allow for a high haemoperfusion flow rate through the system.  
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Chapter 6. General discussion 
6.1 The challenges 
6.1.1 Clinical implications of current EBP treatments 
Conditions such as liver and kidney failure have a devastating effect on patient 
quality of life and bring huge challenges to health care systems worldwide [36, 80]. 
Despite lifesaving EBP therapies such as haemodialysis/haemofiltration and 
plasmapheresis, the quality of life and long term survival of liver or kidney failure 
patients remains a major challenge in the management of these conditions (section 1.2.1 
& 1.2.2). Increasing evidence suggests that the removal of middle to large molecular 
weight and protein bound toxins could improve the outcome of these patients if a 
therapy was developed that could augment current EBP treatments [1, 115]. 
Although the current EBP techniques are successful in prolonging liver or 
kidney failure patients’ lives, their overall long term prognosis and survival remains 
poor. This is suspected to be caused by the selective nature of toxin removal by these 
techniques. There is a need for an optimised EBP system that is capable of removing a 
broad spectrum of toxins to improve the overall outcome of liver and kidney failure 
patients. 
6.1.2 Implications of AC use in EBP treatments 
There is a long tradition of AC use for EBP applications [7, 126]. However, 
concerns over the haemocompatibility of AC prepared from natural precursors have 
limited their use in direct blood contacting applications despite the well established 
adsorptive nature of the AC materials [16, 286]. The traditional packed bed 
haemoperfusion column design has produced a dilemma in which either column flow 
properties or reduced bead adsorption are sacrificed [5, 201]. Therefore new designs 
 216 
 
have been proposed in this study to incorporate AC adsorbent beads into a 
biocompatible matrix with interconnected channels to allow the free passage of whole 
blood. 
6.2 The proposal 
Recent developments in the production of synthetic ACs derived from polymeric 
resins allow the preparation of ACs with tailored porous characteristics for broad 
spectrum toxin adsorption and with high mechanical strength to avoid the release of fine 
carbon particles [139, 163, 184]. This thesis proposes the use of AC and carbon-cryogel 
composites as haemoadsorbents for the treatment of liver and kidney failure. 
This thesis contributes to existing literature in three novel ways: 
 Development of novel carbon-cryogel composites for haemoperfusion 
 Determination of the optimal AC characteristics for haemoperfusion applications 
 Assessment of  the efficacy of novel carbon cryogel composites as haemoadsorbents 
6.3 The methods 
Characterisation methods including low temperature nitrogen adsorption 
analysis, mercury porosimetry analysis, methylene blue adsorption, SEM, confocal 
imaging were applied to the AC and PVA-AC composite systems for the development 
and optimisation of the composite preparation (Chapter 2). Material cytotoxicity was 
assessed using in vitro MTS and LDH assays (Chapter 3). ACs with optimal albumin 
bound toxin removal capabilities were identified by comparing the AC pore 
characteristics with their adsorption profile for model molecules including bilirubin, 
cholic acid, tryptophan, phenol, p-cresyl sulphate and indoxyl sulphate (Chapter 4). 
Finally the haemocompatibility of the composite material was assessed using an ex vivo 
perfusion model by monitoring the erythrocyte and leukocyte numbers before and after 
blood perfusion (Chapter 5). 
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The ACs used in this thesis were all prepared from the same phenolic resins 
using similar production procedures as described in Chapter 2 (section 2.1.1). They 
were given different codes based on variations in particle size and pore characteristics. 
Despite the differences in the particle size and porosity, the production process was not 
considered influential towards the resulting materials’ chemical composition. 
Furthermore, the ACs (A7, A8 and A9) used for AC in vitro cytotoxicity assessment 
were selected to determine the impact of three different activation methods on the 
cytotoxicity of the resulting ACs (Chapter 3). The result suggested that the use of 
different activation methods in AC production did not influence the resulting materials’ 
cytotoxicity. The study described in Chapter 4 used AC beads (250-500 µm particle 
sizes) with increasing micro to macropore size (A1, A2, A3, A4 and A5) to determine 
the optimal porosity for albumin bound toxin removals from human plasma. These 
results suggested that the use of macroporous ACs with 80 nm mean diameter (A4) was 
most efficient in all the toxin removal. In order to incorporate the AC beads into the 
PVA cryogel matrix, ACs with particle size less than 45 µm were required (section 
2.5.1). Therefore, the A6 used in PVA-AC composite preparation were NovaCarbS AC 
beads with less than 45 µm particle size and macropore characteristics (97 nm diameter) 
similar to the A4 beads (80 nm diameter) identified above. As the outer surface area 
(per gram of adsorbent) of the smaller AC particle sizes was greater than the larger 
beads, thus consider to have positive influence in the adsorption kinetics. Therefore, the 
use of smaller AC particle size for composite preparation was carried out without 
separate investigations of the A6 carbon beads albumin bound toxin adsorptive kinetics 
and capacity. Tests were carried out using the PVA and PVA-A6 composites instead 
(section 4.2.2.2). 
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6.4 The Results and Discussion 
6.4.1 PVA cryogel and PVA-AC composite system optimisation 
6.4.1.1 Main findings 
The findings described in Chapter 2 demonstrated that the use of PVA with a 
higher molecular weight of 130 and 88% hydrolysis degree (PVA3) resulted in the best 
preservation of AC porosity and cryogel channel size. The incorporation of AC beads 
into the PVA-GA cryogel matrix successfully introduced AC micro- and macroporosity 
into the PVA-AC composite cryogels as revealed by mercury porosimetry results 
(section 2.5.7) and the desired AC adsorptive nature in the composite was preserved for 
small molecules as revealed by methylene blue adsorption (section 2.5.8 and 2.5.9). The 
presence of large channels in the matrix and preservation of AC macroporosity in the 
PVA-AC composite cryogel reinforced its potential use in haemoperfusion applications. 
The combination of different methods employed during the study of material 
characteristics provided a comprehensive insight into this unique material, and assisted 
in the optimisation of the PVA-AC composite cryogel preparation method. 
6.4.1.2 Implications 
There are many challenges when designing appropriate methodology for the 
characterisation and production of AC and cryogel-AC composites optimised for 
haemoperfusion applications. Characterisation methods including SEM imaging, 
nitrogen adsorption and mercury porosimetry analysis required the use of dehydrated 
samples under reduced pressure. It has been reported that the water in a PVA cryogel 
system consists of a small amount of polymer bound water and a large portion of 
unbound water which fills the cryogel channel spaces [172]. The removal of water could 
result in the shrinkage or even collapse of the cryogel channels. Therefore, during the 
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cryogel characterisation studies, the samples were examined using different methods to 
monitor cryogel behaviour in both dehydrated and hydrated states.  
6.4.1.3 Limitations 
Despite large efforts used to determine the PVA-AC composite porosity, channel 
size and internal structure, difficulties remained when comparing the materials between 
wet and dry states. The elastic properties of the PVA cryogel matrix and the abundant 
micro-, meso- and macroporosity of the AC embedded into the PVA-AC composite 
cryogels, led to unique challenges during the physical characterisation of the PVA-AC 
composite cryogels. Characterisation methods described in Chapter 2 including nitrogen 
adsorption, mercury porosimetry and methylene blue adsorption analysis were all 
limited by their use of ideological mathematical assumptions and calculations, therefore 
may not reflect the real structure of the complex composite system. Although SEM and 
confocal imagining techniques provided more realistic internal porosity and structure of 
the composite channels, they were limited to the resolution available for AC porosity 
determination.  
Despite the limitations of each technique, the combination of various techniques 
described in Chapter 2 demonstrated the potential of PVA3-AC composite cryogels for 
haemoperfusion applications for its useful preservation of AC porosity and adsorptive 
capacity. 
6.4.2 Cytotoxicity assessment of the PVA cryogel and AC beads 
6.4.2.1 Main findings 
Chapter 3 described the short term in vitro cytotoxicity assays using AC leachate 
and monitoring cell viability and membrane integrity after 8 and 24 hours of exposure 
to 100% extract and 50% extract supplemented with fresh media. This study concluded 
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that neither the AC beads nor the glutaraldehyde crosslinked PVA cryogel elutes 
cytotoxic elements towards the tested cell lines. However, the adsorption of culture 
medium nutrients by ACs should be taken into account during similar studies. 
6.4.2.2 Implications 
Despite the well established adsorptive properties of the AC materials, their use 
in direct haemoperfusion applications remains difficult due to the historical 
complications associated with the low biocompatibility of ACs derived from natural 
precursors (section 1.3.2 and 3.1.1). The importance of evaluation of biocompatibility 
during AC development thus became self-evident. In the context of cytotoxicity 
determination, the usually desirable highly adsorptive nature of AC materials became a 
complication during the in vitro biocompatibility assessment due to their adsorption of 
cell culture nutrients [225]. Chapter 3 described that in MTS and LDH assay, the results 
indicated that cell viability and membrane integrity was reduced after exposure to AC 
extracts for 24 hours. Although they were likely to be caused by the loss of nutrients 
during AC extraction, the implications of this finding were not immediately obvious. It 
only becomes noticeable when compared to the use of 50% extracts, where a boost in 
cell viability and membrane integrity was observed. This finding was then further 
supported by the results of cell viability and membrane integrity after 8 hours of extract 
exposure, the nutrients left in the extracts were enough to maintain cell survival, 
resulting in higher cell viability and membrane integrity after treatment. These 
suggested that during AC cytotoxicity determination, their adsorptive capability should 
always be taken into consideration to avoid false cytotoxicity results. 
6.4.2.3 Limitations 
Although cell based in vitro cytotoxicity assays are rapid and economical 
methods employed to determine material biocompatibility, they are largely limited by 
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their use of a single cell line, by-passing the immune response and therefore may not 
correlate to the in vivo or ex vivo model studies. In addition, when testing materials such 
as ACs, complications caused by their high adsorptive capacity should be considered 
during experimental design. The results of in vitro cytotoxicity assays are presented 
without noting the statistical significance. This is due to the controversy surrounding the 
statistical analysis of data presented in the form of percentages. Owning to these 
limitations, further biocompatible study using ex vivo models was described in Chapter 
5. 
6.4.3 Identification of optimal AC characteristics for target toxin removal 
6.4.3.1 Main findings 
Investigations into the influence of AC porous characteristics on the adsorption 
of toxins associated with liver and kidney failure were also conducted in order to select 
a suitable AC haemoadsorbent for use in PVA-AC composite preparation. The results 
from the study described in Chapter 4 revealed an efficient removal of phenol, 
tryptophan and cholic acid by all of the AC beads tested. This  may be because these 
toxins have a relatively low albumin binding affinity coupled with the use of ACs which 
have a high affinity for phenolic compounds [267]. In contrast, the removal of toxins 
with high albumin binding affinity such as bilirubin was related to the presence of an 
increase in the number of meso- and macropores with a mean pore size up to 80 nm 
mean diameter (section 4.5.1). The improvement in bilirubin removal associated with an 
increase in AC pore size could be due to the adsorption of the entire albumin-bilirubin 
complex, or an acceleration in AC deliganding of strongly albumin bound bilirubin over 
the greater surface area provided by the accessible meso- and macropores [264, 269].  
Similarly to AC removal of relatively weakly bound liver toxins such as 
tryptophan and cholic acid, all the AC beads selected for this study demonstrated 
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efficient removal of p-cresyl sulphate and indoxyl sulphate from spiked plasma samples. 
This could also be due to the presence of a phenolic ring structure in both p-cresyl and 
indoxyl sulphate [259, 265]. Although further investigations are required for a better 
understanding of the albumin bound liver toxin removal mechanism by AC, the 
optimum mean AC pore size of 80 nm was determined as most appropriate for future 
use in haemoperfusion applications. 
6.4.3.2 Implications 
In this study, human plasma was used to evaluate AC toxin adsorptive capacity 
in the presence of plasma proteins. AC beads with a range of pore size distributions 
from purely microporous, mesoporous to small macroporous were assessed for their 
ability to adsorb selected liver and kidney biomarkers. Bilirubin, cholic acid, tryptophan 
and phenol are common biomarkers for the evaluation of liver support devices, and 
therefore were selected in this study for the determination of the capacity of the AC to 
adsorb albumin bound liver toxins [98, 269]. Recent studies have suggested a strong 
link between the progression of CKD and the increasing presence of marker protein 
bound uraemic toxins p-cresyl sulphate and indoxyl sulphate. These are poorly removed 
by current RRT systems and were selected as markers for the evaluation of protein 
bound uraemic toxin removal by ACs [44, 46, 287].  
By comparing the adsorption of selected liver and kidney toxins by ACs with a 
pore size range of <1 to 120 nm, this study illustrated that the use of meso- and small 
macroporous AC with a mean pore diameter of up to 80 nm (A4) was most efficient for 
the removal of selected liver and kidney toxins (section 4.5). However, the initial 
experiments using PVA-AC composite cryogel preparation demonstrated that AC beads 
with 250 to 500 µm diameter particle size were not suitable for the preparation of a 
homogenous composite cryogel. Therefore, A6 carbon beads with the same tailored 
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macroporosity of 80 nm mean diameter and less than 45 µm diameter particle size were 
used for the preparation of PVA-AC composite cryogels (section 2.6.1). 
6.4.3.3 Limitations 
The liver and kidney toxin markers selected for the study represent only a small 
portion of toxins/molecules associated with the progression of liver and kidney failure. 
Furthermore, recent studies suggesting inflammatory regulatory cytokines such as IL6 
and IL8 could play a more important role in poor patient prognosis and even death 
compared to the traditionally regarded accumulation of toxin markers such as bilirubin. 
Therefore, further studies could also be carried out to study the adsorption of cytokines 
and other markers. 
6.4.4 Assessment of Uraemic toxin removal by PVA-AC compositea 
6.4.4.1 Main findings 
To assess the efficacy of the PVA-AC composite material in an in vitro 
environment, human plasma samples spiked with p-cresyl sulphate and indoxyl sulphate 
were circulated though the selected PVA-AC composite cryogel column over 60 
minutes, and the subsequent change in p-cresyl sulphate and indoxyl sulphate levels 
were monitored (section 4.4.2). Removal of indoxyl sulphate by PVA-AC composites 
was observed in the study. In contrast, the removal of p-cresyl sulphate by the PVA-AC 
composite was limited (section 4.4.2). 
6.4.4.2 Implications 
The more efficient removal of the indoxyl sulphate from the plasma sample 
could be due to the binding competition between p-cresyl sulphate and indoxyl sulphate 
for their carrier molecule albumin, which could lead to an increase in unbound indoxyl 
sulphate concentration [259]. Although the results from physical characterisation of the 
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PVA3-GA-A6 composite cryogels suggested that the A6 porosity was successfully 
preserved, this composite showed limited indoxyl sulphate and p-cresyl sulphate 
removal in the circulating system (section 4.4.2). In contrast, significant removal of 
both indoxyl sulphate and p-cresyl sulphate from human plasma and blood was 
observed by mesoporous activated carbon monoliths in a continuously circulating 
system [288]. The relatively low p-cresyl sulphate and indoxyl sulphate removal by 
PVA-AC composite cryogel could be due to the fact that only 1 ml PVA3-GA-A6 
composite cryogel containing 30 mg of A6 carbon beads was used for the removal of 
toxins from 20 ml of spiked plasma sample. 
6.4.4.3 Limitations 
The important role of p-cresyl sulphate and indoxyl sulphate in the progression 
of CKD suggests that their clearance could result in the improvement of EBP treatments. 
While ACs demonstrated superior clearance of both molecules, the performance of the 
composite if the AC porosity is preserved should have a similar adsorption capacity. 
However, the study described in section 4.4.2, using a small adsorbent (AC) to spiked 
plasma ratio, resulted in poor removal of both molecules. Optimisation of experimental 
parameters should be carried out in a future study to reflect clinical relevance of 
haemoperfusion treatments. 
6.4.5 Haemocompatibility and efficacy of the PVA-AC composite system 
6.4.5.1 Main findings 
In chapter 6, an ex vivo haemoperfusion experiment was designed to assess the 
haemocompatibility of the PVA-AC composite using blood samples from patients with 
ESRD currently receiving regular haemodialysis. This preliminarily study indicated that 
the reductions in the levels of haemodialysis efficiency markers; urea and creatinine as 
well as the removal of beneficial electrolytes such as calcium and bicarbonate after 
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single pass perfusion. This study also suggested that the PVA3-GA-AC composite 
cryogel had suitable internal structure which enables the passage of the erythrocytes 
through the matrix. However, the loss of leukocytes and platelets in the PVA-AC 
composite cryogel after perfusion indicated a potential biocompatibility issue thus 
suggested that further investigations and optimisation of the composite design are 
required (section 5.5.2). 
6.4.5.2 Implications 
The reduction in the levels of haemodialysis efficiency markers urea and 
creatinine in this study indicated the efficient removal of small molecular weight toxins 
by the composite. AC adsorption is believed to be non-specific. Thus, the reduction in 
the level of these two markers could indicate that other small uraemic toxins with 
harmful effects may also be removed by the PVA-AC composite cryogel. This suggests 
the potential of using this composite as a haemoperfusion therapy to augment current 
RRTs. Although the removal of the beneficial electrolytes such as calcium and 
bicarbonate was observed during ex vivo haemoperfusion through the PVA-AC 
composite cryogels, these electrolytes could be re-supplemented after the 
haemoperfusion treatments. The loss of leukocytes and platelets after perfusion could be 
an indication of poor material haemocompatibility with blood cell interaction triggering 
platelet and leukocyte activation. However, it could also be due to the near static 
condition of the blood during the experimental set up. Further studies could use another 
pumping system for perfusion rather than the syringe pump used in this study. 
6.4.5.3 Limitations 
Due to strict hospital regulations and limited time, a low number of donors were 
recruited for this preliminary study. Small scale ex vivo haemoperfusion experimental 
setup is rarely described in the current literature. Although the experimental design of 
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this preliminary study requires further optimisation, it provided valuable information 
regarding the composite capability in toxin removal and facility for erythrocyte passage. 
6.5 Future work 
6.5.1 Scale up 
Using a PVA cryogel as a model system, the work described in this thesis 
explores the possibility of incorporating the AC beads into a polymeric supporting 
matrix with large interconnected channels for haemoperfusion applications. Although 
successful preservation of the AC porosity for the adsorption of small molecular weight 
molecules such as nitrogen and methylene blue was achieved according to the method 
described, the adsorption of albumin bound uraemic toxins from circulating plasma 
remained limited. This suggested that the use of a PVA-AC composite system in a 
haemoperfusion setup requires further optimisation steps to improve AC pore exposure. 
Further work is required in the scale up of the PVA-AC composite size to meet the 
clinically relevant needs and improve the adsorption of albumin bound toxins from a 
larger volume of plasma or blood. PVA-AC composites can be prepared in the form of 
5 cm diameter discs during cryogelation, and then stacked to form a large scale 
haemoadsorbent column. 
6.5.2 Determining column flow properties 
It has been established that EBP columns with poor flow properties can disturb 
haemodynamics and resulted in poor haemocompatibility. The results in Chapter 5 
confirmed that the large channels in PVA-AC composite cryogels allowed the passage 
of erythrocytes during ex vivo perfusion. However, the flow resistance of PVA-AC 
composite cryogel columns should also be established to determine the composite 
suitability for clinical use. This could be achieved by measuring the cross column 
pressure difference under constant blood flow. 
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6.5.3 Further assessment of haemocompatibility 
The initial haemocompatibility assessment described in Chapter 5 indicated that 
no haemolysis was observed after ex vivo blood perfusion over PVA-AC composite 
columns.  The loss of platelets and leukocytes could be caused by their activation. 
Investigation into the cause of leukocyte and platelet retention during ex vivo 
haemoperfusion should be carried out to determine the haemocompatibility of the PVA-
AC composite cryogels. Methods such as flow cytometry could be employed to search 
for the possible evidence of platelet, leukocyte and even complement system activation. 
The use of other biocompatible polymers such as polyHEMA [289], polysaccharide 
[290], or even polymeric nanoparticles [291] could be considered in the development of 
a supporting matrix for the AC beads to create larger interconnected channels for whole 
blood perfusion. 
6.5.4 Investigating the interaction between AC and albumin bound toxins 
The results in Chapter 4 indicated the potential of AC beads as haemoadsorbents 
for the removal of a broad spectrum of liver and kidney toxins. However, further 
investigations into the mechanisms of albumin bound toxin removal by AC should also 
be carried out to enable further improvements of adsorbents to be used in 
haemoperfusion treatment for liver and kidney failure. The use of Saturation transfer 
difference-nuclear magnetic resonance (STD-NMR) for the determination of protein-
ligand binding mechanisms has been reported [292, 293] and the findings of this study 
can be viewed in Appendix 4. By combining the removal study of toxin-albumin 
interaction before and after incubation with AC, the mechanisms by which these toxins 
are absorbed by AC could be established.  
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6.6 Conclusion 
This thesis described the development of PVA cryogels and a PVA-AC 
composite system for potential use in EBP applications. Through the development and 
characterisation of the PVA-AC composite cryogel, methodologies such as SEM and 
confocal imaging; nitrogen adsorption analysis and mercury porosimetry analysis were 
employed, and the most appropriate PVA-AC composite cryogel preparation method 
was identified. In addition, the connection between AC porosity and liver and kidney 
toxin removal capacity was established in order to determine the optimal porosity for an 
AC haemoadsorbent. Although the performance of PVA-AC composite cryogels in the 
in vitro and ex vivo circulating systems revealed several problems such as limited p-
cresyl sulphate removal capacity and leukocyte and platelet retention, the novel 
composite design described in this thesis has laid the foundation for further optimisation 
of this new material to be used in future haemoperfusion based applications. 
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Appendix 1. ANOVA analysis of the significance of data from toxin 
removal by ACs 
1. The significance in the differences of cholic acid removal by ACs calculated 
based on the adsorbent weight. Prism 5 software package was used for two way 
ANOVA analysis with Bonferroni post-test (method described in section 4.2.3) 
*** is p<0.001 
    * is p<0.5 
 NS is p>0.05 
 
2. The significance in the differences of cholic acid removal by ACs calculated 
based on the adsorbent volume. Prism 5 software package was used for two way 
ANOVA analysis with Bonferroni post-test (method described in section 4.2.3) 
*** is p<0.001 
    * is p<0.5 
 NS is p>0.05 
  
 A1 A2 A3 A4 A5 
A1 -- NS NS to *** *** NS to *** 
A2 NS -- NS *** NS to *** 
A3 NS to *** NS -- *** to NS NS to * 
A4 *** *** *** to NS -- NS 
 A1 A2 A3 A4 A5 
A1 -- NS ** to NS NS * to NS 
A2 NS -- NS NS NS 
A3 ** to NS NS -- * to NS NS 
A4 NS NS * to NS -- NS 
2 
 
3. The significance in the differences of unconjugated bilirubin removal by ACs 
calculated based on the adsorbent weight. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
    * is p<0.5 
 NS is p>0.05 
 
4. The significance in the differences of unconjugated bilirubin removal by ACs 
calculated based on the adsorbent volume. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
  ** is p<0.01 
    * is p<0.05 
 NS is p>0.05  
  
 A1 A2 A3 A4 A5 
A1 -- NS NS to * *** *** 
A2 NS -- NS to * *** *** 
A3 NS to * NS to * -- *** *** 
A4 *** *** *** -- NS to *** 
 A1 A2 A3 A4 A5 
A1 -- NS NS *** *** 
A2 NS -- NS *** *** 
A3 NS NS -- ** to *** *** 
A4 *** *** ** to *** -- NS 
3 
 
5. The significance in the differences of plasma albumin removal by ACs 
calculated based on the adsorbent weight. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
  ** is p<0.01 
    * is p<0.05 
 NS is p>0.05  
 
6. The significance in the differences of plasma albumin removal by ACs 
calculated based on the adsorbent volume. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
  ** is p<0.01 
    * is p<0.05 
 NS is p>0.05  
  
 A1 A2 A3 A4 A5 
A1 -- NS *To *** *** *** 
A2 NS -- NS to *** *** *** 
A3 *To *** NS to *** -- *** *** 
A4 *** *** *** -- NS 
 A1 A2 A3 A4 A5 
A1 -- NS *To *** *** *** 
A2 NS -- NS to *** *** *** 
A3 NS NS to *** -- *** *** 
A4 *** *** *** -- NS to * 
4 
 
7. The significance in the differences of total plasma protein removal by ACs 
calculated based on the adsorbent weight. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
  ** is p<0.01 
    * is p<0.05 
 NS is p>0.05  
 
8. The significance in the differences of total plasma protein removal by ACs 
calculated based on the adsorbent volume. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
  ** is p<0.01 
    * is p<0.05 
 NS is p>0.05  
  
 A1 A2 A3 A4 A5 
A1 -- NS NS to *** *** *** 
A2 NS -- NS to ** *** *** 
A3 NS to *** NS to ** -- *** *** 
A4 *** *** *** -- NS 
 A1 A2 A3 A4 A5 
A1 -- NS NS and * *** *** to ** 
A2 NS -- NS *** *** and ** 
A3 NS and * NS -- 
** and *** 
to* 
** to NS 
A4 *** *** 
** and *** 
to* 
-- NS 
5 
 
9. The significance in the differences of indoxyl sulphate removal by ACs 
calculated based on the adsorbent weight. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
    * is p<0.05 
 NS is p>0.05  
 
10. The significance in the differences of p-cresyl sulphate removal by ACs 
calculated based on the adsorbent volume. Prism 5 software package was used 
for two way ANOVA analysis with Bonferroni post-test (method described in 
section 4.2.3) 
*** is p<0.001 
    * is p<0.05 
 NS is p>0.05  
  
 A1 A2 A3 A4 
A1 -- NS NS NS to * 
A2 NS -- NS NS 
A3 NS NS -- NS to * 
 A1 A2 A3 A4 
A1 -- * to *** * to *** *** 
A2 * to *** -- NS to *** *** 
A3 * to *** NS to *** -- *** 
6 
 
11. The significance of the differences in the removal of liver and kidney toxin 
overtime by each AC used. Prism 5 software package was used for the one way 
ANOVA analysis of the data (incubation time-dependent differences)  
 A1 A2 A3 A4 A5 
Bilirubin  0.9651 0.6298 0.0058 <0.0001 <0.0001 
Cholic acid 0.4974 0.0282 0.0006 0.2648 0.0106 
Tryptophan 0.9706 0.9368 0.7247 0.9706 0.8160 
Phenol 0.9248 0.9252 0.9248 0.9250 0.9250 
Albumin 0.2588 0.2552 0.0327 0.0063 0.2311 
Total protein 0.7720 0.8795 0.6124 0.8785 0.5566 
p-cresyl 
sulphate 
0.4701 0.7705 0.9046 0.9868 ---- 
Indoxyl 
sulphate 
0.0257 0.0259 0.3711 0.1330 ---- 
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Appendix 2. Adsorption Kinetics Calculated Using Pseudo First 
Order Model  
1. Pseudo first order model of albumin adsorption kinetics from the spiked plasma 
using microporous beads with increase meso- to macropore sizes. A linear 
regression equation can be fitted to the data where fitness of this regression was 
indicated by R
2
. The slope of the regression equation was used in calculating the 
equilibrium adsorption capacity (qe) for each AC used, and the intercept was 
used for the calculation of Pseudo first order constant (Kp1).  
Adsorbent Slope Intercept R
2
 qe (mg/g) Kp2 
A1 -0.0004508 1.676 0.1233 5.34 0.0005 
A2 -0.0005388 1.672 0.1403 5.32 0.0005 
A3 -0.001352 1.666 0.4522 5.29 0.0014 
A4 -0.002233 1.626 0.4285 5.08 0.0022 
A5 -0.001572 1.631 0.2950 5.11 0.0016 
 
2. Pseudo first order model of bilirubin adsorption kinetics from the spiked 
plasma using microporous beads with increase meso- to macropore sizes. A 
linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the equilibrium adsorption capacity (qe) for each AC used, and the 
intercept was used for the calculation of Pseudo first order constant (Kp1).  
Adsorbent Slope Intercept R
2
 qe (mg/g) Kp2 
A1 -0.001 -1.78 0.06608 0.17 0.0010 
A2 -0.0011 -1.784 0.07695 0.17 0.0011 
A3 -0.002 -1.792 0.1727 0.17 0.0020 
A4 -0.0094 -1.842 0.7686 0.16 0.0094 
A5 -0.011 -1.857 0.7919 0.16 0.0110 
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3. Pseudo first order model of indoxyl sulphate adsorption kinetics from the 
spiked plasma using microporous beads with increase meso- to macropore sizes. 
A linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the equilibrium adsorption capacity (qe) for each AC used, and the 
intercept was used for the calculation of Pseudo first order constant (Kp1).  
Adsorbent Slope Intercept R
2
 qe (mg/g) Kp2 
A1 -0.0452 -1.794 0.6523 0.17 0.0452 
A2 -0.0460 -2.014 0.6287 0.13 0.0460 
A3 -0.0393 -1.748 0.4999 0.17 0.0393 
A4 -0.0450 -2.566 0.4658 0.08 0.0450 
4. Pseudo first order model of p-cresyl sulphate adsorption kinetics from the 
spiked plasma using microporous beads with increase meso- to macropore sizes. 
A linear regression equation can be fitted to the data where fitness of this 
regression was indicated by R
2
. The slope of the regression equation was used in 
calculating the equilibrium adsorption capacity (qe) for each AC used, and the 
intercept was used for the calculation of Pseudo first order constant (Kp1).  
Adsorbent Slope Intercept R
2
 qe (M/g) Kp2 
A1 -0.01890 5.184 0.5129 178.39 0.01890 
A2 -0.02310 5.225 0.6890 185.86 0.02310 
A3 -0.01501 5.304 0.4893 201.14 0.01501 
A4 -0.03290 4.911 0.6441 135.78 0.03290 
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Appendix 4. Preliminary saturation transfer difference-nuclear 
magnetic resonance study of p-cresyl sulphate-albumin-
activated carbon interactions 
Introduction 
Nuclear magnetic resonance (NMR) analysis is a technique which allows the 
observation of the transition in the atomic nucleus quantum mechanical properties of 
molecule(s) in a magnetic field. By providing a magnetic field and monitoring the 
adsorption and reemission of electromagnetic radiations of protons in the molecules of 
interest, NMR analysis technique can be used to reveal insight into the molecular 
structures [1]. The development of the saturation transfer difference-nuclear magnetic 
resonance (STD-NMR) analysis technique has led to the increasing interests in the use 
of NMR technique for identifying and characterizing protein-ligand interactions [2-4].  
During the STD-NMR analysis, the samples are monitored by interleaved off 
and on scans [3]. The off scan is a normal NMR scan, which produces a NMR spectrum 
for all the molecules present in the sample. In the on scan, an additional on-resonance 
irradiation frequency is used to target only the protein molecule to provide an extra 
energy (Figure 1). If the ligand molecules are bound to this protein molecule, the 
additional energy will be passed onto the ligand, producing a difference between the on 
scan spectrum and the off scan spectrum of the ligand. This difference is then calculated 
and expressed in a STD-NMR spectrum, in which only the protein bound ligand is 
illustrated (Figure 2).  
The aim of this study was to examine the interaction between albumin and p-
cresyl sulphate/indoxyl sulphate and to investigate the mechanisms by which novel 
activated carbons (AC) remove these two albumin-bound uraemic toxins. 
12 
 
 
Figure 1 Principle of saturation transfer difference-nuclear magnetic resonance 
analysis technique 
During the on scan, a radio irradiation frequency is targeting the protein such as 
serum albumin to provide an extra energy to the albumin. This additional energy 
is then transferred to the albumin bound molecules leaving the unbound molecules 
untouched. By comparing the on scan to the normal NMR scan (off scan), the 
difference in the energy emitted by the ligands is used as an indication of ligand-
protein binding (adapted from [3]).  
 
 
Figure 2 The off NMR scan spectrum (A) and STD-NMR scan spectrum (B) of a 
sample containing 10 mM p-cresyl sulphate, 20 mM creatinine and 0.5 mM human 
serum albumin 
Peaks 1 & 5 belong to p-cresyl sulphate (albumin bound) molecules; peaks 2 & 4 
belong to creatinine (non-albumin-bound) molecules. 
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Method 
STD-NMR technique was used to examine the interaction between human serum 
albumin and p-cresyl sulphate to confirm the p-cresyl sulphate binding to albumin, and 
obtain the ratio in which maximum amount of p-cresyl sulphate binds to albumin. In the 
preliminary study, p-cresyl sulphate was used as a model ligand for the STD-NMR 
study. Samples were prepared in deuterium oxide phosphate buffer saline with an 
excess of p-cresyl sulphate concentration of 10 mM and increasing albumin 
concentration ranging from 0.0625 to 1.0 mM.  
In the p-cresyl sulphate/albumin mixture with highest binding percentage, 0.05 g 
of A1 microporous carbon beads (250-500 µm particle size) was added to 400 µl of 
solution containing 0.5 mM albumin and 20 mM p-cresyl sulphate. After the incubation 
with A1 carbon beads, the sample was re-examined by NMR and STD-NMR analysis. 
Sodium-3-trimethylsilylpropionate was used as an external standard for all the NMR 
analysis. The fraction p-cresyl sulphate which was bound to albumin was determined by 
calculating the percentage of the p-cresyl sulphate peak high in the STD spectrum over 
the off spectrum. Prism 5 software package was used for the data analysis, and the one 
phase exponential association model was selected for the determination of the 
maximum binding (Bmax) between p-cresyl sulphate and human serum albumin. 
Preliminary results and discussion 
The STD-NMR results illustrated that with the increase of human serum albumin 
concentration, an increase percentage of albumin bound p-cresyl sulphate was observed 
(Figure 3). The maximum binding of p-cresyl sulphate (75.95%) appeared to be when 
the ratio of p-cresyl sulphate and human serum albumin concentration reached 1:20. 
Therefore, the sample with 0.5 mM of albumin and 10 mM p-cresyl sulphate was 
selected to be incubated with A1 carbon beads.  
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Figure 3 The binding of p-cresyl sulphate to human serum albumin determined by 
STD-NMR analysis 
With the increase of human serum albumin concentration, an increasing 
percentage in albumin bound p-cresyl sulphate was observed. This increase 
reached a plateau of 75.95% (Bmax) when 0.5 mM of albumin and 20 nm of p-cresyl 
sulphate were used. 
 
The presence of peaks representing p-cresyl sulphate in both the off (peak 1 and 
2) and STD (peak 1’ and 2’) NMR spectra (Figure 4 A and B) suggested that greater 
than 75% of the p-cresyl sulphate was bound to the albumin in the solution. After 
incubating the p-cresyl sulphate/albumin mixture with microporous carbon beads A1, p-
cresyl sulphate peaks disappeared from both off and STD NMR spectra (Figure 4 C and 
D) suggested the removal of those albumin bound p-cresyl sulphate by the A1 carbon 
beads. 
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Figure 4 The off NMR scan spectrum and STD-NMR scan spectrum of a sample 
containing 10 mM p-cresyl suphate and 0.5 mM human serum albumin before (A 
&B) and after (C &D) incubating with A1 microporous carbon beads 
Peak 1 and 2 in (A) and (B) represented p-cresyl sulphate; both peaks dispeared 
after the mixture was incubated with A1 carbon beads. 
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These preliminary results suggested that 75.95% of p-cresyl sulphate bound to 
human serum albumin when the p-cresyl sulphate to albumin concentration ratio 
reached over 20 to 1. Previous study indicated that the adsorption of albumin by 
microporous ACs were minimal. Therefore, the results from this study suggested that 
the AC adsorption of albumin bound p-cresyl sulphate could be due to the deliganding 
effects rather than the adsorption of albumin-p-cresyl sulphate complex, rather than the 
adsorption of the whole albumin-p-cresyl sulphate comples. However, the additional 
irradiation frequency used to target albumin may have boosted the energy emitted by 
the albumin bound p-cresyl sulphate and therefore, may have lead to an over-estimation 
of albumin bound p-cresyl sulphate fraction. Future studies can concentrate on 
minimising the interference of this addition irradiation energy. In addition, by using an 
albumin binding competitor with known albumin binding constant, the binding constant 
of p-cresyl sulphate and albumin could be determined [5]. In addition, the STD-NMR 
analysis can also be used understanding the mechanisms of AC removal of other protein 
bound toxins such as indoxyl sulphate, bilirubin and/or cholic acid. 
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